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Zusammenfassung 
Im Kampf gegen eine Virusinfektion spielen CD8+ T Zellen des adaptiven Immunsystems eine be-
sondere Rolle. Sie patroullieren im Körper und entdecken spezifische Virusepitope, welche mittels 
körpereigener MHC Klasse I Moleküle auf der Oberfläche infizierter Zellen präsentiert werden. Wird 
eine virus-infizierte Zelle erkannt, kann diese schnell und effizient eliminiert. Für die Generierung vi-
raler Peptide, welche auf MHC Klasse I Komplexe geladen werden können, ist das Ubiquitin-
Proteasom-System von essentieller Bedeutung. Lange wurde die Funktion des Immunoproteasoms 
vornehmlich darin gesehen, die Generierung antigener Peptide zu verbessern. In letzter Zeit wurden 
weitere Funktionen des Immunoproteasoms aufgedeckt wie zum Beispiel die Regulation von Zellprolif-
eration und -differenzierung, Zytokinproduktion oder der Schutz gegen oxidativen Stress. Diese bisher 
unbekannten Funktionen des Immunoproteasoms beruhen auf einer gesteigerten Abbaurate von 
ubiquitylierten Proteinen im Vergleich zum Standardproteasom. Innerhalb der vorliegenden Arbeit 
konnte die Fähigkeit des Immunoproteasoms gegen eine Akkumulation oxidativ geschädigter Proteine 
zu schützen mit seiner Rolle in der adaptiven Immunantwort, die Generierung von MHC Klasse I 
Liganden zu verbessern, kombiniert und neu interpretiert werden. 
Es konnte gezeigt werden, dass während einer Virusinfektion in Nicht-Immunzellen die Produktion 
reaktiver Sauerstoffspezies durch die alternative NADPH Oxidase Nox4 eine bedeutende Rolle spielt. 
Die Aktivierung von Nox4 resultiert in der Akkumulation oxidativ geschädigter Proteine, welche poten-
tiell toxische Eigenschaften besitzen. Dabei scheint es sich um ein generelles Prinzip zu handeln, da 
ähnliche Resultate anhand zwei verschiedener Virusinfektionsmodelle beobachtet wurden: die langsam 
foranschreitende Infektion mit dem DNA-Virus HCMV und die Infektion mit dem schnell replizierenden 
RNA-Virus Influenza A. Innerhalb von wenigen Minuten nach dem Eintreten von Viruspartikeln in die 
Zellen wurden strukturelle Virusproteine, wie das HCMV Tegumentprotein pp65 und das Influenza A 
Matrixprotein M1, oxidiert und anschließend ubiquityliert. Dabei zeigte sich, dass die Modifikation der 
Virusproteine abhängig von dem Ubiquitin-konjugierenden Enzym UBE2L6 ist. Die gleichzeitige, virus-
induzierte Expression von Immunoproteasomen führte zu einem schnellen und effizienten Abbau oxi-
dierter und ubiquitylierter Virusantigene. Infolgedessen konnten immun-dominante Virusepitope, 
pp65495-503 beziehungsweise M158-66, vermehrt freigesetzt werden, welches sich positiv auf die adaptive 
Immunantwort auswirkt.  
Folglich wurde ein soweit unbekannter translations-unabhängiger Mechanismus gefunden, welcher 
Substrate für das Proteasom zur Generierung von MHC Klasse I Liganden bereitstellt. Dabei handelt es 
sich um einen komplementären Signalweg zur DRiP Hypothese, welche besagt, dass defekte riboso-
male Produkte die Hauptquelle für MHC Klasse I Liganden darstellen. Offenbar spielen Mechanismen 
der angeborenen Immunantwort, wie die Induktion von Sauerstoffradikalen, eine wichtige Rolle, um 
den Proteinnachschub für das Proteasom zur Generierung antigener Peptide zu garantieren. So 
werden neben neu translatierten, defekten Proteinen durch Oxidation stabile, exogene Virusproteine 
dem Proteasom zugänglich gemacht. In Anlehnung an die DRiP Hypothese wird dieser Proteinpool als 
DrOPs, direkt oxidierte Proteine, bezeichnet. 
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Zusammenfassend konnte innerhalb dieser Arbeit gezeigt werden, dass das Immunoproteasom den 
Schutz vor oxidativen Stress mit der Generierung antigener Peptide verbindet, wodurch eine effektive 
adaptive Immunantwort etabliert werden kann.  
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Abstract 
An efficient immune control of virus infection is predominantly mediated by CD8+ T cells which patrol 
through the body and eliminate infected cells. Infected cells are recognized when they present viral 
antigenic peptides on their surface via MHC class I molecules. To make antigenic peptides available 
for loading on MHC class I complexes, the ubiquitin proteasome system plays a crucial role. Moreover, 
the induction of a special subunit composition of the proteasome, the i-proteasome, is known to sup-
port the generation of MHC class I ligands. Recently, new functions of the i-proteasome, independent 
of MHC class I antigen processing, have been discovered. Evidence is increasing that the i-proteasome 
is involved in diverse processes such as lymphocyte survival, the regulation of cell proliferation and 
differentiation, the production of cytokines and the protection of cells against oxidative stress. These 
previously unknown functions of the i-proteasome likewise depend on its increased ability to degrade 
ubiquitylated proteins as compared to standard proteasomes. Within this thesis the characteristic of 
the i-proteasome to protect cells against the accumulation of oxidant-damaged proteins could be 
linked to its role in the adaptive immune response to improve the generation of MHC class I ligands. 
It could be demonstrated that during a virus infection in non-immune cells the production of reactive 
oxygen species by the alternative NADPH oxidase Nox4 is of critical importance resulting in the accu-
mulation of potentially toxic oxidant-damaged proteins. This appears to be a general principle, as 
shown by comparing two different virus models: the slow progressing DNA virus HCMV and the fast 
replicating RNA virus influenza A. Indeed, within two hours of infection structural virus proteins, such 
as either the HCMV tegument protein pp65 or the influenza A Matrix protein M1, were oxidized and 
subsequently poly-ubiquitylated. This required the activity of components of the UPS, for instance the 
ubiquitin-conjugating enzyme UBE2L6. The concomitant virus-induced formation of i-proteasomes led 
to a rapid and efficient degradation of the oxidized and ubiquitylated virus antigens thereby improving 
the liberation of the immunodominant viral epitopes pp65495-503 and M158-66, respectively, which ame-
liorated the adaptive immune response.  
In conclusion, a so far unknown translation-independent mechanism to fuel proteasomal substrates 
into the MHC class I antigen presentation pathway has been revealed. This imposes a complementary 
pathway to the DRiP hypothesis, which declares that defective ribosomal products represent the major 
source for MHC class I ligands, by making stable virus proteins available. Evidently, DRiPs represent 
not the sole source for virus epitopes and indeed an innate immune mechanism, i.e. the induction of 
oxygen radicals, can provide the protein supply for the proteasome in order to generate antigenic 
peptides, too. Here, a new protein pool providing proteasomal substrates in the very early phase of a 
virus infection has been uncovered. According to the DRiP hypothesis these proteins will be referred to 
as DrOPs, directly oxidized proteins, representing fully folded, exogenously delivered viral proteins 
which become accessible for the proteasome through their oxidation. 
Within the scope of this thesis the i-proteasome has been shown to link the protection against oxida-
tive stress, initiated directly by pathogen recognition as part of the innate immunity, with the genera-
tion of antigenic peptides. Together, an effective adaptive immune response is triggered. 
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1. Introduction 
Our immune system protects us against numerous kinds of pathogens, such as viruses, bacteria, fungi 
and parasites. A successful immune response depends on: i) the detection of a wide variety of patho-
gens, ii) the generation of appropriate pathogen-specific effector responses, and iii) the establishment 
of long-term immunity, named memory. Therefore, in multi-cellular organisms specialised immune 
cells have evolved. These cells recognise, phagocytise and kill foreign cells as well as their own cells 
that became infected (Murphy, 2011). The following chapters will discuss basic immune defence 
mechanisms with regard to an immunological challenge caused by virus infection. 
 
1.1 Interplay between innate and adaptive immunity 
When a pathogen attacks the host, a first line of defence is provided by the innate immune system. 
This system is complemented with a second layer of protection, called the adaptive immune system. 
Specialised cells of the innate immune system, such as dendritic cells (DCs), macrophages, neutrophils 
etc., are activated by the recognition of so-called pathogen-associated molecular patterns (PAMPs). 
Through secretion of cytokines, not only the innate immune cells, but also tissue cells and a wide 
variety of other cells, initiate inflammatory cascades and anti-microbial defence mechanisms. They 
release chemokines to recruit phagocytic cells to the site of infection and modulate the strength of 
both innate and adaptive immune responses. Moreover, the innate system presents pathogen-derived 
antigens to cells of the adaptive immune system, in this way orchestrating their activation. Antigen-
specific cells of the adaptive immune response comprise CD4+ and CD8+ T cells, B cells and plasma 
cells. Virus infections, as well as intracellular bacteria or transformed cells, are predominantly con-
trolled by CD8+ T cells. Upon activation CD8+ T cells produce cytokines, mainly IFNγ, and acquire cy-
totoxic functions which mediate killing of infected and transformed cells, respectively. Notably, adap-
tive immune responses also exert effects on innate immune cells. For example, cytokines produced by 
CD8+ T cells can enhance anti-microbial activities of innate immune cells. In conclusion, innate and 
adaptive immunity interact at various levels and mutually depend on each other (Murphy, 2011). 
 
1.2 Antigen recognition and presentation 
The innate immune response relies on germ-line encoded receptors, which are called pattern recogni-
tion receptors (PRRs). The PRRs were first detected by Charles Janeway in 1989, these receptors rec-
ognise invariant pathogen-associated molecular patterns (PAMPs) (Janeway, 1989). In contrast, the 
adaptive immune system generates a diverse repertoire of lymphocyte receptors which recognise 
numerous foreign antigens presented by major histocompatibility complex (MHC) molecules. T cell 
receptors (TCRs) as well as B cell receptors (BCRs) are generated de novo in each organism by a ran-
dom rearrangement of several, repetitive gene segments allowing for highly specific adaptive immune 
responses (von Boehmer et al., 1988). These different strategies of antigen recognition by innate and 
adaptive immune system complement each other in order to enhance pathogen detection and eradi-
cation. 
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1.2.1 Innate immune response to viral infection 
Several viral PAMPS have been identified to date, such as viral nuclear proteins, capsid proteins, enve-
lope proteins, glycoproteins as well as viral DNA and RNA. Moreover, throughout the viral replication 
cycle replicative intermediates like unmethylated CpG DNA or single- and doublestranded RNA, which 
appear structurally different from cellular RNA, can be recognised by PRRs (Akira et al., 2001). 
The signaling through most PRRs induces the expression of a set of specific genes leading to the es-
tablishment of antiviral immunity, such as the induction of the type I interferons, IFNα and IFNβ, or 
pro-inflammatory cytokines. Further, by increasing the expression of costimulatory molecules like 
CD80, CD86 or CD40 maturation of dendritic cells (DCs) is triggered. MHC class I antigen presentation 
is enhanced, thereby facilitating cross-presentation of viral antigens too. Antigen-specific CD8+ T cell 
responses are induced and the secretion of chemokines stimulates the recruitment of lymphocytes 
and monocytes to the sites of infection. Moreover, hundreds of effector molecules directly influencing 
protein synthesis and cell growth are upregulated (Kawai and Akira, 2006).  
According to their cellular localisation, PRRs are broadly grouped into two classes: transmembrane 
receptors and intracellular receptors. The transmembrane Toll-like receptors (TLRs) can be further 
divided into those patrolling the extracellular and those guarding the endosomal compartments (Kawai 
and Akira, 2010). The cytosolic retinoic acid-inducible gene I (RIG I)-like RNA helicases (RLHs) are 
expressed in most cell types and recognize ssRNA and some dsRNA viruses (Rehwinkel and Reis e 
Sousa, 2010).  
Toll-like receptors represent key sensors of PAMPs and are expressed on many cell types, but the 
highest levels are found on DCs and macrophages. They are named after their homology to Toll pro-
teins, which were originally discovered in 1996 in Drosophila melanogaster (Lemaitre et al., 1996). 
Subsequently, a mammalian homologue, now known as TLR4, was identified (Medzhitov et al., 1997). 
The TLR family consists of 13 members in humans and mice, TLR1 to 9 are common in humans and 
mice, TLR10 can only be found in humans, TLR11 to 13 only in mice (Thompson and Locarnini, 2007). 
The surface TLRs, which recognise PAMPs in the extracellular space, include TLR1, 2, 5, 6 and 11 and 
discover mostly lipids, lipoproteins and glycoproteins present on the surface of pathogens. The intra-
cellular TLRs TLR3, 7, 8, and 9, reside in the endoplasmic reticulum (ER), endosomes and lysosomes, 
and recognise viral DNA and RNA. TLR4, which responds to LPS (lipopolysaccharides), is described to 
signal both at the cell surface and from intracellular locations. By formation of homo- and heterodi-
mers TLRs detect a wide variety of pathogens (Akira et al., 2006). Due to their compartmentalisation 
TLRs have restricted access to host nucleic acids which protects cells against inappropriate immune 
responses (Thompson and Locarnini, 2007).  
For the innate immune response to viruses the Toll-like receptors TLR2, 3, 4, 7, 8 and 9 play im-
portant roles. On the cell surface TLR2 and TLR4 mediate the detection of viral structural proteins like 
envelope glycoproteins. Compton et al. reported that TLR2 mediates the induction of pro-
inflammatory cytokines via NFκB activation in response to human cytomegalovirus (HCMV) infection 
by detection of the envelope glycoproteins gB and gH of HCMV (Compton et al., 2003). Major ligand 
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of TLR4 represents lipopolysaccharide which can be found in the outer membrane of gram-negative 
bacteria, but recently evidence was shown that TLR4 also recognizes some viral components (Kurt-
Jones et al., 2000). These interactions may serve the virus more than the host, for example pro-
inflammatory cytokine responses may lead to upregulation of certain receptors which the virus uses 
for entry and spread. 
Internal TLRs are able to recognise virus infection after invasion of virus particles into the host cells. 
TLR3 detects viral dsRNA which occurs as replication intermediate of many viruses but also constitutes 
the genome of dsRNA viruses. Activation of TLR3 can also be triggered by the synthetic dsRNA ana-
logue poly(I:C) and mimic viral infection (Alexopoulou et al., 2001). Moreover, TLR3 was shown to be 
involved in the innate immune response to influenza A infection (Guillot et al., 2005). TLR7 and TLR8 
recognise viral ssRNA, representing the most sensitive antiviral receptors recognising almost all RNA 
viruses including influenza A (Heil et al., 2004). Finally, TLR9 mediates recognition of viral unmethyl-
ated CpG nucleotides, which are rare in vertebrates but present in viruses and bacteria. Thus, TLR9 is 
involved in the detection of infection with dsDNA viruses such as the murine cytomegalovirus MCMV 
(Tabeta et al., 2004).  
Upon ligand recognition, TLR signaling is initiated resulting in specific gene transcription and activation 
of innate immune responses. All TLRs are characterised by cytoplasmic TIR (Toll/interleukine-1 recep-
tor) domains which interact by homo- or heterodimerisation of TLRs leading to recruitment of several 
downstream TIR-domain-containing adaptors, such as MyD88 (myeloid differentiation factor 88), Mal 
(MyD88-adaptor like; also called TIRAP), TRIF (TIR-domain containing adaptor protein inducing IFNβ) 
and TRAM (TRIF-related adaptor molecule) (Boo and Yang, 2010).  
TLR signaling, summarized in figure 1.1A, is roughly divided in MyD88-dependent and -independent 
pathways. The TLRs 7, 8 and 9 use the MyD88-dependent pathway. MyD88 forms complexes with 
IRAK (IL1-receptor-associated kinase) family members, which themselves interact with TRAF6 (TNF 
receptor associated factor 6), an E3-ligase. This causes the recruitment of ubiquitin-conjugating en-
zyme NEMO (NFκB essential modulator) and IκB kinases into a multi-protein complex. Subsequently 
IκB, the inhibitor of NFκB, is phosphorylated, ubiquitylated and degraded. As a result, NFκB is re-
leased and translocates into the nucleus, where the expression of pro-inflammatory cytokines (ICs) 
like IL1, IL6 or TNFα is induced (Karin and Ben-Neriah, 2000).  
TLR3 uses an alternative MyD88-independent pathway by interaction with the adaptor protein TRIF 
(figure 1.1A). Next, TRIF interacts with TRAF3 (TNF receptor associated factor 3) to activate TBK1 
(TANK-binding kinase 1) and IKKε (inhibitor of NFκB kinase), which subsequently directly phosphory-
late IRF3 (IFN regulatory factor 3). Phosphorylated IRF3 dimerises and shuttles to the nucleus where 
it activates the transcription of IFNβ. Signalling via TRIF also leads to NFκB activation. Therefore, the 
C-terminal non-TIR region of TRIF associates with TRAF6 (Kawai and Akira, 2006). In the case of 
TLR4, firstly the MyD88-dependent pathway is activated at the plasma membrane. Primarily, Mal re-
cruits MyD88 to TLR4 which leads to initial activation of NFκB. Subsequently, TLR4 is taken up by 
endocytosis. Inside the endosome the adaptor TRAM recruits TRIF inducing activation of IRFs and 
NFκB (Kagan et al., 2008). 
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Figure 1.1 Signaling pathways of Toll-like receptors and RIG-I-like helicases. A) The endosomal 
TLRs, TLR7/8 and 9, use the adaptor MyD88 to activate transcription factor NFκB, which in turn induces tran-
scription of pro-inflammatory cytokines (ICs) such as TNFα. In contrast TLR3 uses MyD88-independent signaling 
via TRIF to induce transcription factor IRF3, which initiates the expression of IFNβ. TLR4 is able to induce by 
usage of further adaptor proteins MyD88-dependent and –independent signaling. B) The RLHs RIG-I and MDA-5 
both activate the mitochondrial located adaptor MAVS, which is able to activate IRFs and NFκB. For further ex-
planations see text. 
 
RNA helicases In 2004 Yoneyama and colleagues discovered a TLR-independent mechanism that 
senses viral infections and identified RIG-I (retinoic acid inducible gene 1) (Yoneyama et al., 2004). 
Shortly after, also the structurally related MDA-5 (melanoma differentiation-associated protein 5) was 
identified. Both proteins represent DExD/H box RNA helicases which interact with dsRNA, a common 
intermediate during the replication cycle of many RNA viruses, and thereby trigger the production of 
type I IFNs and pro-inflammatory cytokines. RIG-I for example was shown to play a crucial role during 
the innate immune response to orthomyxoviruses like influenza A (Pichlmair et al., 2006). 
Downstream signal transduction of RNA helicases is mediated through N-terminal CARD (caspase acti-
vation and recruitment) domains. Upon binding to dsRNA CARD domains dimerise and interact with 
adaptor proteins (figure 1.1B). An important adaptor protein was identified simultaneously by 4 differ-
ent groups and therefore is known under 4 different names: MAVS (mitochondrial antiviral signalling 
protein (Seth et al., 2005)), Cardif (CARD adaptor inducing IFNβ (Meylan et al., 2005)), VISA (virus-
induced signalling adaptor (Xu et al., 2005)) or IPS-1 (IFNβ promoter stimulator (Kawai et al., 2005)). 
MAVS is targeted via a C-terminal hydrophobic transmembrane domain to mitochondria and signals 
via TRAF3 to activate Tbk1 and IKKε, which in turn phosphorylate and activate IRF3 as well as IRF7. 
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Further in a parallel pathway MAVS also interacts with FADD and RIP1, which represent death domain 
containing proteins and activate the transcription factor NFκB (Kawai and Akira, 2006) (figure 1.1B). 
Type I interferon response The type I interferons IFNα and IFNβ represent the key cytokines dur-
ing an immune response against viral infection. The IFNβ promoter possesses binding sequences for 
the transcription factors NFκB, AP1 and IRFs, particularly activated in response to viral infection are 
IRF3 and IRF7. These three components along with cofactors like p300/CBP (CREB binding protein) 
assemble to the IFNβ-enhanceosome which binds to positive regulatory domains (PRDs) of the IFNβ 
promoter and stimulates its transcription (figure 1.2A). Thus, IFNβ is secreted and activates via auto- 
or paracrine binding the IFNα receptor (IFNαR) (figure 1.2B). Upon ligand binding the IFNαR signals 
to the tyrosine kinases Jak1 and Tyk2 which phosphorylate STAT1 and 2 (signal transducer and acti-
vator of transcription). Phosphorylated STATs heterodimerise and translocate to the nucleus (figure 
1.2C). There they associate with IRF9 forming the heterotrimeric transcription complex ISGF3 (IFN-
stimulated gene factor 3), which binds to ISREs (IFN-stimulated response elements) and induces the 
expression of antiviral proteins including the myxovirus-resistance protein (Mx) GTPase, RNA-
dependent protein kinase (PKR), oligoadenylate synthetase (OAS), ribonuclease L (RNase L) and fur-
ther ISGs (IFN stimulated genes) (Stark et al., 1998) (figure 1.2D). Notably, the IFN-stimulated gene 
ISG15 represents an ubiquitin-like modifier which is conjugated to target proteins in a process called 
ISGylation conveying different cellular functions. For example, it is reported that ISGylation of IRF3 
inhibits its degradation, thereby further enhancing the type I IFN response (Lu et al., 2006). 
 
 
Figure 1.2 The type I interferon 
response. A) Assembly of the IFNβ 
enhanceosome which is composed of 
NFκB, AP1, IRFs and cofactors such as 
CBP. Binding to positive regulatory 
domains initiates the transcription of 
IFNβ. B) Secretion of IFNβ activates 
via auto- or paracrine binding the IFNα 
receptor. C) The IFNαR associated 
tyrosine kinases Jak1 and Tyk2 phos-
phorylate STAT1 and STAT2, which 
subsequently heterodimerise and con-
stitute together with IRF9 the tran-
scription complex ISGF3. D) ISGF3 
binds to ISREs and induces the tran-
scription of ISGs, such as Mx GTPase, 
protein kinase R, oligoadenylate syn-
thetase and RNase L. 
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1.2.2 Adaptive immune response to viral infection 
The adaptive immunity provides the most powerful defence mechanism against pathogens, using an-
tigen-specific immune responses which can result in complete inactivation or removal of pathogens. 
Two major systems constitute the adaptive immunity: humoral immunity and T cell-mediated immuni-
ty. While humoral immunity is mediated by antibody producing B cells, T cell-mediated immunity can 
further be distinguished in CD8+ and CD4+ T cell responses according to the coreceptor molecules 
they express which are involved in antigen recognition. However, a virus infection is predominantly 
controlled by CD8+ T cells, which will be explained in detail in the following chapter. 
The antigen-specific receptor of T cells recognises peptides, which are presented by major histocom-
patibility complex (MHC) molecules. During their development in the thymus, T cells are determined to 
develop either into CD8+ or CD4+ T cells depending on the recognition of peptides presented by MHC 
class I or MHC class II molecules respectively (Singer et al., 2008). While CD8+ T cells possess cyto-
toxic activity and are directly involved in the elimination of e.g. virus-infected cells, the function of 
CD4+ T cells is to shape immune responses and to support other immune cells. 
MHC class II molecules are only found on specialised antigen-presenting cell types (APCs), like 
macrophages, DCs and B cells. The peptides presented by MHC class II molecules derive from extra-
cellular or membrane proteins, that have been internalized by APCs through endocytosis 
(Ramachandra et al., 1999). The resulting endosomes fuse with lysosomes, where the pathogens are 
digested. Thereby, antigenic peptides are generated which are loaded onto MHC class II molecules. 
Finally, the peptide-MHC class II complex is transported to the plasma membrane and displayed at the 
cell surface to CD4+ T cells (Medd and Chain, 2000).  
The antigen presentation of intracellular pathogens like viruses, but also in case of for instance trans-
formed cells expressing aberrant, mutated proteins, is mediated by another system, the MHC class I 
pathway. For this, intracellular proteins are degraded in the cytosol and the resulting peptides are 
transported via TAP (transporter associated with antigen processing) into the lumen of the ER, where 
they are bound to MHC class I molecules. Thus peptide-MHC class I complexes are presented on the 
cell surface for detection by the immune system (Goldberg and Rock, 1992; Rock and Goldberg, 
1999). 
The TAP transporter is a heterodimeric ABC transporter composed of the subunits TAP1 and TAP2 
(Spies et al., 1992). The TAP1 and TAP2 genes are inducible by IFNγ and encoded within the MHC 
class II gene locus. Peptide binding is mediated by both subunits and upon an ATP-dependent change 
in conformation the peptide is translocated through the ER membrane (Neumann and Tampé, 1999). 
The binding preferences of TAP have a selective influence on the availability of antigenic peptides in 
the ER for loading on MHC class I molecules (Neefjes et al., 1995; Van Endert et al., 1995). TAP pre-
fers the transport of peptides with a length of 8 to 16 amino acids and with a hydrophobic or basic C-
terminus, which indeed correlates with peptide binding to MHC class I complexes.  
The MHC class I molecule is a transmembrane glycoprotein which is constituted by the non-covalent 
association of heavy α-chain and β2microglobulin (β2m). Its expression is also induced by IFNγ in all 
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cell types with few exceptions. As mentioned, MHC class I molecules prefer the binding to peptides 
with basic C-terminus comprising 8 to 10 amino acids (Falk and Rötzschke, 1993; Rammensee et al., 
1993). The peptide binding groove of MHC class I is encoded within a highly polymorphic gene clus-
ter, in humans referred to as human leukocyte antigen (HLA) complex (Geraghty et al., 2002).  The 
classical human MHC class I genes are HLA-A, -B and –C. Thereby, MHC molecules gain highly varia-
ble binding specificities and thus provide the specificity for efficient T cell responses.  
Peptide loading on MHC class I is carried out in association with TAP and takes place within a peptide 
loading complex (PLC) under the assistance of several chaperones like calnexin, calreticulin and 
tapasin. Notably, tapasin provides direct proximity to TAP thereby building a bridge between MHC 
class I and TAP. After binding of an antigenic peptide, the fully folded MHC class I complex dissociates 
from the PLC and subsequently leaves the ER. Only by peptide binding MHC class I acquires stability 
and can be transported to the cell surface. In case of TAP deficiency MHC class I surface expression is 
strongly reduced due to defective assembly, transport and consequently cytosolic degradation of MHC 
class I molecules (van Kaer et al., 1992). In uninfected cells, retention of empty MHC class I mole-
cules in the ER by tapasin provides MHC class I in a surplus to antigenic peptides, so that MHC class I 
molecules are immediately available for peptide loading upon an immunological challenge (Schoenhals 
et al., 1999). In figure 1.3 the MHC class I antigen presentation pathway is summarized.  
 
 
Figure 1.3 The MHC class I anti-
gen presentation pathway. In a first 
step pathogens are degraded in the cyto-
sol by a multicatalytic enzyme complex, 
the proteasome. Generated peptides can 
be further trimmed by cytosolic amino-
peptidases or are transported directly via 
TAP into the ER lumen. Assembly of MHC 
class I molecules occurs inside the ER with 
the help of chaperones. Upon binding of 
β2m the peptide loading complex (PLC) 
assembles including tapasin which pro-
vides proximity to TAP, so that transported 
peptides can be loaded directly on MHC 
class I molecules. At the same time fur-
ther trimming by aminopeptidases like the 
ER-resident aminopeptidase (ERAP) can 
take place. Finally, the peptide-MHC class 
I complex is transported via the Golgi 
apparatus to the cell surface where it is 
presented to cytotoxic T cells (CTLs). 
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After transport through the Golgi apparatus and trans-Golgi network to the cell surface peptide-MHC 
class I complexes are recognized by the TCR of CD8+ T cells. With support of costimulatory interac-
tions by professional APCs, CD8+ T cells differentiate into effector T cells, called cytotoxic T lympho-
cytes (CTLs). CTLs eliminate virus-infected cells by several mechanisms. Firstly, they release lytic 
granules which contain cytotoxic proteins like perforin and granzyme. Furthermore, CTLs express Fas 
ligand (Fas L) which binds to Fas on target cells thereby activating caspases (Henkart, 1994). Finally, 
they secret numerous cytokines like IFNγ, IL12, TNFα and TNFβ (Callan et al., 2000). 
A central question in this thesis was how viral antigenic peptides for loading on MHC class I molecules 
are generated? Like displayed in figure 1.3 the degradation of intracellular pathogens in the cytosol is 
mediated by a multicatalytic protease complex, the proteasome. The generation of peptides with an 
appropriate size for transport by TAP and loading on MHC class I molecules requires degradation by 
the proteasome (Kloetzel, 2001; Reits et al., 2000), which was also shown by the inhibition of pro-
teasome activity resulting in abolished MHC class I antigen presentation (Benham and Neefjes, 1997; 
Rock et al., 1994). Proteasomes generate peptides of 8 to 10 amino acids in length, which is a suited 
size for binding to MHC class I molecules and they preferentially cleave at the carboxyl terminus after 
hydrophobic or basic residues thereby generating the C-terminal anchor residue of MHC class I lig-
ands. In conclusion, peptides released by the proteasome exhibit TAP and MHC class I binding prefer-
ences (Van Endert et al., 1995). To improve the generation of MHC class I ligands the immunopro-
teasome (i-proteasome), an isoform of the proteasome, has evolved. Likewise TAP and MHC class I 
chains also the subunits of the i-proteasome are encoded within the MHC gene locus and are inducible 
by IFNγ. The role of the i-proteasome during the presentation of certain viral epitopes was thoroughly 
studied within this thesis and will be described in detail in the following chapters.  
Cross-presentation Before focusing on the proteasome and its role during virus infection another 
mechanism of antigen presentation which is of particular importance during viral infection shall be 
mentioned. Because most viruses infect other cells than professional APCs, like for example epithelial 
cells of the lung, there must exist pathways to deliver intracellular pathogens into APCs. Any infected 
cell can present antigens via MHC class I complexes, but due to the lack of costimulatory molecules on 
their surface they are not capable of priming naïve CD8+ T cells. Professional APCs, like DCs and mac-
rophages, possess the unique ability to present not only endogenous but also external antigens on 
MHC class I molecules, in a process called cross-presentation (Heath et al., 2004). They take up in-
fected or dying cells by endocytosis. The endosome that forms fuses with a lysosome and degradation 
is initiated. Somehow, by a yet unknown process antigens pass into the cytosol where they are de-
graded by proteasomes. The resulting antigenic peptides are transported by TAP into the ER, where 
they are loaded on MHC class I molecules (Cresswell et al., 2005). A second possible pathway, called 
the vacuolar pathway, does not involve degradation by the proteasome and TAP transport. Instead, 
MHC class I molecules enter the phagosome and peptide loading occurs there (Rock et al., 2010). As 
described above, peptide-MHC class I complexes are subsequently displayed at the cell surface and 
along with surface expression of costimulatory molecules an efficient triggering of CD8+ T cells to 
differentiate into cytotoxic T lymphocytes is possible. 
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1.3 Ubiquitin proteasome system 
In 2004 Aaron Ciechanover, Avram Hershko and Irwin A. Rose were awarded with the Nobel Prize in 
Chemistry for their discovery of controlled ubiquitin-mediated protein degradation via the ubiquitin 
proteasome system (UPS) (Giles, 2004). The proteasome represents a complex, high molecular prote-
ase with multicatalytic activity (Tanaka, 2009) and is responsible for the major part of non-lysosomal 
protein degradation in eukaryotic cells of proteins in the cytosol, the nucleus and the ER (Wójcik and 
DeMartino, 2003). Proteasomes constitute up to 1% of the soluble protein content of a cell (Tanaka et 
al., 1986). This high concentration, as also determined by Kuehn and colleagues with 1 to 20 µg/mg 
of soluble protein in rat cell extracts (Kuehn et al., 1986), underlines the major role of the proteasome 
in protein degradation providing the continuous turnover of proteins and protection of cells from toxic 
accumulation of defect and aberrant proteins (Rock et al., 1994).  
Besides the generation of the majority of MHC class I peptides (Goldberg et al., 2002; Goldberg and 
Rock, 1992; Kloetzel, 2004; Rock et al., 1994) the UPS fulfills several general biological functions. 
Ubiquitin-mediated proteasomal degradation of proteins is an essential mechanism for the regulation 
of numerous important cellular processes like transcription, cell cycle, cell differentiation, regulation of 
apoptosis or cellular stress response (Coux et al., 1996; Glickman and Ciechanover, 2002). For exam-
ple, progression of the cell cycle is controlled through selective degradation of cyclins (Hershko et al., 
1991). Via control of levels of transcription factors gene transcription is affected (Collins and Tansey, 
2006), which is described for example for the processing and activation of NFκB (Palombella et al., 
1994). Likewise, the UPS is involved in signal transduction (Taylor and Jobin, 2005), cell proliferation 
and apoptosis (Naujokat and Hoffmann, 2002). Further, proteasomal degradation is involved in the 
embryogenesis of Caenorhabditis elegans (Bowerman and Kurz, 2006) as well as in fertilization and 
gametogenesis in general (Karabinova et al., 2011; Sakai et al., 2004).  
In particular, the UPS plays a central role in maintaining the protein homeostasis of cells (Goldberg, 
2007). During protein synthesis a large fraction of newly synthesized proteins exhibits defects due to 
errors in transcription, translation or misfolding. More than 30% of the newly synthesized proteins in a 
cell are thought to end up as so-called defective ribosomal products (DRiPs) (Qian et al., 2006; 
Schubert et al., 2000). The UPS preserves cell viability by preventing accumulation of these irreversi-
bly damaged and potentially toxic proteins (Seifert et al., 2010; Szeto et al., 2006). Recently discov-
ered special adaptations of the UPS to situations of enhanced protein synthesis such as virus infection 
and oxidative stress causing an increase of oxidatively damaged DRiPs were also of major importance 
for the investigations in this thesis and will be discussed more detailed in chapter 1.4.3.  
Further, membrane and secreted proteins which are generated inside the lumen of the ER are sub-
jected to quality control by the ER-associated degradation (ERAD) system. Because their degradation 
is mediated in the cytosol as well, these proteins are transferred by retrograde translocation to the 
cytosol where their proteasomal degradation takes place (Smith et al., 2011). 
Defects in the UPS result in severe disturbance of protein homeostasis and can cause diverse malig-
nant diseases such as autoimmune diseases, viral infections, chronic inflammation, cancer, muscle 
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degradation (cachexia) or neurodegenerative diseases (Dahlmann, 2007; Golab et al., 2004; Wang 
and Maldonado, 2006). Further, a correlation between age and change of proteasome activity is re-
ported (Keller et al., 2004). 
The required specificity to fulfil such manifold functions is mediated by the small molecule ubiquitin 
(ub). Covalent labelling of protein substrates with ub delivers the protein to proteolytic degradation by 
the 26S proteasome (Weissman, 2001). This posttranslational modification (PTM) is carried out in an 
ATP-dependent enzyme cascade, in a process called ubiquitylation (Pickart and Eddins, 2004), which 
will be described in the following paragraphs. 
 
1.3.1 The Ubiquitylation cascade 
Ubiquitin was first isolated by Gideon Goldstein and colleagues in 1975 (Goldstein et al., 1975) and 
represents a highly conserved small ubiquitous protein of 76Aa (8.6 kDa) which can be found in the 
cytoplasm and nucleus of all eukaryotic cells (Wilkinson et al., 1980). The major function of a post-
translational modification with ub is the regulated degradation of protein substrates (Ciechanover et 
al., 1984; Hershko et al., 1980; Hough et al., 1986; Wilkinson et al., 1980). In mammalia, ubiquitin is 
encoded by four ub genes which express ubiquitin either as poly-ubiquitin (poly-ub) in tandem repeats 
or as fusionprotein with ribosomal subunits (Baker and Board, 1987; Kimura and Tanaka, 2010; 
Ozkaynak et al., 1987; Wiborg et al., 1985). Special proteases, so called deubiquitylating enzymes 
(DUBs), cleave poly-ub into single ub molecules (Reyes-Turcu and Wilkinson, 2009), which makes 
them thereby available for ubiquitylation to protein substrates. Further functions of DUBs will be de-
scribed later. 
Ubiquitylation The carboxyl group of the C-terminal glycine of the ub molecule is linked to an ε-
amino group of a lysine residue of the target protein via an isopeptide bond. Connection of the single 
ubiquitin moieties within the poly-ub chain occurs in the same way. The process of ubiquitylation is 
carried out in a three step enzyme cascade (figure 1.4) by the interaction of three enzymes: E1 ub-
activating enzyme, E2 ub-conjugating enzyme and E3 ub-protein ligase (Hershko and Ciechanover, 
1998). The cascade is initiated with the ATP-dependent activation of ubiquitin by an E1. Thereby, a 
thioester bond between the cysteine in the active centre of the E1 and the carboxy terminus of ub is 
generated forming an E1-ub-conjugate. Subsequently, ub is transferred to a cysteine residue in the 
active centre of an E2 again via thioester bond. The E2 enzyme conveys already specificity regarding 
ub linkage control and selection of the E3. Finally, E2 and E3 associate so that an isopeptide bond 
between the C-terminal Gly76 of ubiquitin and an ε-amino group of a lysine residue within the sub-
strate bound to the E3 can be established (Hershko et al., 1983). This process is repeated several 
times building an ub chain (Li et al., 2007). Alternatively, the whole ub chain can be pre-assembled 
while bound to the E2 and is later transferred en bloc to the substrate. In humans two E1 enzymes 
(Haas et al., 1982; Jin et al., 2007), around 35 E2s (van Wijk and Timmers, 2010) and several hun-
dred E3s (Pickart and Eddins, 2004) are described. The E3 enzymes confer substrate recognition, 
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recruitment of the E2 and transfer of ub from the E2 to the substrate. In conclusion, substrate speci-
ficity is given by the selection of different E2 and E3 enzymes.  
E3 ligases can be grouped into two classes based on their catalysis mechanism: HECT domain (ho-
mologous to E6-AP carboxyl terminus) and RING (really interesting new gene)/U-Box domain (UFD2 
homology) E3 enzymes. While HECT domain ligases bind ub via a thioester bond to a cysteine in their 
active centre in order to transfer ub in the next step to the substrate, RING domain E3s only function 
as platform to bring substrate and E2 in contact. RING domain ligases also possess several cysteine 
and histidine residues which coordinate two zinc ions to establish the conformation of the enzyme, 
which is important for the binding of the E2. Consequently, ub is directly transferred to lysine residues 
of the substrate (figure 1.4) (Ardley and Robinson, 2005).  
 
 
Figure 1.4 The ubiquitylation cascade. The 
process of ubiquitylation is initiated with the ATP-
dependent activation of ubiquitin (ub) by an ub-
activating enzyme (E1). Thereby, a thioester bond 
between E1 and ub is generated forming an E1-ub-
conjugate. Subsequently, ub is transferred to an ub-
conjugating enzyme (E2). Finally, E2 associates with 
an ub-protein ligase (E3) which conveys substrate 
specificity. The E3 establishes an isopeptide bond 
between ub and a lysine residue of the substrate 
bound to the E3. Based on the catalytic mechanism 
two classes of E3s are differentiated. HECT domain 
ligases bind ub via a thioester bond and transfer ub in 
a second step to the substrate. RING E3s only func-
tion as platform and ub is directly transferred to a 
lysine residue of the substrate. Adapted from (Woelk 
et al., 2007). 
Substrate recognition Substrates for ubiquitylation are recognised through specific sequence motifs 
(Wilkinson, 2000). For example, the PEST sequence which is rich in proline, glutamine, serine and 
threonine (PEST). Marchal and colleagues proposed that phosphorylation within the PEST sequence 
could enhance or inhibit ubiquitylation of nearby lysine residues of mostly short lived proteins (Marchal 
et al., 2000). Further, the N-end rule indicates that destabilising amino acids like arginine, lysine, phe-
nylalanine or tryptophan at the N-terminus of proteins could trigger ub-mediated degradation. Nota-
bly, other substrate-specific amino acid sequences were identified as ubiquitylation signals. Moreover, 
hydrophobic areas at the surface of proteins which indicate misfolding or dissociation of protein com-
plexes can initiate ubiquitylation (Wilkinson, 2000). Further, misfolded proteins are targeted for pro-
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teasomal degradation with the help of chaperones. If the chaperone-mediated refolding of a damaged 
protein fails and the native state of a protein is unattainable, an interaction of E3 ligases with chaper-
ones is thought to selectively target irreversibly misfolded proteins to proteasomal degradation, so 
that the recognition of the substrate is in fact mediated by chaperones (Kriegenburg et al., 2012). 
Forms of ubiquitylation The ubiquitin molecule exhibits seven lysine residues: Lys6, Lys11, Lys27, 
Lys29, Lys33, Lys48 and Lys63, all of which can be used for linkage (figure 1.5). Of major importance 
is the generation of ub chains linked via Lys48 which labels proteins for degradation by the 26S pro-
teasome (Chau et al., 1989). Thereby, a minimum length of four ub moieties is required for efficient 
targeting to proteasomal degradation (Thrower et al., 2000). Besides linkage via Lys48 several kinds 
of ub chains can be assembled through connection of different lysine residues. The topology of an ub 
chain, i.e. length and linkage type, conveys different functions (Komander, 2009) (figure 1.5). Post-
translational modification with just one ub moiety, called mono-ubiquitylation, was shown to play a 
role in signalling during virus budding (Patnaik et al., 2000), histone regulation and DNA repair 
(Bergink et al., 2006; Hoege et al., 2002). A linkage of single ubs to several different lysine residues 
of one protein is called multi-ubiquitylation and was shown, for example, to be involved in endocytosis 
of receptor tyrosine kinases (Haglund et al., 2003).  
Ubiquitylation via Lys63 mostly does not lead to proteasomal degradation, but plays a role in DNA 
repair, signalling cascades or labels proteins for lysosomal degradation (Spence et al., 1995). The 
formation of Lys63-linked ub chains by E3 ligase TRAF6 is an essential step in the signalling pathway 
leading to activation of NFκB (Deng et al., 2000; Skaug et al., 2009). Notably, ubiquitylation via Lys11 
was shown to be connected to ER-associated protein degradation (ERAD) and perhaps also to cell 
cycle regulation (Xu et al., 2009). Lys29- and Lys33-linked ub chains were described to play a role in 
the regulation of kinase activity (Al-hakim et al., 2008). However, in some cases also proteins labelled 
with Lys11-, Lys29- or Lys63-linked ub chains can be degraded by the proteasome (Jin et al., 2008; 
Kim et al., 2007; Saeki et al., 2009; Xu et al., 2009). Branched ub chains which are generated by con-
nection of ub moieties via different lysine residues poorly bind to the 26S proteasome (Kim et al., 
2009). One function of branched ub chains was described by Boname and colleagues in 2010, the 
viral E3 ligase K3 produces branched Lys11-Lys63-linked ub chains at the cytosolic tail of MHC class I 
molecules thereby triggering their endocytosis (Boname et al., 2010). Forms and functions of ubiq-
uitylation are summarised in figure 1.5. 
Ubiquitin-like modifiers Numerous structurally homologous proteins to ubiquitin have been de-
scribed up to date. Several so called ubiquitin-like modifiers are known, such as SUMO, NEDD8, ISG15 
or FAT10. The ub-like modifiers are similarly added as posttranslational modification to specific recog-
nition sequences on proteins in a three step enzyme cascade (Schwartz and Hochstrasser, 2003). 
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Figure 1.5 Forms of Ubiquitylation. The 
ub molecule exhibits seven lysine residues: K6, 
K11, K27, K29 K33, K48 and K63, all of which 
can be used for linkage. Ubiquitylation with just 
one ub moiety is called mono-ubiquitylation 
and has been shown to fulfil signalling func-
tions during virus budding, histone regulation 
and DNA repair. Linkage of several single ub 
moieties to one substrate, called multi-
ubiquitylation, is involved in endocytosis. Ub 
chains linked via K48 deliver substrate proteins 
to degradation by the 26S proteasome. Poly-
ubiquitylation via the lysine residues K11, K29, 
K63 was shown to play a role in DNA repair, 
targeting of proteins for lysosomal degradation 
or in signalling pathways such as NFκB activa-
tion. Branched ub chains were proposed to 
trigger endocytosis. Modified from (Woelk et 
al., 2007). 
Deubiquitylation enzymes (DUBs) cleave the isopeptide bond between ub and its substrate protein, 
but also between single ub moieties. Thereby DUBs either sequentially cleave off single ub moieties, 
parts of an ub chain or entire ub chains in one step. Around 80 DUBs are known, for specific linkage 
types and substrates specific DUBs exist. Further, specific DUBs antagonise specific E3 ligases regulat-
ing substrate degradation and activity, respectively (Komander, 2009). Thus, DUBs fulfil manifold 
functions, for example they cleave ub from its precursor and help to recycle ub.  
 
1.3.2 Structure and assembly of the proteasome 
Representing a high molecular, multicatayltic protease the proteasome is characterised by a complex 
structure displayed in figure 1.6. The 20S core of the proteasome which comprises 670 kDa repre-
sents a cylindric, barrel-like structure. The 26S proteasome spanning approximately 2.5 MDa consists 
of 20S core and an additional 19S regulatory particle of 700kDa (see chapter 1.3.3.) (Tanaka, 2009). 
The core is constituted of four stacked heptameric rings created by the assembly of 28 homolog but 
different subunits which range in size from 21 to 31 kDa (Baumeister et al., 1998; Coux et al., 1996). 
In eukaryotes, the two outer rings are composed of seven α-subunits, α1 to α7, which control the 
access to the catalytic chamber and interact with the regulators (Groll et al., 1997). The two inner 
rings are formed by seven β-subunits, β1 to β7, which build the catalytic chamber of the proteasome. 
Three of them, namely β1, β2 and β5, harbour the all in all six active sites of the proteasome (figure 
1.6).  
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Figure 1.6 The Structure of the proteasome. The 26S proteasome is composed of two subcomplexes: 
the 19S regulatory complex and the 20S core proteasome. The 20S core consists of four stacked heptameric 
rings. The two outer rings are composed of seven homolog but different α-subunits, α1 to α7. They control the 
access to the catalytical chamber and interact with regulators. The two inner rings are formed of seven β-
subunits, β1 to β7, which build the catalytic chamber of the proteasome. The 19S regulator is further composed 
of two subcomplexes: base and lid. The base caps the α-ring and is composed of six ATPase subunits, Rpt1 to 6, 
and two Rpn subunits, Rpn1 and 2. The lid consists of up to ten non-ATPase Rpn subunits. Modified from (Murata 
et al., 2009). 
 
In order to control the access to the catalytic chamber the N-terminal tails of the seven α-subunits 
close the chamber under normal conditions (Groll et al., 2000; Groll et al., 1997; Unno et al., 2002). 
Groll and colleagues could show that a deletion of the N-termini opens the channel to the core particle 
(Groll et al., 2000). The group further argued that the 20S proteasome alone without binding of regu-
latory particles has no proteolytic activity in vivo because the access to the inner, catalytical β-
subunits is blocked (Groll et al., 2000). Thus, opening of the gate is controlled by additional protein 
complexes which bind to the α-rings and induce a conformational change to the N-termini of the α-
subunits (see chapter 1.3.3). The gating process also protects cells from uncontrolled proteolysis.  
Belonging to the family of aminoterminal nucleophile (Ntn) hydrolases the catalytical active subunits of 
the proteasome β1, β2 and β5 are characterised by N-terminal threonine which protruds into the cata-
lytic chamber and mediates the nucleophilic attack of peptide bonds (Bochtler et al., 1999). Peptide 
bonds are cleaved at the C-terminus of acidic, neutral or hydrophobic amino acids (Tanaka, 2009). 
According to their cleavage specificities the three catalytical β-subunits are distinguished:  β1 caspase-
like activity (cleavage after acidic amino acids), β2 trypsin-like (cleavage after basic amino acids) and 
β5 chymotrypsin-like (cleavage after hydrophobic amino acids) (Cardozo, 1993; Dahlmann et al., 
1986; Dick et al., 1998; Orlowski and Wilk, 2000). 
In mammalian, besides the mentioned standard subunits β1, β2, β5 specialised immunosubunits (i-
subunits) β1i, β2i, β5i have evolved which are expressed for example after IFNγ stimulation. These i-
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subunits are incorporated into nascent 20S proteasomes replacing the constitutive standard subunits 
in order to form i-proteasomes (Groettrup et al., 1996b; Kloetzel, 2004). In chapter 1.4 the functions 
and relevance of i-proteasomes will be described in detail. 
The biogenesis of the proteasome in mammalian cells is a highly regulated process which com-
prises the biosynthesis of all subunits, their assembly and maturation. The first step during de novo 
synthesis of proteasomes is the expression of all 14 α- and β-subunits of the 20S core complex. These 
subunits are expressed as proforms with N-terminal elongation, called precursors. The heptameric α-
ring assembles with the help of the heterodimeric proteasome assembly chaperones Pac1/2 and 
Pac3/4. Fricke and colleagues found in 2007 that main steps of the 20S proteasome biogenesis take 
place at the ER membrane mediated by the proteasome maturation protein (POMP) which interacts 
with ER membranes (Fricke et al., 2007). Further, POMP regulates the recruitment of β-subunits to 
the α-ring which serves as matrix for their attachment (Burri et al., 2000; Witt et al., 2000). After 
stepwise binding of all β-subunits a half-proteasome consisting of one α- and one β-ring is formed 
(Frentzel et al., 1994; Hirano et al., 2008; Nandi et al., 1997). Subsequently, two half-proteasomes 
come together to form an intermediate before the processing of the precursors is carried out. The 
catalytical active β-subunits β1, β2 and β5 cleave off their prosequence in an autocatalytic process 
and subsequently mature the adjacent, inactive subunits. Only after the last maturation step is com-
pleted the proteasome becomes active (Kruger et al., 2001) and degrades its first substrates repre-
sented by POMP and PAC1/2 (Hirano et al., 2005; Hirano et al., 2008; Ramos et al., 1998; Witt et al., 
2000). 
 
1.3.3 Regulators of the proteasome 
Binding of regulatory complexes to the 20S core complex can influence proteasomal activity and sub-
strate selection. While the 20S proteasome is able to degrade substrates alone (Coffino, 2001), asso-
ciation with different regulatory complexes occurs (Kloetzel, 2001). So far, three different regulators 
which bind to the outer α-rings of the 20S core complex are known: 19S, PA28α/β and PA28γ.  
Proteasomal activity of 19S-bound proteasome is dependent on ATP and ub, while binding of PA28α/β 
and PA28γ to the 20S leaves proteasomal degradation ATP- and ub-independent. Further, also the 
degradation of unlabelled proteins by the 20S proteasome is independent of ATP. Moreover, the 26S 
proteasome can degrade substrates independent of ub, for example proteasomal degradation of orni-
thin-decarboxylase which is mediated by antizym (Murakami et al., 1992; Zhang et al., 2003). 
The 19S regulator, which is also known as PA700, binds to 20S and activates the core particle to 
degrade poly-ubiquitylated proteins. Therefore, 19S mediates the binding, deubiquitylation, unfolding 
and translocation of substrates into the catalytic chamber in an ATP-dependent manner (Groll et al., 
1997). The 19S is characterised by a complex structure composed of approximately 20 subunits which 
are arranged in two subcomplexes, namely base and lid (Ferrell et al., 2000; Glickman et al., 1998) 
(figure 1.6). The base caps the α-ring and is composed of six different ATPases of the AAA+ family 
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(Rpt1 to 6) and two Rpn subunits (Rpn1 and Rpn2) which mediate substrate unfolding and gate open-
ing in an ATP–dependent manner (Glickman et al., 1999). The lid is constituted of up to ten non-
ATPase subunits which mediate the recognition and binding of poly-ubiquitylated protein substrates 
(Pickart 2001). The 20S proteasome can be associated with one or two 19S regulators forming the 
26S or 30S proteasome, respectively.  
Another regulatory particle is represented by the proteasome activator 28 (PA28), also called 11S, 
which can also induce gate opening and activation of the 20S core complex (Stohwasser et al., 2000). 
PA28 is composed of seven alternating nonATPase PA28α and β subunits or PA28γ subunits in hep-
tameric rings (Zhang et al., 1999). While PA28α/β is mainly found in the cytoplasm, PA28γ localises 
predominantly to the nucleus (Wójcik et al., 1998). PA28 does not bind to ubiquitylated subtrates and 
further does not mediate the degradation of large substrates (Whitby et al., 2000). The expression of 
the PA28α and β subunits is induced by IFNγ signalling and a role for PA28α/β in the processing of 
antigenic peptides for MHC class I antigen presentation is described (Kloetzel, 2001), while the mech-
anisms remain largely unknown.  
Further complexity is given by the fact that IFNγ stimulation of Hela cells induces besides PA28α/β-
20S proteasome also the formation of PA28α/β-20S-19S proteasome (Tanahashi et al., 2000). While 
19S can bind to one side PA28α/β or PA28γ can bind to the other side forming a hybrid proteasome 
which is supposed to enhance the effectivity of degradation of ubiquitylated substrates (Hendil et al., 
1998). Hybrid proteasome is reported to be more active than 26S and to generate a different peptide 
pool (Cascio et al., 2002). Thereby, the binding of PA28α/β has no direct effect on the active sites of 
the 20S core but the association to the outer α-rings triggers the N-terminal tails of the α-subunits to 
flip upwards and open the gate. Consequently, substrate entry as well as product exit are facilitated, 
which might support the release of longer, N-terminally-elongated peptides in order to fuel the MHC 
class I antigen presentation pathway (Sijts and Kloetzel, 2011). A task that the 19S regulator could 
probably fulfil alone and the special role of PA28 still needs to be elucidated. 
 
1.4 Immunoproteasome 
Apart from the constitutive standard proteasomes (s-proteasome) different isoforms of the pro-
teasome are described. Accordingly, proteasomes form a heterogeneous population of enzyme com-
plexes in the cell (Tanaka, 2009). The appearance of a certain isoform in immune cells and immune 
tissue led to the designation immunoproteasome (i-proteasome), which was introduced firstly in 1994 
by Aki and colleagues (Aki et al., 1994). 
While the s-proteasome occurs in all cell types, the i-proteasome is constitutively expressed in im-
mune relevant cells and formed upon exposure to interferons and certain cytokines (Groettrup et al., 
1996b; Shin et al., 2006). Predominantly IFNγ induces the expression of specialised i-subunits, β1i 
(also known as Lmp2), β2i (Mecl-1) and β5i (Lmp7), which replace the catalytical active standard sub-
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units β1, β2 and β5, respectively. The i-subunits are incorporated into newly assembled proteasome 
complexes thereby forming the i-proteasome (figure 1.7).  
 
 
 
Figure 1.7 Formation of the i-proteasome. Upon certain stimuli, e.g. IFNγ signalling, the expression of 
the i-subunits β1i, β2i and β5i is induced leading to the formation of i-proteasomes. Adapted from (Strehl et al., 
2005). 
 
While all other proteasome genes are dispersed throughout the genome, β1i and β5i are encoded in 
the MHC class II region on chromosome six directly upstream of the TAP1 and TAP2 genes (Rock and 
Goldberg, 1999). The third i-subunit β2i was discovered later, in 1996, and is encoded on chromo-
some 16 (Groettrup et al., 1996a; Nandi et al., 1996).  
A basal expression level of i-subunits was found in lymphoid tissue such as thymus, spleen and lymph 
nodes, the highest i-proteasome activity was measured in spleen (Noda et al., 2000). Moreover, also 
spleen of IFNγ-deficient mice was shown to exhibit similar levels of i-proteasome expression in com-
parison to wild type mice (Barton et al., 2002) which shows that i-proteasome abundance in lymphoid 
tissue is independent of further stimuli. The cells concerned in these tissues are professional APCs. 
Especially immature DCs exhibit high levels of i-subunit expression (Li et al., 2001; Macagno et al., 
1999), further macrophages (Basler et al., 2004), B cells (Hensley et al., 2010) and T cells (Ossendorp 
et al., 2005). 
The expression of i-subunits in non-lymphoid tissue is rather low (Murata et al., 2007). Most non-
immune cells induce the formation of i-proteasomes upon an immunological challenge. In tissue cul-
ture a treatment with type I and II interferons or pro-inflammatory cytokines like TNFα up-regulates 
the expression of i-subunits. In vivo during infection with lymphocytic choriomeningitis virus (LCMV) or 
Listeria monocytogenes an exchange of the catalytical subunits has been observed in mice (Khan et 
al., 2001b; Strehl et al., 2006). After fungal infection with Histoplasma capsulatum the exchange of i-
subunits was shown to be dependent on IFNγ signalling (Barton et al., 2002). While during Hepatitis C 
virus (HCV) infection in chimpanzees an increase of i-subunit expression in the inflamed liver was 
measured before IFNγ signalling occurred and coincided with the type I interferon response (Shin et 
al., 2006). In conclusion, in the very early stage of infection pro-inflammatory cytokines and type I 
interferons contribute to the formation of i-proteasome in the inflamed tissue, while later IFNγ re-
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leased by NK and T cells which arrive one to several days later at the site of infection further induces 
the expression of i-subunits. 
Though the i-proteasome represents the predominant proteasome type in lymphoid tissue, constitu-
tive proteasomes are never replaced completely (Macagno et al., 1999). Instead, the expression of i-
proteasome in non-lymphoid tissue after infection rises only slightly above 60% of the whole pro-
teasome population (Strehl et al., 2006). Moreover, the i-proteasome is characterised by a shorter 
half-life of around 27 hours compared to s-proteasome with a half-life of 5 days in HeLa cells (Heink 
et al., 2005). 
Notably, another isoform of the proteasome which is exclusively expressed in cortical thymic epithelial 
cells is known as the thymoproteasome. Thymoproteasomes are characterized by the incorporation of 
a β5t subunit, which displays a high homology to β5i, and are required during the development and 
positive selection of CD8+ T cells in the thymus (Tomaru et al., 2009).  
Moreover, mixed-type proteasomes occur when only one or two of the three catalytical β-subunits are 
exchanged so that proteasome complexes containing constitutive as well as i-subunits are formed 
(Dahlmann et al., 2000; Griffin et al., 1998). 
 
1.4.1 Generation of MHC class I ligands 
The high expression level of i-proteasomes in DCs as well as the induction of i-proteasome formation 
during an infection suggested a functional role for the i-proteasome during the epitope generation for 
MHC class I antigen presentation to cytotoxic T lymphocytes. Both, s-proteasome as well as i-
proteasome, are able to generate MHC class I ligands as part of the adaptive immune response (see 
chapter 1.2.2), but in most instances the i-proteasome was shown to generate antigenic peptides 
more efficiently and at a higher rate (Sijts and Kloetzel, 2011).  
First evidence for a role of the i-proteasome in epitope generation derives from in vitro digestion stud-
ies with β1i/β5i-containing proteasomes which generated a qualitatively and quantitatively altered set 
of peptides from a synthetic 25-mer polypeptide containing an immunodominant epitope of the MCMV 
pp89 protein (Boes et al., 1994). Further groups have confirmed altered cleavage site preferences of i-
proteasomes compared to s-proteasomes (Driscoll et al., 1993; Gaczynska et al., 1993; Kuckelkorn et 
al., 1995; Toes et al., 2001; Ustrell et al., 1995).  
In vitro experiments as well as in vivo mice studies underline a major role for i-proteasomes during an 
immune response. Altered MHC class I expression and T cell responses were observed in β1i/β5i-
deficient mice already in 1994 (Fehling et al., 1994; van Kaer et al., 1994). I-proteasome deficiency 
was shown to impair the presentation of bacteria- as well as virus-derived epitopes to CD8+ T cells 
(Cerundolo et al., 1995; Sibille et al., 1995). For example, in cell culture it was shown in HeLa cells 
infected with a Vaccinia virus expressing the Hepatitis B virus (HBV) core antigen that the efficient 
liberation and presentation of the HBVcAg141-151 epitope essentially required stimulation of the cells 
with IFNγ and formation of i-proteasomes (Sijts et al., 2000a). During Listeria monocytogenes infec-
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tion β5i-deficient mice showed a delayed clearance of pathogens from liver (Strehl et al., 2006). Fur-
thermore, in a mouse model of Coxsackievirus B3 (CVB3) infection resistance to chronic infection cor-
related with an early type I IFN response and the concomitant up-regulation of MHC class I pathway 
components and i-proteasomes (Jäkel et al., 2009). Numerous other publications have demonstrated 
a positive influence of i-proteasome activity on the generation of MHC class I epitopes (Schwarz et al., 
2000; Sijts et al., 2000b; Tu et al., 2009).  
A quantification of CD8+ T cell responses to seven viral epitopes during influenza A infection revealed 
that i-proteasomes exert different effects on the liberation of different epitopes. CD8+ T cell responses 
in β1i-deficient mice were dramatically reduced for two immunodominant epitopes, while the frequen-
cies of CTLs directed against two subdominant epitopes were increased compared to wild type mice 
(Chen et al., 2001). Similarly, during LCMV infection in mice the presentation of a subdominant 
epitope was enhanced in the absence of β1i or β5i (Basler et al., 2004). Another group observed that 
LCMV infection was cleared with similar kinetics in β1i/β5i-deficient and wild type mice (Nussbaum et 
al., 2005). Consequently, i-proteasome-deficient mice also mount CD8+ T cell responses though with 
different immunodominance hierarchies thereby affecting the fine specificity of CD8+ T cell responses 
(Sijts and Kloetzel, 2011). These distinct efficiencies in the processing of different antigens (Kloetzel, 
2001) can be explained by altered cleavage site preferences of i-proteasomes compared to s-
proteasomes producing a different set of peptides which is better suited for TAP transport and MHC 
class I binding. Indeed, i-proteasomes tend to cleave behind residues representing the correct C-
terminus of a MHC class I epitope (Strehl et al., 2008). Due to increased chymotrypsin- and trypsin-
like activity and decreased caspase-like activity i-proteasomes generate peptides with either hydro-
phobic or basic and less acidic C-terminus more effectively (Aki et al., 1994; Dahlmann et al., 2000). 
Another explanation could be that i-proteasomes generate indeed a similar set of peptides compared 
to s-proteasomes but in higher amounts in order to counteract the destruction of released peptides by 
aminopeptidases (Sijts and Kloetzel, 2011). 
In 2000 Sijts and colleagues transfected a mouse embryonal cell line with an inducible TET-expression 
system for i-subunits to analyse the influence of i-subunit exchange on the presentation of an Adeno-
virus E1B-derived epitope. They observed a more efficient epitope presentation in CTL assays when i-
proteasomes were expressed (Sijts et al., 2000b). Later, in 2007 another group performed experi-
ments with DCs lacking i-subunit expression and used mass spectrometry to analyse the generation of 
the same E1B-derived epitope. They observed that the epitope was also generated by s-proteasome 
only less efficiently (Deol et al., 2007). These observations suggest that i-proteasomes mostly influ-
ence the quantity of generated peptides and therefore exhibit a greater efficiency in epitope genera-
tion.  
A limiting factor for the efficient generation of MHC class I ligands and subsequently the effective 
induction of adaptive immunity represents the availability of substrates for proteasomal degradation. 
According to the DRiP hypothesis the major source of proteins for the generation of antigenic peptides 
is represented by defective ribosomal products (Yewdell, 2007). In case of an enhanced protein syn-
thesis rate, as it occurs for instance during viral infection, also errors in transcription, translation and 
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protein folding increase resulting in elevated levels of DRiPs. DRiPs are degraded faster than the na-
tive functional gene product (Reits et al., 2000; Schubert et al., 2000; Yewdell, 2002), thereby also 
stable viral antigens can be targeted fast and directly into the MHC class I antigen presentation path-
way (Khan et al., 2001a), so that the cellular immune systems gains early access to viral proteins 
(Yewdell, 2005). Within the scope of this thesis a complementary mechanism to the DRiP hypothesis 
providing substrates for the proteasome in order to generate antigenic peptides has been found.  
 
1.4.2 Other functions of the i-proteasome 
During an inflammation process in infected tissues the signalling of pro-inflammatory cytokines induc-
es the formation of i-proteasomes in all cells, thus, also in uninfected, adjacent cells which do not 
require an up-regulation of the antigen processing machinery (Krüger and Kloetzel, 2012). Only re-
cently, research focussed on functions which i-proteasomes might fulfil apart from antigen processing. 
Several research groups suggested already an influence of i-proteasome expression on cytokine pro-
duction or T cell differentiation, survival and function (Groettrup et al., 2010; Nussbaum et al., 2005; 
Yewdell, 2005). 
Indeed, i-proteasomes have been shown to occur in a wide array of non-immune cells and organs. 
The β5i-subunit is constitutively expressed in several normal tissues, for example colon, liver or pla-
centa. Ebstein and colleagues recently reviewed the appearance of i-proteasomes or i-subunits in non-
immune cells (Ebstein et al., 2012).  
Mouse models and studies with specific proteasome inhibitors have helped to understand and explore 
i-proteasome functions in innate immunity and non-immune processes. Several publications report a 
role for the i-proteasome in the regulation of T cell proliferation and differentiation (Basler et al., 
2006; Moebius et al., 2010; Zaiss et al., 2008). The contribution of proteasomal degradation during 
cell cycle regulation is well established while a role of the i-proteasome in this process is so far un-
studied. By degradation of positive as well as negative regulators of the cell cycle (Naujokat and 
Hoffmann, 2002) the i-proteasome might affect these processes (Ebstein et al., 2012).  
Another unexpected role for i-subunits was observed in the regulation of pro-inflammatory cytokine 
production (Hensley et al., 2010; Muchamuel et al., 2009; Schmidt et al., 2010; Visekruna et al., 
2006). It is known that the key regulator controlling the expression of pro-inflammatory cytokines 
NFκB is activated by proteasomal degradation of IκB, the inhibitor of NFκB. In turn, released NFκB 
translocates to the nucleus and induces the transcription of cytokines. I-proteasome activity might 
accelerate the activation of NFκB (Ebstein et al., 2009). Seifert and colleagues observed that the turn-
over of IκB is much higher in cells over-expressing the three i-subunits and that i-proteasomes de-
grade IκB faster than s-proteasomes (Seifert et al., 2010). Further, in vivo during CVB3 infection β5i 
knockout mice show an impaired activation of NFκB (Opitz et al., 2011). 
In conclusion, the capacity of the i-proteasome to accelerate the turnover of poly-ub substrates not 
only affects the generation of epitopes for MHC class I antigen presentation but also the degradation 
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of critical regulators such as cyclins or IκB, thereby influencing many cellular processes such as gene 
transcription, signalling, cell proliferation and differentiation.  
 
1.4.3 Oxidative stress and the i-proteasome 
During an innate immune response immune cells such as phagocytes produce large amounts of reac-
tive oxygen species (ROS) as well as reactive nitrogen species (RNS) through activation of the NADPH 
oxidase 2 (Nox2) and the inducible nitric oxide synthetase (iNOS). As a matter of fact, also non-
immune cells exposed to cytokines produce ROS and RNS (Rada and Leto, 2008). Possible sources for 
the production of free radicals in other cell types are the NADPH oxidases Nox1 and Nox4 which have 
been shown to be involved in host defense. Upon IFNγ signaling fibroblasts and epithelial cells induce 
Nox1 and almost all cell types express Nox4 (Manea et al., 2010b; Orient et al., 2007). 
Oxidative stress is caused because ROS and RNS, besides foreign pathogens, also attack own cellular 
molecules (Krüger and Kloetzel, 2012). Protein modifications through oxidative stress include amino 
acid carbonylation, cross-linking of disulfide bonds and cleavage of peptide backbones. Subsequently, 
oxidant-damaged aberrant proteins tend to aggregate in large and dynamic ub-rich cellular inclusions 
called aggresome-like induced structures (ALIS). Such protein aggregations occur in neurons during 
ageing and age-related diseases such as Alzheimer (Mishto et al., 2006), but also transiently during 
physiological processes in various cell types following cytokine stimulation. For example, during the 
maturation of DCs and macrophages following a microbial stimulus large ub-positive protein aggre-
gates transiently accumulate which, in this case, are called dendritic cell aggresome-like induced 
structures (DALIS) (Lelouard et al., 2002). Moreover, stress and starvation induce ALIS in non-
immune cells as it has been shown in fibroblasts (Szeto et al., 2006).  
Irreversibly oxidant-damaged proteins are potentially toxic and require elimination which is mediated 
by autophagy or the UPS in order to preserve cell viability (Fujita and Srinivasula, 2011; Kriegenburg 
et al., 2011; Seifert et al., 2010; Szeto et al., 2006). The removal of oxidized proteins by proteasomes 
is clearly established (Davies, 2001; Grune et al., 1997). Recently, i-proteasomes have been shown to 
contribute to the elimination of oxidatively damaged proteins (Pickering et al., 2010) and therefore to 
protect cells against oxidative stress (Seifert et al., 2010), which will be discussed together with the 
results of this thesis in chapter 4.3. 
 
 
1.5 Virus infection 
During a virus infection virus particles invade living host cells and use them to replicate and to pro-
duce new virus particles. Complete virus replication may kill the infected cell, but some viruses persist 
in cells without fully replicating. In this latent state they can survive for long periods. Viruses are often 
highly adapted to the infection of their host and interfere with the host immune response at different 
levels. These intracellular pathogens represent an immunological challenge in which proteasomal deg-
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radation and MHC class I antigen presentation to virus-specific CD8+ T cells play a crucial role for 
clearance of infection. In this chapter the two employed virus models will be introduced. 
 
1.5.1 Human cytomegalovirus 
Human cytomegalovirus (HCMV) is a worldwide distributed virus with an increasing infection rate of 
approximately 50% in developed states and up to 100% in developing countries (Reddehase, 2002). 
Transmission occurs intrauterine or via exchange of body fluids (Pass, 1985). Therefore, blood trans-
fusion and organ transplantation are common causes of HCMV infection (Pass, 1985). The pathology 
of infection is highly variable in symptoms and progress and, interestingly, shows age-dependent dif-
ferences (de Jong et al., 1998). In 10% of cases, congenital infection results in severe malformation 
of the fetus like microcephaly, deafness, blindness, mental retardation, hepatosplenomegaly and multi 
organ failure (Alford et al., 1990; Jahn et al., 1988). In healthy humans, i.e. in immunocompetent 
individuals, a primary HCMV infection is normally asymptomatic or shows unspecific symptoms like 
fever (Zaia, 1990). However, in immunocompromised humans, such as recipients of transplants and 
bone marrow or HIV patients, HCMV infection can cause severe complications like pneumonia, hepati-
tis, retinitis, enteritis-colitis and neurological disorders with life threatening consequences. This shows 
that the course of infection is strongly dependent on the status of the immune system of the infected 
individual, cytomegaly represents a disease of the immunocompromised (Reddehase, 2002). Also 
newborns are referred to as immunological immature, since they do not possess a fully developed 
immune system.  
HCMV belongs to the family of β-herpesviridae (Roizman and Baines, 1991) and is also known as hu-
man herpes virus 5 HHV5 (Roizman et al., 1981). In cell culture HCMV infection shows a specific cyto-
pathic effect (CPE), which is the characteristic enlargement of infected cells (cytomegaly) with for-
mation of typical intranuclear inclusion bodies, also referred to as ‘owl’s eyes’ (Reddehase, 2002). 
Structure HCMV is an enveloped virus with a large DNA genome and a characteristic virion structure, 
comprising 200 to 300nm in diameter. The virus particle consists of three main structural components: 
the nucleocapsid, the tegument and the envelope (figure 1.8). The nucleocapsid contains the linear 
doublestranded DNA and is built of capsomers forming an icosahedral protein core. Between nucle-
ocapsid and envelope several structural proteins are embedded forming a further layer, the tegument. 
During infection this protein matrix, which constitutes 40% of the protein amount of the virion 
(Gibson, 1996), is delivered to the cytosol. Tegument proteins like the lower-matrix phosphoprotein 
pp65 (UL83) or the upper-matrix protein pp71 (UL82) play roles during assembly and disassembly of 
virus particles, but also function as immunomodulators of the host cell immune response. The viral 
envelope derives from the cytoplasmic membrane of the host and presents a lipid bilayer with inserted 
glycoproteins, e.g. gB, gH, gM and gL (Britt and Mach, 1996). These glycoproteins play a role in the 
attachment to host cell receptors, penetration and uptake into the cells, as well as in the transmission 
of viruses from cell to cell. The genome comprises 235kb and encodes for approximately 200 proteins. 
Thereby, the CMV genome represents the biggest genome of humanpathogenic herpes viruses 
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(Crough and Khanna, 2009). The laboratory strain Ad196, which was used for the infection studies 
described in this thesis, has been fully sequenced and encodes the information for 180 potential open 
reading frames (ORFs) of which the functions are not fully known yet (Jahn and Mach, 1990). In con-
trast to laboratory strains like the Ad169, clinical isolates have an additional 15kb fragment, compris-
ing 22 ORFs, which code mostly for glycoproteins. This difference in the genome results in different 
virulence and cell tropism, since infection with Ad169 causes seroconversion but no CMV disease (Cha 
et al., 1996). 
 
 
Figure 1.8 Structure of HCMV. A CMV particle 
consists of three structural components: envelope, 
tegument and nucleocapsid. The envelope is a lipid 
bilayer with several inserted glycoproteins. The teg-
ument represents a protein matrix composed of 
several different structural proteins. The icosahedral 
nucleocapsid contains the dsDNA genome. 
 
Laboratory strains versus wild type virus The wild type virus possesses the ability to infect lots 
of different cell types in vivo. Targets are epithelial cells, endothelial cells, smooth muscle cells and 
fibroblasts, but also macrophages, neutrophils and mononuclear leukocytes in peripheral blood, 
hepatocytes, neurons and retina cells (Gerna et al., 1992; Grefte et al., 1994). HCMV can therefore 
infect many different organs like brain, heart, lung, placenta and the gastrointestinal tract and occurs 
ubiquitiously in the organism (Sinzger et al., 1995). A possible mechanism is that infected endothelial 
cells may get detached from the basal lamina and circulate in the blood. In such a mechanism, infect-
ed cells eventually get trapped in the fine capillary of organs. As such, the virus may be distributed 
and could cause multiple organ infection (Grefte et al., 1995). Because HCMV is highly host specific, 
investigations in animal models are not possible. Nevertheless, several useful cell culture systems 
have been established to study HCMV infection in vitro for which mostly permissive fibroblast cell lines 
are employed. Consequently, laboratory strains that have been passaged over long time in fibroblasts 
have developed a decreased cell tropism, i.e. they have lost the ability to infect endothelial cells and 
are no longer human pathogenic, in contrast to less passaged clinical isolates (Quinnan et al., 1984). 
Genetically the loss of endothelial cell tropism might be associated to the loss of a genome region 
(Cha et al., 1996), which encodes a factor that is crucial for the transport of viral DNA to the host cell 
nucleus, since the cell tropism is not dependent on virus entry but relies on cellular transport mecha-
nisms by which the viral DNA reaches the nucleus (Sinzger et al., 2008). Also the laboratory HCMV 
strain Ad169 ATCC which was employed for investigations in this thesis exhibits this characteristic. 
Replication cycle HCMV infection is characterized by a slow replication cycle (Emery et al., 1999). A 
full infection cycle in cell culture, from adsorption of the virus to release of newly assembled virus 
particles, lasts 72 hours. Replication resulting in release of new virus particles occurs in epithelial cells, 
endothelial cells and fibroblasts (Plachter et al., 1996), while HCMV persists life long in liver, kidney 
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and lymphoreticulocytes, where it sporadically can be reactivated from latency (Sinclair and Sissons, 
2006). 
The lytic replication cycle, which is displayed in figure 1.9, begins with the adsorption of virus particles 
to the host cell surface which is mediated by glycoproteins (Compton, 2004). HCMV either enters the 
cell via the endocytotic pathway or via direct fusion of the viral envelope with the cell membrane. This 
process, called penetration, releases the nucleocapsid and tegument proteins into the cytoplasm of 
the host cell. Subsequently, the components are transported to the nucleus (Compton, 2004). The 
uncoating, i.e. the release of viral DNA, occurs directly into the nucleus. The expression of viral genes 
is coordinated in a timely cascade of three overlapping phases: immediate early (IE phase, 0 to 2h), 
early (E phase, up to 24h), late (L phase, after 24h) (Crough and Khanna, 2009). Despite the relative-
ly slow replication cycle of 72h to the production of new virus particles, the expression of IE genes 
starts directly after virus entry and is initiated by tegument proteins. In turn these IE genes code for 
proteins that function as transactivators of early genes and some late genes, but also trigger expres-
sion of cellular genes. During the early phase proteins involved in viral DNA replication and repair as 
well as immunomodulatory gene products are synthesized. During the late phase structural proteins 
for the assembly of new virus particles like tegument and capsid proteins are transcribed. The assem-
bly of the capsid and the packing of the viral DNA takes place in the nucleus. A secondary envelop-
ment process including tegument proteins occurs at the endoplasmic reticulum Golgi intermediate 
compartment (ERGIC). Final envelopment and egress then releases virus particles by exocytosis at the 
plasma membrane. 
	  
Figure 1.9 Replication cycle of HCMV. HCMV enters the cell either via direct fusion with the host cell 
membrane or via the endocytotic pathway. Attachment of viral glycoprotein to specific host cell surface receptors 
is followed by penetration, which releases the viral nucleocapsid into the cytoplasm. Subsequently, nucleocapsids 
are transported into the nucleus, where viral DNA is released during the uncoating. The viral gene expression 
cascade begins with the translation of IE genes, which in turn transactivate E genes and cellular genes and coor-
dinate viral replication. During the early and late phase further proteins for viral DNA replication and encapsula-
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tion are produced. Capsids are transported from the nucleus to the cytoplasm. The envelopment with tegument 
proteins occurs at the ERGIC and is followed by the final envelopment and exocytosis at the plasma membrane. 
Antiviral immune response and viral countermeasures HCMV infection is efficiently controlled 
by the innate as well as the adaptive immune response. Most important to control the spread of the 
virus are cellular immune mechanisms. In particular, dendritic cells recognize viral glycoproteins 
(Juckem et al., 2008), internalize virus particles and present viral antigens to virus-specific CTLs 
(Arrode and Davrinche, 2003), which subsequently lyse infected cells and block virus replication by 
secretion of IFNγ (Davignon et al., 1996). 
Part of the innate immune response to HCMV infection are Toll-like receptors and the type I interferon 
response. Activation of TLRs activates signal transduction pathways that lead to secretion of inflam-
matory cytokines and the upregulation of costimulatory molecules like CD80 and CD86. For example, 
an interaction of the viral glycoproteins gB and gH with TLR2 results in activation of NFκB (Compton 
et al., 2003).  
The adaptive immune response to HCMV includes humoral responses as well as T cell-mediated im-
munity. The production of antibodies restricts viral dissemination and limits the severity of disease 
(Boppana and Britt, 1995). The glycoprotein gB is a major target for neutralizing antibodies (Britt et 
al., 1990), but the predominant mechanism controlling the spread of HCMV infection is the induction 
of strong CD8+ T cell responses. An essential role for HCMV-specific CD8+ T cells was shown by 
Reusser and colleagues, who found that half of the patients lacking a detectable anti-HCMV T cell 
response developed HCMV disease (Reusser et al., 1991). Further work showed that infusion of do-
nor-derived HCMV-specific CD8+ T cells effectively restored antigen-specific cellular immunity in BMT 
recipients (Riddell et al., 1992; Walter et al., 1995). Moreover, high frequencies of IE1-specific CD8+ T 
cells correlated with protection from HCMV disease in heart and lung transplant recipients (Bunde et 
al., 2005). 
The fine specificity of HCMV-specific CD8+ T cell responses and the viral antigens against which they 
are directed have been comprehensively examined in healthy HCMV-seropositive donors. A variety of 
virus proteins was shown to be recognised, including structural proteins as well as immunomodula-
tors, viral proteins expressed at different stages (IE, E and L antigens) and with diverse functions 
(capsid, tegument, glycoproteins, immunoevasins). Examples are: pp28, pp50, pp150, gH, gB, US2, 
US3, US6, US11, UL16, UL18.  Ex vivo T cell assays revealed that CD8+ and CD4+ T cells are directed 
towards more than 70% of the virus ORFs (Elkington et al., 2003). To the most frequently recognised 
antigens belong the immediate-early protein 1 IE1, also known as UL123 or pp72 a transcription fac-
tor of 72kDa (Kern et al., 1999), and the phosphoprotein pp65 (UL83) (McLaughlin-Taylor et al., 
1994).  
The lower matrix protein pp65 (UL83) is a phosphoprotein of 65kDa and the major component of the 
tegument. Apparently pp65 has no essential function for the virus replication (Schmolke et al., 
1995b), but plays an important role during the assembly of virus particles (Chevillotte et al., 2009). 
During virus entry, pp65 is delivered from the tegument directly into the cytosol of the host cell. Via a 
C-terminal nuclear localization signal (NLS) pp65 translocates directly after infection into the nucleus, 
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where it is observed within five minutes after infection (Schmolke et al., 1995a). Due to this pro-
cessing pp65 gains access to the antigen processing machinery before the virus replication starts 
(Reddehase, 2002) and represents the most dominant antigen for activation of the cellular immune 
response (McLaughlin-Taylor et al., 1994). Therefore pp65-derived antigens play an important role for 
the early control and limitation of HCMV infection. Of all HCMV-specific CD8+ T cells 70 to 90% recog-
nize MHC class I presented pp65 antigenic peptids (Wills et al., 1996). Often the HCMV-specific CD8+ 
T cell population is focused on only one peptide (Weekes et al., 1999). One of these is the immu-
nodominant, HLA-A2 restricted pp65 epitope comprising the aminoacids 495 to 503, therefore called 
pp65495-503 (sequence: NLVPMVATV). Presentation of this epitope is detected in persistent infection 
despite HCMV immune escape mechanism (Besold et al., 2007). The phosphoprotein 65 itself exhibits 
immunomodulatory effects, for example it interferes with MHC class II surface expression (Odeberg et 
al., 2003), limits the cytotoxicity of natural killer cells (Arnon et al., 2005), inhibits the proteasomal 
processing of IE1 preventing thereby the presentation of IE1-derived antigenic peptides (Gilbert et al., 
1996) and impedes cell cycle progression (Castillo and Kowalik, 2002; Zhu et al., 1995).  
The human cytomegalovirus is highly adapted to the infection of its host and has developed many 
strategies to subvert the immune control at different levels. To evade recognition and elimination by 
the host immune system many HCMV gene products possess specific immunomodulatory functions, 
such as the impairment of MHC function, inactivation of leukocytes, inhibition of cytokine production, 
arrest of the cell cycle and decrease of the humoral immune defense (Mocarski, 2004). The major 
evasion mechanism is concentrated on the inhibition of MHC class I restricted antigen presentation. 
Four HCMV glycoproteins interfere with this pathway and trigger rapid downregulation of MHC class I 
surface expression: US2, US3, US6 and US11. US2 and US11 mediate the retrograde transport of 
newly synthesized MHC class I molecules from ER to cytosol, where they are ubiquitylated and de-
graded by the proteasome (Wiertz et al., 1996). US3 inhibits the transport of loaded MHC class I 
complexes to the cell surface, which therefore accumulate in an ER-associated compartment (Ahn et 
al., 1996). US6 is a transmembrane protein that interacts with TAP and thus impairs TAP function 
(Ahn et al., 1997; Hengel et al., 1996). Further Halenius and colleagues found a transcriptional down-
regulation of TAP2 and TAP1 gene expression in HCMV-infected cells (Halenius et al., 2011). 
 
1.5.2 Influenza A virus  
According to the World Health Organisation WHO (www.who.int), each year seasonal influenza virus 
infections affect 3 to 5 million people resulting in up to 500.000 death cases globally. The severity of 
illness can range from mild, cold-like symptoms, to death (Wright et al., 2007), which occurs mainly 
among high-risk groups like young children, elderly or chronically ill people. Over the last century eve-
ry 10 to 40 years an influenza pandemic, i.e. a global epidemic, has occurred (Wright et al., 2007). 
The most devastating recorded pandemic, the Spanish flu, occurred in 1918 (influenza A subtype 
H1N1). Worldwide 40 million humans died and an estimated number of 700 million was infected 
(Johnson and Mueller, 2002). Moreover, unusually large numbers of especially young people died 
during the 1918 influenza pandemic (Reid and Taubenberger, 2003). Less severe pandemics occurred 
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in 1957, the Asian flu (H2N2), in 1968, the Hong Kong Flu (H3N2), and in 1977, the Russian flu 
(H1N1) (Cox and Subbarao, 2000). The transmission of the influenza virus results via droplet infec-
tion, but also via contact with a contaminated surface or an infected individual.  
Structure The influenza A virus belongs to the family of orthomyxoviridae, which is characterized by 
a linear single-stranded and segmented RNA genome of negative polarity. The virus particle is pleo-
morph in shape and comprises 80 to 120nm in diameter. The genome of the influenza A virus is com-
posed of 8 RNA segments, which constitute 13kb of sequence encoding for up to 11 proteins. Nine of 
these proteins represent structural proteins building the virus particle: three polymerase polypeptides 
PB1, PB2 and PA; the nucleoprotein NP; three proteins present in the lipid envelope of the virion, the 
glycoproteins hemagglutinin HA and neuraminidase NA as well as the pH-dependent ion channel M2; 
the matrix protein M1; and the nuclear export protein NEP (also known as NS2). Furthermore two 
proteins, PB1-F2 and the nonstructural protein NS1 can only be found in infected cells (Figure 1.1010) 
(Nayak et al., 2009).  
An interesting feature of the influenza genome is that it is packed in viral ribonucleoprotein complexes 
(vRNPs). While the nucleoprotein NP is complexed with the viral RNA (vRNA), trimeric viral polymer-
ase complexes composed of PB1, PB2 and PA bind to the ends of the vRNPs (Klumpp et al., 1997). 
The transmembrane glycoproteins HA and NA fulfill important tasks during the attachment, penetra-
tion and budding of virus particles. The HA protein plays two major roles: i) binding to sialic acid re-
ceptors on the host cells; and ii) fusion of virus and host endosomal membranes (Daniels et al., 
1987). The neuraminidase NA cleaves sialic acid residues of newly formed viral and cellular glycopro-
teins, thereby promoting the release of virus particles from the host cell (Gottschalk, 1958). The M2 
protein plays an important role in the uncoating process, which ends with the release of RNP com-
plexes into the cytoplasm of the host cell. The conduct of protons from the acid environment of the 
endosome into the virion through the M2 ion channel allows vRNP complexes to dissociate from M1 
proteins. Furthermore, the matrix protein M1 constitutes the tegument and possesses several func-
tions: i) it acts as a chaperone during virus assembly, ii) it aids the export of vRNPs out of the nucleus 
and iii) it recruits vRNPs to the virion assembly sites at the plasma membrane (Bouvier and Palese, 
2008). The nonstructural protein NS1 influences the cellular transport, splicing and translation of 
vRNA. Further, both NS proteins, NS1 and NS2, block the induction and signaling of type I IFNs, and 
so they represent IFN-antagonists (Palese and Shaw, 2007; Wright et al., 2007).  
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Figure 1.10 Structure of the influenza A 
virus. An influenza virus particle is composed of 
the following proteins: hemagglutinin (HA), neu-
raminidase (NA), matrix protein 1 (M1), matrix 
protein 2 (M2), nonstructural protein NS1 and 
NS2, nucleoprotein (NP), trimeric polymerase 
complex constituted of PB1 (polymerase basic 1), 
PB2 (polymerase basic 2) and PA (polymerase 
acid). Figure adapted from (Horimoto and 
Kawaoka, 2005). 
 
 
Influenza viruses are classified into subtypes based on the antigenicity of their viral surface molecules 
HA and NA. There are 16 different HA and 9 different NA subtypes known, which are used for the 
naming of influenza subtypes according to the scheme HxNx. These different types of surface anti-
gens have an impact on host specificity and virulence. Point mutations in the HA and NA genes result 
in virus variants that can no longer be recognized by pre-existing host immunity, which was directed 
at the ‘parent’ virus (Hensley et al., 2009). This process accounts for the antigenic drift that is com-
mon among orthomyxoviruses and is the reason for the yearly flu epidemics.  
The segmentation of the influenza genome allows the exchange of single RNA gene segments, there-
by leading to another phenomenon, the antigenic shift. When two different virus subtypes infect the 
same cell, they are able to reassort their genome segments and thereby can generate a new influenza 
strain. Antigenic shift results in high infection rates in immunologically naive populations, which can 
possibly lead to the occurrence of pandemics (Wright et al., 2007).  
Replication cycle The primary infection site of influenza A virus represents human epithelial cells of 
the upper respiratory tracts. However, the virus also replicates in monocytes, macrophages and other 
leukocytes (Majde, 2000). The replication cycle begins with the binding of HA proteins to sialic acid-
containing receptors of the host cells. This adsorption process is followed by receptor-mediated endo-
cytosis resulting in an up-take of virus particles into endosomal vesicles. Due to the lower pH inside 
the endosomes a proton influx via M2 ion channels takes place and leads to conformational changes 
of HA glycoproteins, which results in the fusion of endosomal and viral membranes. The release of 
vRNPs into the cytosol is mediated with the help of matrix protein M1 which finishes the uncoating 
process (Bui et al., 1996). The whole process of uncoating beginning with the attachment of virus 
particles to the host cell takes no more than 25 minutes. Already after another 10 minutes vRNPs 
enter the nucleus (Martin and Helenius, 1991). This occurs because vRNPs are featured with nuclear 
localization sequences (NLS) which interact with host cell importing mechanisms (Boulo et al., 2007). 
Inside the nucleus mRNA for protein biosynthesis and complementary cRNA for synthesis of new vRNA 
is transcribed. The ribosomal synthesis of early viral proteins subsequently takes place in the cyto-
plasm. Afterwards early virus proteins are actively and passively transported back into the nucleus. 
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There, the replication of vRNA and the transcription of mRNA for the late structural proteins HA, NA, 
M1 and M2 occurs. The active export of newly synthesized nucleocapsids is dependent on the M1 
protein. Subsequently the late structural proteins are translated and glycosylated. Finally, all viral 
components localize to the apical plasmamembrane of the polarized epithelial cells, where the packing 
and budding of new virus particles mediated by HA and NA takes place (Nayak et al., 2004). 
Antiviral immune response to influenza A For the immune response to influenza A infection in-
nate as well as adaptive immune mechanism play important roles. The production of cytokines like 
TNFα, IL1 and IL6, chemokines like MIP-1α and RANTES, but especially the type I interferon response 
are of crucial importance. Via interaction with Toll-like receptors TLR3 and TLR7 as well as the RNA 
helicases RIG-I and MDA5 the NFκB and MAPK signaling pathways are activated. Through activation 
of the transcription factors IRF3 and IRF7 the production of IFNα and IFNβ is induced (Wright et al., 
2007).  
A special relevance is attached to the innate immune response of respiratory epithelial cells. Some 
highly pathogenic influenza A subtypes like the avian H5N1 virus can cause massive viral pneumonia, 
systemic disease and death due to enhanced cytokine and chemokine production. A so-called ‘cytokine 
storm‘ can damage the lung tissue and contribute to pathology instead of controlling viral replication 
(Oslund and Baumgarth, 2011). 
Notably, the nonstructural protein NS1 represents an antagonist of the type I IFN response. Deletion 
of NS1 leads to 100-fold enhanced IFNα production in comparison to infection with wild type virus.  
One mechanism by which NS protein is believed to inhibit IFN induction is by sequestering viral repli-
cation intermediates and thus masking them from RNA sensors, e.g. preventing activation of RIG-I 
(Pichlmair et al., 2006). NS1 is also supposed to impair activation of the OAS/RNaseL pathway (Min 
and Krug, 2006) as well as of the translation inhibitory kinase PKR (Li et al., 2006). 
Humoral immunity encounters a special challenge during influenza infection, since antibody responses 
are often strain-specific and even drive the antigenic drift, especially when directed against the he-
magglutinin molecule (Kreijtz et al., 2011). Cellular immunity includes virus-specific CD4+ T helper 
cells and CD8+ cytotoxic T cells. These cells are mainly directed against conserved proteins and there-
fore could provide protection against different influenza A subtypes and potentially pandemic influenza 
viruses (Kreijtz et al., 2011). One well described immunodominant antigenic peptide represents the 
HLA-A2 restricted M158-66 epitope, which derives from Matrix protein 1 and comprises the amino acids 
58 to 66 (sequence: GILGFVFTL) (Bednarek et al., 1991; Gotch et al., 1987; Morrison et al., 1992). 
 
1.6 Aims and objectives 
Recently, an important new role for the i-proteasome in the clearance of oxidatively damaged proteins 
has been discovered and widely discussed. It has long been accepted that the proteasome plays an 
important role in the elimination of toxic aggregates of accumulating oxidant-damaged proteins, but 
lately the i-proteasome has been demonstrated to clear ub-rich protein aggregates more efficiently 
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during inflammation-induced stress. Further, within a virus infection it could be demonstrated that i-
proteasome deficiency contributes to tissue damage and disease progression as a consequence of lack 
of protection against oxidative protein damage. The concept of the i-proteasome to solely represent a 
component of the MHC class I antigen presentation pathway promoting the generation of antigenic 
peptides has profoundly changed and new functions of the i-proteasome in non-immune cells have 
emerged. 
Within this thesis the long-established role of the i-proteasome during the generation of MHC class I 
ligands has been investigated and linked to its function in efficient degradation oxidant-damaged pro-
teins. Therefore, several key questions were raised, wich have been analysed in infected target cells:  
- How fast is the induction of i-proteasomes in non-immune cells in response to viral infection? 
- Does the i-proteasome exhibit a special composition and does i-proteasome induction affect 
the generation of immunodominant epitopes? 
- Which signalling pathways lead to the rapid induction of i-proteasome formation in response 
to virus infection? 
- Where do viral proteins derive from in order to provide the supply for the proteasome to gen-
erate antigenic peptides?  
- At which rate are reactive oxygen species induced and to which extent do they cause oxida-
tive damage inside the infected cells with respect to endogenous and viral proteins?  
- Does oxidative damage of viral proteins affect the antigen presentation of immunodominant 
epitopes? 
- What is the source of reactive oxygen species in response to viral infection, focusing on the 
role of NADPH oxidases? 
 
To address these questions two different virus infection models in cell culture were chosen: i)  human 
cytomegalovirus infection in fibroblasts, as example for a large DNA virus which is highly adapted to 
the infection of its host, and ii) the influenza A virus which represents a small and fast replicating RNA 
virus. An effective immune response controlling the spread of both viruses is predominantly mediated 
by CD8+ T cell responses directed against immunodominant virus epitopes.  
In summary, this work brings together the different functions of the i-proteasome during the response 
to inflammation-induced oxidative stress and during antigen presentation.  
Methods  P a g e  | 31 
2. Methods 
2.1 Cell biological methods 
2.1.1 Cell culture reagents 
Substance Supplier 
Basal Iscove medium 
RPMI1640 
OptiMEM 
Biocoll 
human AB-Serum 
Fetal calf serum (FCS) 
L-glutamine 
Trypsin/EDTA 
Dimethylsulfoxid (DMSO) 
Penicilline/Streptomycine 
Gentamycine 
Puromycine 
Hygromycine B 
Epoxomicin 
Sulforaphane 
Cycloheximide 
BX-795 
MMHAR-2 (CD118) 
Interleukin 2 (IL-2) 
Interleukin 6 (IL-6) 
Interleukin 12 (IL-12) 
Interleukin 4 (IL-4) 
GMCSF 
Phytohaemagglutinin (PHA) 
Lipopolysaccharide (LPS) 
human Interferon-α (hIFN-α) 
human Interferon-β (hIFN-β) 
human Interferon-γ (hIFN-γ) 
Lipofectamin 2000 transfection reagent 
HiPerfect transfection reagent 
DMSO 
Trypane blue Solution 
ActinomycinD 
MTT  
BrefeldinA 
Biochrom AG 
Biochrom AG 
Gibco 
Biochrom AG 
PromoCell 
Biochrom AG 
PAA Laboratories GmbH 
PAA Laboratories GmbH 
Sigma Aldrich 
PAA Laboratories GmbH 
LONZA 
PAA Laboratories GmbH 
Roche 
Calbiochem 
LKT Laboratories 
Sigma Aldrich 
Axon Medchem 
R&D Systems 
Chiron Therapeutics 
Strathmann Biotec 
Strathmann Biotec 
Strathmann Biotec 
Fa Berlex 
Sigma Aldrich 
Sigma Aldrich 
Miltenyi Biotec 
Miltenyi Biotec 
Roche 
Invitrogen 
Qiagen 
Roth 
Sigma Aldrich 
Sigma Aldrich 
Sigma Aldrich 
Sigma Aldrich 
Table 2.1 Used cell culture reagents. 
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2.1.2 Cell lines and media 
BASAL ISCOVE’s Medium + 2mM L-glutamine + 10% FCS (heat inactivated) + antibiotics (see table 
2.2) 
RPMI1640 Medium + 2mM L-glutamine + 10% FCS (heat inactivated) + antibiotics (see table 2.2). 
For cultivation of cytotoxic T lymphocytes FCS was replaced by 10% human AB serum (heat inactivat-
ed). 
All cells were cultivated in sterile cell culture dishes from Greiner in their respective media at 37°C, 
5% CO2 and 95% humidity. 
 
Notation Cell type Culture Media Antibiotics 
HeLa human cervix epithelial 
carcinoma 
Adherent Basal 
ISCOVE 
100U/ml penicillin + 
100µg/ml streptomycin 
HeLa A2+ HLA-A2 positive HeLa cell, 
stable expressing MHC 
class I HLA-A*0201 
Adherent Basal 
ISCOVE 
100U/ml penicillin + 
100µg/ml streptomycin + 
2µg/ml puromycin  
MRC5 Human lung fibroblast 
(ATCC CCL-171) 
Adherent Basal 
ISCOVE 
50µg/ml gentamycin 
EBV-B Epstein-Barr virus trans-
formed human B-
lymphocyte 
Suspension RPMI1640 100U/ml penicillin + 
100µg/ml streptomycin 
WEHI Lymphoma cell line Suspension RPMI1640 100U/ml penicillin + 
100µg/ml streptomycin 
CTL cytotoxic T lymphocyte Suspension RPMI1640 100U/ml penicillin + 
100µg/ml streptomycin 
Table 2.2 Used human cell lines, their appropriate media and respective antibiotic additive. 
 
2.1.3 Transfection of cells 
Transfection of plasmid DNA 
Transfection of plasmid DNA (table 2.3) in human lung fibroblasts was conducted according to manu-
facturer’s instructions with Lipofectamin 2000. The ratio of DNA to Lipofectamin was adjusted. After 6 
to 8h of transfection the cell culture medium was exchanged with fresh medium and cells were further 
cultivated according to the respective protocol. 
 
Notation Insert Vector Supplier/source 
pcDNA3.1-Zeo/lacZ 
pCAT-PSMB9 
lacZ (ORF) 
part of the PSMB9 
promoter 
pcDNA3.1-Zeo(+) 
pCAT3basic 
Invitrogen 
J. Steffen 
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Table 2.3 Used plasmids and DNA constructs. 
Transfection of siRNA 
Transient transfection of siRNA (table 2.4) was conducted with HiPerfect. Transfection reagent and 
siRNA were diluted in optiMEM transfection medium and added drop wise onto the cells directly after 
these were plated and still in suspension. Due to this fast forward procedure the transfection efficien-
cy could be highly improved for the strongly adherent fibroblasts. All used siRNAs were employed in a 
final concentration of 25 to 50nM and incubated for 48h. Subsequently, the knockdown was either 
directly confirmed by western analysis and PCR or was followed by further experiments as described. 
 
siRNA Dharmacon catalogue number 
IRF3 
Nox1 
Nox4 
PSMB8 
PSMB9 
PSMB10 
PSMD4 
PSME1 
PSME2 
UBE2L6 
OFF-target 
L-006875-00-0005 
L-010193-00-0005 
L-010194-00-0005 
L-006022-00-0005 
L-006023-00-0005 
L-006019-00-0005 
L-011365-00-0005 
L-012254-00-0005 
L-011370-01-0005 
L-008569-00-0005 
D-001810-10-05 
Table 2.4 All used ON-TARGET plus siRNAs were purchased from Thermo Scientific Dharmacon. 
 
2.1.4 Interferon stimulation 
HeLa cells and MRC5 fibroblasts were treated with 10ng/ml human IFNα, 10ng/ml human IFNβ or 
100U/ml human IFNγ. Analysis of stimulated cells was carried out after indicated time points.  
 
2.1.5 Virus infection 
The human cytomegalovirus (HCMV) laboratory strain Ad169 variant ATCC was kindly provided from 
Prof. Hartmut Hengel (University hospital Düsseldorf). The human influenza A viruses (IAV) APR8 as 
well as KPV (classical bird flu) were obtained from Dr. Michael Veit (Free University Berlin). 
For viral infection target cells were plated in 6-well cell culture plates with an approximated density of 
1x106 cells/well at the day of infection. The virus titer was diluted to a concentration of 3 to 5x106 
virus particles/ml in cell culture medium so that addition of 1ml virus suspension in one 6-well yielded 
a multiplicity of infection (moi) of 3 to 5, i.e. one cell was infected by 3 to 5 virus particles. For the 
timely synchronization of infection the 6-well plates were centrifuged twice for 15min at 2000rpm and 
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37°C, after 15min the plates were rotated by 180° in order to guarantee a fast and simultaneous at-
tachment of the virus particles to the cells all over the well (personal communication with Anne Hale-
nius, University hospital Düsseldorf). After several time points the infected cells were harvested and 
further treated according to the described protocols. 
 
2.1.6 Generation of epitope-specific CTL 
CTL clones specific for the HLA-A0201 (A2+) restricted viral epitopes M158-66 derived from influenza A 
(Bednarek et al., 1991; Gotch et al., 1987; Morrison et al., 1992) and pp65495-503 from HCMV 
(Diamond et al., 1997; McLaughlin-Taylor et al., 1994; Wills et al., 1996) were generated as described 
by Fonteneau et al. (Fonteneau et al., 2001) with the help of peptide-pulsed dendritic cells (DCs). 
Therefore, peripheral blood mononuclear cells (PBMCs) were isolated from fresh buffy coats via biocoll 
gradient centrifugation. PBMCs of different donors were analysed for HLA-A2+ MHC class I by FACS 
with FITC-labeled anti-HLA-A2+ antibody. In order to separate monocytes from the PBMCs of HLA-A2+ 
donors magnetic cell separation (MACS® Milteny Biotec) was used. In a first step CD14+ monocytes 
were directly labeled with MACS® microbeads, a CD14 receptor coupled to a magnetic particle. The 
magnetically labeled cells were detained inside the MACS® LS Column as long as the column was 
placed in the MACS® separator in a strong magnetic field. Removing the LS column from the magnetic 
field released CD14+ monocytes. The flow through from the first separation step was further used for 
isolation of CD8+ monocytes via anti-CD8 MACS® microbeads. The CD8+ cells were frozen for the time 
being in 90% FCS and 10% DMSO. The CD14+ cells were further differentiated to DCs which therefore 
were cultivated in big cell culture flasks under addition of 100U/ml Interleukin-4 (IL-4) and 500U/ml 
granulocyte macrophage colony-stimulating factor (GMCSF). After the fifth day the CD14+ monocytes 
were transferred onto 24-well plates covered with 3% poly-MA in order to prevent adhesion of the 
dendritic cells and stimulated by addition of 500U/ml GMCSF, 100U/ml IL-4 and 1µg/ml lipopolysac-
charides (LPS). The following day, dendritic cells were harvested and pooled, adjusted to a cell num-
ber of 1x106 cells/ml and pulsed for 1h on ice with 10µg/ml M158-66 or pp65495-503 peptide, respectively. 
Subsequently, CD8+ monocytes were thawed and cocultivated with the autologous peptide-loaded 
DCs. Therefore, 2x105 CD8+ cells were combined with 2x104 DCs in 96-well cell culture plates in RPMI 
medium supplemented with 10% human AB serum, 1000U/ml recombinant human IL-12 and 
1000U/ml human IL-6. A restimulation by repeated addition of peptide-pulsed DCs and the growth 
factor IL-2 in a final concentration of 20U/ml was carried out after 7 days. After one further week of 
cocultivation T cells were tested for peptide specificity by TNFα assay (see chapter 2.1.7.1). Moreover, 
positive wells were verified by intracellular cytokine staining (see chapter 2.1.7.2). Finally, confirmed 
wells were selected for cloning of an epitope-specific T cell clone by limiting dilution in the presence of 
irradiated feeder cells, IL-2 and phytohaemagglutinin (PHA). 
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2.1.7 CTL assay 
For testing polyclonal CTLs for peptide specificity TNFα assay and intracellular cytokine staining were 
performed. In order to investigate antigen presentation on virus-infected cells IFNγ assays were used. 
2.1.7.1 TNFα   assay 
As target HLA-A2+ HeLa cells were employed with and without loading of 10µg/ml peptide (pp65495-503 
and M158-66 respectively) for 15min on ice. 5x104 target cells were cocultivated for 3 to 6h at 37°C in 
96-well plates with the CTLs to be tested. At the same time TNFα-sensitive WEHI cells were cultivated 
in RPMI1640 supplemented with 1M lithium chloride and actinomycin D. The supernatant of the cocul-
tivation was added to 3x106 WEHI cells/well and incubated over night. Addition of 2.5mg/ml MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromid) and incubation for 3h at 37°C induces a 
colour reaction based on the reduction of the yellow tetrazolium salt into purple formazan by enzy-
matic activity reflecting the glycolysis rate. A decreased colour change therefore indicated decreased 
cell viability. The insoluble purple formazan was dissolved by addition of 10% SDS and the absorbance 
of the coloured solution was measured at 550nm. Thus, TNFα-sensitivity of WEHI cells showed pep-
tide-specific activation of the CTLs. 
2.1.7.2 Intracellular cytokine staining 
Again HLA-A2+ HeLa cells with and without peptide loading were co-incubated in 96-well cell culture 
plates with the CTLs to be tested for peptide specificity. The addition of 10µg/ml Brefeldin A impeded 
the transport of IFNγ through the Golgi apparatus out of the cell. After incubation over 5 to 6h at 37°C  
the cells were analysed by flow cytometry with PE-coupled anti human IFNγ antibody (see table 2.6). 
2.1.7.3 INFγ   assay 
To analyse epitope presentation after viral infection of MRC5 fibroblasts with HCMV or HLA-A2+ HeLa 
cells with IAV, respectively, the release of IFNγ by activated epitope-specific CD8+ T cells was meas-
ured. Target cells were seeded and infected in 6-well cell culture plates and depending on the exper-
iment pre-treated according to the protocol. Cellular proteasome function was inhibited by adding 
200nM epoxomicin directly after virus infection. Viral gene expression was abolished either by UV 
radiation (5000 J/m²) or by adding 50 µg/ml of the translation inhibitor cycloheximide 1h prior to 
virus infection. To prevent ROS formation the isothiocyanate sulforaphane was added in a final con-
centration of 10µM 24h prior to virus infection. 1µM of the kinase inhibitor BX-795 and 10µg/ml neu-
tralizing monoclonal antibody MMAHR2 were added to the cells 1h prior to virus infection. Application 
of siRNA (see chapter 2.1.3) was performed 48h prior to infection and analysis of antigen presenta-
tion. 
The assay was performed in round bottom 96-well cell culture plates. The target cells were harvest-
ed, washed, adjusted to a cell number of 6x105 cells/ml and seeded in an 8-fold dilution series start-
ing with 50µl i.e. 3x104 cells. The epitope-specific CTLs generated as described in chapter 2.1.6 were 
freshly thawed, washed and also adjusted to a cell number of 6x105 cells/ml. Per well 3x104 CTLs 
were seeded resulting in different effector to target cells ratios ranging from 1:1 to 1:128. As control, 
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each sample was loaded with 0.5 µg/ml synthetic pp65495-503 or M158-66 peptide, respectively. Target 
cells and effector CTLs were cocultivated at 37°C over night. The next day the culture plates were 
centrifuged for 7min at 2000rpm and 4°C. The supernatant containing the released IFNγ in case of 
CTL activation was collected and frozen at -20°C prior to the further analysis. The activation of 
epitope-specific CTL could then be determined by quantification of secreted IFNγ by ELISA following 
manufacturer’s instructions (see chapter 2.3.1). The CTL response was expressed as percentage re-
garding the peptide-loaded control samples as 100% response. 
 
2.1.8 CAT assay 
MRC5 cells were pre-treated for 48h with 25nM off-target as well as IRF3-targeting siRNA (Dharma-
con) as described above. Subsequently, 5x105 cells were transfected with 2µg β1i-CAT construct pro-
vided by Dr. Janos Steffen and 2µg pcDNA3.1-Zeo/LacZ as an internal control according to the 
Lipofectamin 2000 manual. After 8h of transfection cells were infected with HCMV Ad169 at moi 3 to 
5 and harvested 8h post infection. The CAT-concentrations in all samples were measured with CAT-
ELISA kit from Roche and normalized against β-galactosidase activity, which was determined by 
cleavage of CPRG substrate. 
 
2.2 Biochemical methods 
2.2.1 Chemicals and antibodies 
Chemical Method Supplier 
ECL PlusTM  
BCA Protein Assay Kit 
OxyBlotTM protein oxidation 
detection kit 
Protein G Sepharose 4FF 
Suc-LLVY-AMC 
Western Blot 
Western Blot 
Western Blot 
 
Immunoprecipitation 
Native Gel Overlay 
Inhibitor 
Inhibitor 
Inhibitor 
Inhibitor 
GE Healthcare 
Thermo Fisher Scientific 
Chemicon International 
 
GE Healthcare 
Bachem 
Sigma-Aldrich 
Calbiochem 
Roche 
VWR International 
N-Ethylmaleimide (NEM) 
Epoxomicin 
Complete® Inhibitor Mix 
MG132 
Table 2.5 Chemicals 
Antibody Method Origin Supplier 
anti-human-HLA-A2-FITC clone BB7.2 
anti-human-HLA-A,B,C-PE 
anti-human IFN-γ-PE 
PE/FITC-labeled IgG1/2a isotype control 
FACS 
 
 
 
mouse 
mouse 
mouse 
mouse 
BD Biosciences                                      
BD Biosciences 
BD Biosciences 
BD Biosciences 
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anti-pp65 (MA1-7597) 
anti-Ubiquitin (FK2) 
anti-pp72 (6E1) 
anti-α2 (MCP21) 
anti-pp65 (CH12) 
anti-M1 (ab34848) 
anti-Lmp7 
anti-Lmp2 
anti-Mecl1 (K223) 
anti-α4 
anti-β5 
anti-β2 (mcp168) 
anti-POMP 
anti-PA28α 
anti-PA28β 
anti-Rpn10 (S5a) 
anti-GAPDH 
anti-UBE2L6 
anti-phosphoS6 
anti-Stat1 (9172) 
anti-phospho-IRF3 (Ser396) 
anti-IRF3 
anti-p53 (DO7) 
anti-Ubiquitin (FK2) 
anti-Ubiquitin (FK1) 
anti-Ubiquitin 
anti-rabbit-HRP 
anti-mouse-HRP 
anti-goat-HRP 
Alexa Fluor 633 anti-mouse IgG 
Alexa Fluor 488 anti-mouse IgM 
Alexa Fluor 488 anti-rabbit IgG  
IP, IF 
 
 
 
WB primary ab 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
WB secondary ab 
 
 
IF secondary ab 
 
 
mouse 
mouse 
mouse 
mouse 
mouse 
goat 
rabbit 
rabbit 
rabbit 
rabbit 
rabbit 
mouse 
rabbit 
rabbit 
rabbit 
mouse 
rabbit 
mouse 
rabbit 
rabbit 
rabbit 
rabbit 
mouse 
mouse 
mouse 
rabbit 
goat 
rabbit 
donkey 
goat 
goat 
goat 
Thermo Scientific 
Biomol 
Santa Cruz 
AG Kloetzel 
Santa Cruz 
Abcam 
AG Kloetzel 
AG Kloetzel 
AG Kloetzel 
AG Kloetzel 
AG Kloetzel 
AG Kloetzel 
AG Kloetzel 
AG Kloetzel 
NEB 
AG Kloetzel 
Santa Cruz 
Abnova 
CellSignaling 
CellSignaling 
Millipore 
Santa Cruz 
Novocastra 
Biomol 
Biomol 
Dako 
Dianova 
Seramun 
Dianova 
Invitrogen 
Invitrogen 
Invitrogen 
Table 2.6 Antibodies (ab: antibody; IF: immunofluorescence; IP: immunoprecipitation; WB: Western blot) 
 
2.2.2 SDS-PAGE and Western analysis 
2.2.2.1 Cell lysis 
RIPA lysis buffer: 50mM Tris-HCl, 150mM NaCl, 1% (v/v) Nonidet P40, 0.5% (w/v) Sodium-
deoxycholate, 0.1% (w/v) SDS and Complete, adjusted to pH 8.0 with NaOH 
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Triton lysis buffer: 50mM Tris-HCl, 50mM NaCl, 5mM MgCl2, 0.1% (v/v) Triton X-100 and Complete, 
adjusted to pH 7.5 with NaOH 
After harvesting the cells were washed once in 1ml ice-cold 1x PBS and centrifuged. The pellet was 
resuspended in lysis buffer. In case of preparation of lysate for analysis of ubiquitin conjugates the 
lysis buffer was additionally completed with 1µM epoxomicin and 10mM NEM. Lysis with RIPA buffer 
was carried out for 1h on ice with occasional vortexing. Cell pellets lysed with Triton lysis buffer were 
subjected 3-times to freeze and thaw in liquid nitrogen. In order to separate lysate from cell debris 
the lysates were centrifuged for 20min at 14.000rpm and 4°C. The supernatants were collected and 
stored at -80°C for further experiments such as immunoprecipitation or SDS-PAGE. The protein con-
centration was determined with BCA protein assay kit according to manufactures instructions in micro-
titer plates. 
2.2.2.2 Sodiumdodecylsulfoxide-polyacrylamide gel electrophoresis 
10x SDS-sample buffer: 500mM Tris-HCl pH 6.8, 60% (v/v) glycerol, 20% (w/v) SDS, 1M DTT, 1% 
(w/v) bromphenol blue 
4x stacking gel buffer: 0.5M Tris-HCl pH 6.8, 0.4% (w/v) SDS 
4x separating gel buffer: 1.5M Tris-HCl pH 6.8, 0.4% (w/v) SDS 
10x electrophoresis running buffer: 250mM Tris-HCl pH 8.8, 2M glycine, 1% (w/v) SDS 
For the separation of proteins under denaturating conditions SDS polyacrylamide gel electrophoresis 
(SDS-PAGE) adapted from Laemmli (Laemmli, 1970) was performed. Therefore, 5 to 25µg total cell 
lysate depending on the used antibodies for Western Blot were denaturized in SDS-sample buffer at 
95°C for 5min and subsequently loaded onto SDS polyacrylamide gels with a concentration ranging 
between 10%, 12.5% and 15% acrylamide depending on the desired resolution range. The precise 
composition of the gels is given in table 2.7. The electrophoresis was performed for 1 to 2h at 120V. 
The protein marker PageRuler prestained protein ladder was used as standard to estimate the mo-
lecular weight of the separated protein bands. 
 
Solution Vol. Separating gel Stacking gel 
  8% AA 10% AA 12,5% AA 15% AA 18% AA 5% AA 
30% acrylamide Ml 9.6 12 15 18 21.5 4.5 
H2O Ml 17.4 15 12 9 5.5 10.5 
4x separating gel buffer Ml 9 9 9 9 9 - 
4x stacking gel buffer Ml - - - - - 7.5 
TEMED µl 25 25 25 25 25 30 
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10% APS µl 300 300 300 300 300 300 
Table 2.7 Composition of SDS polyacrylamide gels. Indicated volumes of the solutions were mixed to 
achieve the final concentrations of acrylamide for 5 gels (Hoefer system). (AA – acrylamide) 
 
In special cases to separate both high and low molecular weight proteins in one run gradient gels 
were used with a separating gel ranging from 8 to 18% AA. For one long gel (Hoefer system) 5.5ml 
gel solution was prepared by firstly pulling up 3ml 8% AA solution and subsequently 2.5ml 18% AA 
stained with bromphenol blue in one 10ml-pipette. After waiting for the gradient to establish inside 
the pipette the gel solution was slowly and steadily poured into the gel chamber. 
2.2.2.3 Western Blot and immunodetection 
Wet Blot buffer: 25mM Tris-HCl, 200mM glycine, 10% (v/v) methanol 
Semidry blot buffer: 25mM Tris-HCl, 200mM glycine, 0.1% (w/v) SDS, 20% (v/v) methanol 
Blocking solution: 1x TBS, 0.5% (v/v) Tween-20, 2.5% (w/v) milk powder 
Washing buffer: 1x TBS, 0.5% (v/v) Tween-20 
Amido black solution: 45% (v/v) MilliQ H2O, 45% (v/v) methanol, 10% (v/v) acetic acid, 0.1% 
(w/v) amido black 
For the transfer of high molecular weight proteins as well as the ladder-like pattern of ubiquitin conju-
gates from SDS polyacrylamide gels to PVDF membranes the Wet blot procedure with the appropriate 
buffer was used. In contrast, for the transfer of lower molecular weight proteins under 30kDa the 
semidry blot method was employed. The transfer was carried out over 1h at a constant electric cur-
rent of 4000mA. To verify the protein transfer PVDF membranes were stained in amido black solution 
and washed in water.  
Thereafter, free binding sites of the membrane were blocked for 1h at room temperature with block-
ing solution. The Incubation with the primary antibody against the antigen of interest was carried out 
over night at 4°C. The next day the membranes were washed twice for 20min in TBS-T followed by 
the incubation with the appropriate secondary antibody targeting an antigen from the first antibody 
diluted in blocking solution for 1h at room temperature. For the final washing the membranes were 
washed again twice for around 20min in washing buffer and finally soaked in water. For visualization 
of the horseradish peroxidase (HRP)-labeled secondary antibodies ECL PlusTM Western Blotting Detec-
tion Reagents were used. The produced chemiluminescence signal was detected on autoradiography 
film X-OMAT UV (Kodak) or with the CCD camera of a VersaDocTM Imager (BioRad). The obtained 
signals were densitometrically evaluated with ImageJ software. 
 
2.2.3 Native Page 
Anode buffer: 50mM BisTris 
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Cathode buffer: 15mM BisTris, 50mM tricine 
Activity buffer: 50mM Tris-HCl pH 7.5, 5mM MgCl2 
For the separation of proteasome complexes under native, non-denaturing conditions Native poly-
acrylamide gel electrophoresis was performed. Therefore, cell pellets were lysed in triton lysis buffer 
with the freeze and thaw method under addition of 10% (v/v) glycerol. After clearing the lysates from 
cell debris with a centrifugation step at 4°C and 14.000rpm for 20min, the supernatant was directly 
subjected to gel electrophoresis without previous storage. 50 to 75µg of total cell lysate was supple-
mented with 6-fold NativePAGETM sample buffer and loaded onto NativePAGE™ Novex® Bis-Tris 3 to 
12% gels from Invitrogen. The electrophoretic separation was carried out over night at 4°C and 80V. 
Due to the native conditions of the separation proteasome complexes in native and active confor-
mation were obtained and could be tested for their proteolytic activity in gel. Therefore, the poly-
acrylamide gels were equilibrated after the run in activity buffer freshly supplemented with 1mM ATP 
and 100µM of the fluorogenic substrate Suc-LLVY-AMC (Suc-Leu-Leu-Val-Tyr-aminomethylcoumarin). 
The chymotrypsin-like activity of the proteasome was thereby visualized in gel by cleavage of the AMC 
group of the substrate. The free AMC was monitored by UV-excitation with a VersaDocTM Imager from 
BioRad. 
For immunodetection Native polyacrylamide gels were transferred onto PVDF membranes with the 
Wet blot method. Transfer was performed on special Hybond-LFP PVDF membranes from GE 
Healthcare which provide a better sensitivity due to lower background with usage of fluorescence-
coupled antibodies. After the transfer membranes were blocked, incubated with primary antibodies 
directed against an epitope in the native conformation of the protein and washed as described for 
normal immunodetection above. The secondary antibodies obtained from Invitrogen were coupled to 
fluorescent dyes (Alexa fluorophores, see table 2.6) with different excitation wavelengths. Fluores-
cence signals were monitored with a VersaDocTM Imager from BioRad. 
 
2.2.4 Oxyblot 
For the immunodetection of oxidized proteins the OxyBlotTM protein oxidation detection kit (Chemicon 
International) was used according to the manufacturer’s instruction. The reaction relies on the immu-
nodetection of carbonyl groups in oxidized proteins. The samples were prepared in RIPA buffer (see 
chapter 2.2.2.1) and 5µg of total lysate were employed per reaction. 
 
2.3 Immunological methods 
2.3.1 IFNγ ELISA 
Coating buffer: 0.1M sodium carbonate pH 9.5 
Washing buffer: PBS and 0.05% (v/v) Tween-20 
Blocking buffer: PBS and 10% (v/v) FCS 
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To quantify IFNγ secreted from epitope-specific CTLs an anti human IFNγ ELISA (enzyme-linked im-
munosorbent assay) kit from BD Bioscience was employed according to manufacturer’s instructions. 
ELISA plates were coated with the capture antibody diluted 1:250 in coating buffer over night at 4°C. 
The next morning, the plates were washed 3-times with PBST in order to remove unbound capture 
antibody. Thereafter, unspecific binding sites were blocked with PBS and 10% (v/v) FCS for 1h at 
room temperature. A standard curve was pipetted in a 1:2 dilution series of 300 pg/ml recombinant 
human IFNγ. The samples, i.e. the supernatants from the CTL assay, were diluted 1:20 up to 1:50 in 
blocking buffer and incubated for one hour at room temperature. After washing 5-times with PBST the 
biotinylated secondary antibody was added together with Streptavidin-HRP in one step, both in a dilu-
tion of 1:250, and incubated for 1h. Again the samples were washed 5-times before the substrate 
reagent TMB (Tetramethylbenzidine, BD Bioscience) and hydrogen peroxide was added and incubated 
for 30min in the dark. The colour reaction was stopped by addition of 50µl 1M H3PO4 per well and 
measured in a photometer at 450nm wavelength. The absolute IFNγ concentration was determined 
with a double logarithmic standard curve. To each sample a peptide loaded control sample was car-
ried along (see chapter 2.1.7.3). The IFNγ release measured with peptide loading was set as 100% 
response and the IFNγ secretion in each sample then displayed as relative response.  
 
2.3.2 Immunoprecipitation 
By immunoprecipitation (IP) a certain protein is targeted and pulled out of total cell lysate. Depending 
on the IP conditions modifications of the proteins as well as interaction partners can be identified (co- 
immunoprecipitation, Co-IP). In this work, either for investigation of ubiquitylation and oxidation of 
certain viral proteins or the incorporation of i-subunits in proteasome complexes (Co-IP) different pro-
tocols were used. 
2.3.2.1 Ubiquitylation and Oxidation of viral Proteins 
IP buffer: 20mM Tris-HCl pH 7.5, 10mM EDTA, 100mM NaCl, 1x Complete + freshly added: 1% (v/v) 
Nonidet P-40, 10mM NEM, 1µM Epoxomicin, 1mg/ml BSA 
Protein pellets retrieved from virus infection experiments were lysed in RIPA buffer for 1h on ice and 
centrifuged for 15min at 14.000rpm and 4°C to separate cell debris (see chapter 2.2.2.1). After de-
termination of the protein concentration approximately 150µg of total cell lysate was employed and 
adjusted with IP buffer to a volume of 1ml. The fresh supplements were added together with 5µg of 
the appropriate antibodies (see table 2.6) per sample. The samples were incubated over night at 4°C 
and gently agitated on a wheel to form immune complexes between the specific viral antigen and the 
antibody. The following day immune complexes were precipitated by Protein G-Sepharose. Therefore, 
30µl protein G slurry was employed per sample. The beads were washed 3-times for 15min in cold 1x 
PBS and equilibrated in IP buffer without supplements for 20min. After centrifugation of the beads for 
5min at 3000rpm and 4°C the supernatant was discarded and replaced with the 1ml samples. As con-
trol only lysate without antibody was added to the sepharose beads. For the specific binding of Protein 
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G to the Fc portion of the IgG antibodies to isolate immune complexes the samples were incubated for 
another 4 to 6h at 4°C on a rotating wheel. 
After washing the samples 3-times in 2x PBS plus 0.1% Nonidet P-40, once in 1x PBS and once with 
MilliQ H2O to remove unbound proteins, 30µl 2x SDS sample buffer were added. To elute bound pro-
teins the samples were heated for 5min at 95°C and centrifuged at 3000rpm and 4°C for 5min. For 
analysis of ubiquitylation of viral proteins half of the eluate (15µl) was loaded on SDS-PAGE gels, blot-
ted and stained with αubiquitin antibody from Dako. In order to investigate oxidation of virus proteins 
the DNPH reaction for the Oxyblot kit (see chapter 2.2.4) was modified. The 30µl beads coupled to 
immune complexes which were obtained after all washing steps were complemented with 15µl RIPA 
buffer, 6.4µl 20% (w/v) SDS and 21µl 1x DNPH. The reaction was incubated for 15min at room tem-
perature and then stopped by adding 12.7µl of the neutralization solution and 5.5µl 1mM DTT. Subse-
quently, a mild elution for 10min at 80°C was carried out. Evaluation of the oxidation was performed 
by loading 40µl sample onto SDS-PAGE and immunoblot with the antibodies from the Oxyblot kit ac-
cording to the manufacturer’s instructions.  
2.3.2.2 Co-immunoprecipitation 
IP buffer: 50mM Tris-HCl, 50mM NaCl, 5mM MgCl2, 0.1% (v/v) Triton X-100 and Complete, adjusted 
to pH 7.5 with NaOH + freshly added: 0.1% (v/v) Nonidet P-40 and 1mg/ml BSA 
A similar protocol was used to test the incorporation of certain proteasome subunits into proteasome 
complexes. 200µg of total cell lysate were adjusted with IP buffer to a total volume of 500µl. The 
specific αalpha2 antibody (MCP21, see table 2.6) was used to pull out proteasome complexes. Wash-
ing of the Protein G sepharose, incubation to form immune complexes and elution was performed as 
described above (chapter 2.3.2.1). 30µl of the eluate were loaded on SDS-PAGE and analysed with 
different αproteasome antibodies. 
 
2.3.3 Flow cytometry 
Surface expression of MHC class I molecules was analysed by labelling cells with αHLA-A2-FITC or 
αHLA-A,B,C-PE antibodies. Pretreated cells were harvested, washed in PBS and counted. Per 96-well 
1x105 cells were seeded in 150µl PBS + 1% (w/v) BSA. The FACS antibodies were added in a dilution 
of 1:50 and incubated for 20min at 4°C in the dark. Thus, unbound antibody was removed by washing 
twice with 200µl PBS. Finally, the cells were taken up in 200µl PBS, filled in FACS tubes and measured 
with a FACSCaliburTM flow cytometer from BD Bioscience. 
2.3.3.1 DCFH-DA staining – Quantification of ROS 
Induction of ROS after virus infection was quantified by FACS analysis using an adjusted protocol. 
Directly after infection cells were treated with 10µM 2’-7’-dichlorofluorescin diacetate (DCFH-DA) from 
Sigma Aldrich which was de-esterified intracellulary by reactive oxygen species into highly fluorescent 
dichlorofluorescein. 1x105 cells were grown in 24-well cell culture plates, washed once with 500µl 
HBSS and incubated with 10µM DCFH-DA in 500µl medium without FCS for 30min in the dark at 37°C. 
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Afterwards, cells were washed twice with 500µl HBSS, harvested with Trypsin/EDTA and diluted in 
500µl medium in order to transfer them into FACS tubes. Dichlorofluorescein was measured in the 
FITC channel of a FACSCaliburTM flow cytometer from BD Bioscience. 
 
2.3.4 Immunofluorescence 
Cells were grown in 24-well cell culture plates and allowed to adhere to cover slides. After viral infec-
tion for indicated time points the cells were fixed and permeabilized with ice-cold methanol for 5min at 
-20°C and subsequently blocked with 3% FCS in PBS for 30min at room temperature. The staining 
with primary and fluorescent secondary antibodies (see table 2.6) was carried out in each case for 1h 
at room temperature and in between washed 3-times with PBS. Nuclei were stained with DAPI in a 
dilution of 1:1000 for 5min. The Immunofluorescence analysis was performed with a Leica DMR mi-
croscope. 
 
2.4 Molecular biological methods 
2.4.1 Primer 
Primers employed for standard RT-PCR were generated by BioTeZ GmbH in a scale of 0.01µmol. Used 
primers are listed in table 2.8. Stock solutions were constituted in MilliQ to 50µM and stored at -20°C. 
In standard PCR a final concentration of 4µM of each primer was applied. For real time PCR primers 
were purchased from Applied Biosystems. 
 
Primer Forward sequence Reverse sequence 
Nox1 CTGGAGAGAATGGAGGCAAG TTAACAGCACGCTGATCCTG 
Nox4 
GAPDH 
CTTCCGTTGGTTTGCAGATT 
ATGGGGAAGGTGAAGGTC 
TGGGTCCACAACAGAAAACA 
TTACTCCTTGGAGGCCATG 
Table 2.8 Self-designed Primers for RT-PCR were ordered from BioTeZ GmbH. 
 
2.4.2 Preparation of RNA and cDNA synthesis 
Total RNA was extracted from frozen cell pellets using the High Pure RNA Isolation kit (Roche Diag-
nostics). Absorption at 260nm was measured to determine the RNA concentration with the following 
formula c (µg/ml) = 40*dilution factor*A260nm. Total RNA was stored at -80°C. 1µg total RNA was 
reverse transcribed using the First Strand cDNA synthesis kit (Roche Diagnostics) with oligo(dT) pri-
mers and reverse transcriptase according to manufacturer’s instructions. 
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2.4.3 Standard PCR 
The FastStart High Fidelity PCR System from Roche was applied together with primers from Biotez 
(see table 2.8) according to the manual. The PCR program was employed as described below, the 
annealing temperature was adapted to the melting temperature of the used primer pair.  
 
 
 
5min   95°C   denaturation 
35cycles  30sec  95°C 
30sec  55-60°C  annealing 
45sec  72°C  DNA polymerization 
7min   72° 
∞   4°C 
 
6x DNA sample buffer: 50% (v/v) glycerine, 50mM EDTA, 0.25% (w/v) bromophenol blue 
1x TAE buffer:   40mM Tris, 1mM EDTA, 20mM acetic acid 
 
The PCR products were supplemented with 6-fold DNA sample buffer and separated electrophoretical-
ly on 1.5% to 3% agarose gels at 60V. The gels were stained with SYBR® safe DNA gel stain (Invitro-
gen) and visualized under UV light. To estimate the size of separated bands the 1kb DNA ladder from 
Invitrogen was used as molecular weight standard.  
 
2.4.4 Taqman® real-time PCR 
Real-time PCR in order to quantify mRNA levels of different genes after viral infection was performed 
in duplicates using primers and probes of TaqMan® Gene Expression Assays (Applied Biosystems) 
with a Rotor Gene 3000 (Corbett Research). Firstly, relative amounts of each gene were acquired and 
calculated with comparative cycle threshold values using the Rotor Gene Monitor Software (version 
4.6) and normalised to an endogenous reference (HPRT1, hypoxanthine phosphoribosyltransferase 1). 
Further, for the analysed target genes cDNA was amplified and sub-cloned into the pCR2.1-TOPO TA-
cloning vector (Invitrogen), which was performed by Dr. Frédéric Ebstein. The resulting plasmids were 
then linearized and used to prepare an 8-fold dilution series of amplification standards from 5×105 to 
328 copies per µl in order to calculate quantitative mRNA amounts. 
 
2.4.5 Microarray and data analysis 
For microarray analysis isolated total RNA (see 2.4.2) was previously tested on a RNA gel. The human 
U133 2.0 Plus-Array (Affymetrix) was custom hybridized and evaluated by standard procedures from 
Signature Diagnostics AG. The data discussed in this thesis have been deposited in NCBIs Gene Ex-
pression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series 
accession number. 
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3. Results 
Addressing the key questions which were raised in this thesis focus was laid on the model system of 
HCMV infection in permissive, primary fibroblasts. Later, investigation of particular interesting aspects 
was expanded to influenza A infection. Prior to the actual experiments virus infection in the appropri-
ate cell culture system had to be established. Especially for the analysis of chronological events inside 
the target cells which are initiated in a very early phase of infection directly by entry of virus particles 
into the cells the temporal reliability of infection had to be assured.  
In a first step the course of i-proteasome induction in response to virus infection and the nature of de 
novo formed proteasome complexes were scrutinized. Attention was drawn to the generation of 
mixed-type proteasome complexes containing constitutive as well as i-subunits and their role during 
the processing of viral epitopes. Thereby, very early time points of infection starting two hours post 
infection were included. The second point was subjected especially to the induction of i-proteasomes 
in response to HCMV infection. Little is known so far about the viral components or the cellular recep-
tors which interact in order to initiate an eminent early immune response. In this work crucial roles of 
the type I interferon response and the transcription factor IRF3 were explored. The last part of this 
thesis comprised a detailed analysis of the processing of viral antigenic peptides beginning with the 
HCMV pp65 model antigen and later pointing out potential general mechanisms. During the investiga-
tions the DRiP hypothesis was revisited and prominent aspects of ubiquitylation and oxidation as well 
as their impact on epitope generation were examined.  
 
3.1 Synchronising viral infection 
In order to analyse kinetic effects of viral infection on the ubiquitin proteasome system and the MHC 
class I antigen presentation there was the prerequisite to establish a reproducible virus infection with 
a certain multiplicity of infection and certain duration. For the latter demand the process of infection 
needed to be synchronized. Therefore, the respective cells were subjected to an improved infection 
procedure which is described in chapter 2.1.5 and was adapted from Anne Halenius. This procedure 
provided a timely focused virus entry which played a role especially in the case of the bigger HCMV 
particles (about 200nm in diameter).  
Synchronicity and multiplicity of infection was proven by staining for structural and non-structural viral 
proteins in Western blot. The HCMV phosphoprotein pp65 is a late expressed protein in the viral gene 
expression cascade, but also a structural component of the virus particle (Crough and Khanna, 2009; 
Mocarski, 2002; Stinski, 1978). As shown in figure 3.1A the structural protein pp65 was constantly 
detected during the whole time course of infection. The remarkable increase of pp65 levels observed 
after 24h post infection might be attributed to de novo synthesis of pp65, this hypothesis will be ex-
amined later in chapter 3.2.2. The pp72 viral protein is an immediate early viral protein which is not 
incorporated in the virion. A pp72 band in western blot was visible after 4h known as the time point of 
expression of immediate early genes in the HCMV gene expression cascade (Stinski, 1978). 
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For influenza A infection protein levels of the matrix protein M1 and the non-structural protein NS1 
were assessed by Western analysis. While M1 as a structural component of the virus particle was de-
tected during the whole time course using a longer exposure of films to the immunoblots, the NS1 
protein was only detected after 6hpi (figure 3.1B), the time point of de novo synthesis of NS1 (Palese 
and García-Sastre, 1999). Likewise, M1 is newly synthesized approximately after 6h of influenza A 
infection, which could be recognised in immunoblot by the significant increase of M1 protein levels 
after this time point. 
 
 
Figure 3.1 Levels of structural and non-structural viral proteins during the course of infection. A) 
Pp72 (upper panels) and pp65 (lower panels) protein levels analysed by immunoblot with αpp72 and αpp65 anti-
body, respectively, during the time course of HCMV Ad169 infection in MRC5 fibroblasts (short and long exposure 
time). Staining with αGAPDH antibody served as loading control. B) Immunoblot analysis of the structural matrix 
protein 1 (M1) and the non-structural protein 1 (NS1) during the course of influenza A virus (IAV) infection in 
HeLa cells (IAV data provided by Theresa Bergann). 
 
3.2 The Mystery of the very early CTL response 
The pp65495-503-specific CTL clone, whose generation is described in chapter 2.1.6, was used to study 
the generation of the immunodominant pp65495-503 epitope in HCMV-infected target cells during a time 
course. In this work for the first time the very early kinetics immediately after entry of virus particles 
into the target cell was investigated. Surprisingly, presentation of the pp65495-503 epitope was observed 
on the surface of infected MRC5 fibroblasts as early as 2h post infection. Remarkably, the strongest 
presentation of about 60 to 70% of peptide loaded target cells was reached between 2 and 4hpi. After 
24 to 72hpi a significant decrease in epitope presentation occurred (figure 3.2A black bars) which can 
be attributed to the expression of immunomodulatory gene products of HCMV discussed in chapter 4.  
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Figure 3.2 Presentation of the pp65495-503 epitope is proteasome-dependent. MRC5 were infected 
with HCMV Ad169 at moi 5 for indicated time points. 200nM proteasome inhibitor epoxomicin was applied directly 
after infection. A) pp65495-503 specific CTL assay analysis comparing infection of untreated MRC5 (black bars) with 
epoxomicin treated cells (grey bars). IFNγ release by effector T cells was measured by ELISA and displayed as 
percentage of the response received by loading MRC5 with 1µg/ml pp65495-503 peptide (n = 6 of 3 independent 
experiments; error bars represent standard deviation ±SD; ∗∗ p<0.01 ∗∗∗ p<0.001). B) Effect of 200nM epox-
omicin on the accumulation of poly-ub conjugates and of the viral protein pp65 2h, 4h and 24h post HCMV infec-
tion displayed by immunoblot with αubiquitin (FK2), αpp65 and αGAPDH antibody serving as loading control. 
 
3.2.1 Support by the proteasome 
In a publication of Besold and colleagues in 2007 a proteasome dependent presentation of the 
pp65495-503 epitope was observed (Besold et al., 2007). To assess whether this also applies to the gen-
eration of the immunodominant pp65495-503 epitope in the employed model system in this work cells 
were treated directly after viral infection with 200nM of the proteasome inhibitor epoxomicin. Epox-
omicin represents a specific inhibitor of both the standard and i-proteasome by irreversible and cova-
lent binding to the β2 and β5 catalytical subunits (Meng et al., 1999). A significant decrease of antigen 
presentation at each time point throughout the course of HCMV infection was observed (figure 3.2A 
grey bars). By Western blot analysis proper epoxomicin activity was confirmed due to the accumula-
tion of poly-ub conjugates (figure 3.2B). Moreover, an accumulation of pp65 at the early time points 4 
and 8hpi was observed which suggests that the epitope generation was affected on the level of pro-
teasomal degradation. After 24hpi pp65 protein levels were reduced, at this time point de novo gen-
eration of pp65 in the viral gene expression cascade starts which is known to be blocked by pro-
teasome inhibitors (Kaspari et al., 2008; Tran et al., 2010).  
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Figure 3.3 Presentation of the M158-66 
epitope is dependent on proteasomal activity. 
HLA-A2+ HeLa cells were infected with IAV at moi 5 
during a time course of 0 to 8hpi. 200nM proteasome 
inhibitor epoxomicin was added directly after infection 
to each sample. M158-66 specific CTL response was 
measured by IFNγ release in an ELISA and displayed 
as percentage of the response received by loading 
cells with 1µg/ml M158-66 peptide (n = 3 of 2 inde-
pendent experiments, error bars represent ±SD). 
 
An analogous experiment was performed for the presentation of the immunodominant M158-66 epitope 
after influenza A infection. Stably transfected HLA-A2+ HeLa cells were infected with influenza A virus 
for several time points and treated directly after infection with 200nM epoxomicin. The M158-66-specific 
CTL clone was used to assess epitope presentation. Again at each time point of infection antigen 
presentation decreased about 20 to 30% (figure 3.3). Presumably, also the generation of the M158-66 
epitope was dependent on proteasomal degradation of M1. 
 
3.2.2 Where the pp65495-503 epitope derives from 
3.2.2.1 UV-inactivation and Cycloheximide treatment reveal the source of pp65 
Since pp65 represents a late transcribed gene in the viral gene expression cascade whose expression 
begins not earlier than 24hpi (Stinski, 1978), the question arises where the pp65 epitope derives from 
at earlier time points of infection. The onset of pp65 de novo synthesis in the course of the viral gene 
expression cascade at 24hpi was observed by western analysis of pp65 protein levels in total cell ly-
sate of infected fibroblasts using short exposure times (figure 3.1A, lower panels). The occurrence of 
pp65 at early time points by using longer exposure in western analysis suggested the detection of 
non-translated pp65, since pp65 is a structural component of the virus, incorporated in the virus parti-
cle and delivered to the cytoplasm of the infected host cell during the virus entry process (McLaughlin-
Taylor et al., 1994).  
Therefore, two different approaches were used to block translation: i) treatment of the infected host 
cell with translation inhibitor cycloheximide and ii) in a more sophisticated approach by UV inactivation 
of the virus particles. Ten minutes of UV irradiation destroyed the viral genome while the virus pro-
teins remained intact. Firstly, total cell lysate of cycloheximide pretreated cells was analysed by im-
munoblot. To verify translation inhibition blots were stained for the transcription factor p53, which is 
known to represent an unstable, short-lived protein but also to be induced during HCMV infection 
(Fortunato and Spector, 1998). The tumour suppressor and cell cycle regulator p53 was induced al-
ready 2h after HCMV infection and its expression was further increased at 4hpi. The induction was 
abolished by application of cycloheximide. As well the expression of pp72, an immediate early viral 
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gene product translated at 4hpi, was blocked after cycloheximide application. In contrast, protein 
levels of pp65 remained unaffected (figure 3.4A). Infection with UV-inactivated virus was similarly 
tested by assessing protein levels of the nonstructural pp72, which could not be detected, while pp65 
protein levels were steady (figure 3.4B). The Western analysis revealed also slightly increasing pp65 
levels at the early time points from 2 to 8hpi. This induction was not attributed to de novo translation, 
since UV inactivation and translation inhibitor completely abolished pp72 and p53 expression while not 
affecting pp65 levels, but to ongoing infection i.e. the entry of virus particles into cells thereby enlarg-
ing the cellular pp65 pool. 
 
 
Figure 3.4 Inhibition of translation by cycloheximide application and UV-inactivation. A) MRC5 fi-
broblasts were left untreated or were pre-treated with 50µg/ml cycloheximide 1h prior to infection with HCMV 
Ad169 at moi 5. Total cell lysate was stained in immunoblot for the late expressed HCMV protein pp65 and the 
immediate early HCMV protein pp72. Further, tumor suppressor protein p53 was stained to prove translation 
inhibition. B) Infection of MRC5 with either wild-type virus or UV-irradiated HCMV at moi 5. C) Infection of HeLa 
cells with IAV at moi 5. Total cell lysate was employed for immunoblot with αM1 and αNS1 antibodies. αGAPDH 
served as loading control (IAV blots provided by Theresa Bergann). 
 
A similar experimental approach was followed for the influenza A infection in order to analyse the 
origin of the M158-66 epitope. The matrix protein M1, likewise pp65, presents a structural component of 
the virus particle. Similarly, M1 could be found in the cytoplasm of infected cells before it is synthe-
sized de novo, which is reported to occur around 6hpi (Palese and García-Sastre, 1999). Using long 
exposure times for the detection of M1, the viral protein was found already 2hpi in total cell lysate of 
infected HeLa cells, with a remarkable increase at the time point of M1 de novo synthesis (figure 3.4C, 
upper panels). When cells were infected with UV-irradiated influenza virus matrix protein 1 was still 
found at early time points of infection but not in later stages, when de novo synthesis should occur 
which was presumably blocked due to the UV inactivation. As control served the nonstructural viral 
protein NS1 which was expressed as seen in the lower panel after 8h and not detected earlier. NS1 
expression was abolished after infection with UV-inactivated virus (figure 3.4C, lower panels). Hence, 
the presence of both viral proteins, pp65 and M1, at early time points of infection was independent of 
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translation, but dependent on the delivery of these proteins to the cytoplasm of the host cell during 
the virus entry process. 
To complete the picture, the presentation of the pp65495-503-epitope assessed by CTL assay of 4 and 
8h HCMV-infected fibroblasts either treated with 50µg/ml translation inhibitor cycloheximide or infect-
ed with UV-irradiated virus was also unchanged and still reached 70 to 80% (figure 3.5). Together 
with the biochemical analysis it became clear that the pp65495-503 epitope presented on the cell surface 
at the early time points was not newly synthesized in the infected host cells, but had to derive from 
structural components of the virus particles. The tegument protein was directly delivered into the cy-
toplasm of the cell during the virus entry process and thereby gained access to the antigen processing 
machinery before the viral gene expression started, which has been postulated already in 2000 by 
Matthias Reddehase (Reddehase, 2000). 
 
Figure 3.5 Translation-independent gener-
ation of the pp65495-503 epitope. CTL assay 
analysis of MRC5 cells infected for 4h and 8h with 
HCMV Ad169 comparing UV-inactivated virus or 
pretreatment of cells with 50µg/ml cycloheximide 1h 
prior to virus infection. IFNγ release by pp65495-503 
specific CTL was measured by ELISA and displayed 
as percentage of the response received by loading 
MRC5 with 1µg/ml pp65495-503 peptide (n = 5 of 2 
independent experiments, error bars represent 
±SD). 
 
3.3 What happens in the infected cells? 
As it is outlined in chapter 1.5 virus infection inflicts several profound changes in the infected cell, 
primarily on the transcription and translation of many cellular genes. In this work, focus was laid firstly 
on effects on the ubiquitin proteasome system. Therefore, an Affymetrix microarray analysis was per-
formed to monitor cellular gene expression in uninfected and 4h HCMV-infected MRC5 fibroblasts, as 
well as in uninfected and 4h IAV-infected HeLa cells. Already in a publication from Zhu et al. expres-
sion of around 6600 human mRNAs was analysed in primary human foreskin fibroblasts after 8h and 
24h infection with HCMV Ad169 (Zhu et al. 1998). They observed an induction of several UPS genes 
and among these a 4-fold induction of β5i mRNA 8h after HCMV infection. Similarly, in this thesis a 
significant upregulation of UPS components such as i-subunits and ubiquitylation enzymes was ob-
served (see attachment). 
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3.4 Proteasomal adaptation 
Type I interferons, IFNα and IFNβ, and type II interferon IFNγ, but also heat stress or viral infection 
induce the expression of the i-subunits, β1i, β2i and β5i (Callahan et al., 2006; Jamaluddin et al., 
2001; Shin et al., 2006), and their subsequent incorporation into nascent proteasome complexes in 
order to form i-proteasomes (Frentzel et al., 1994; Groettrup et al., 1997; Nandi et al., 1997). In pro-
fessional antigen presenting cells (APC) the i-proteasome represents the predominant type of pro-
teasome, while in non-lymphoid organs the expression of i-proteasome does not exceed 60% (Strehl 
et al., 2006). Moreover, mixed-type proteasome complexes containing constitutive as well as i-
subunits are reported (Dahlmann et al., 2000; Griffin et al., 1998). Likewise, an induction of the pro-
teasome activator PA28 is reported in response to IFNγ stimulation (Ahn et al., 1995). In this thesis, 
formation of mixed-type proteasomes and induction of PA28 during viral infection were elucidated. 
 
3.4.1 HCMV infection induces the formation of mixed-type pro-
teasomes and the proteasome activator complex PA28 
The examination of the cellular proteasome pool in infected cells during HCMV infection approved the 
results from microarray studies and revealed a very fast induction of mixed-type proteasome com-
plexes as well as of the proteasome activator PA28. Real-time PCR analysis confirmed that expression 
of the i-subunits β5i and β2i as well as of both PA28 subunits α and β was induced on mRNA-level 
4hpi and strongly reduced after 24hpi (figure 3.6A). In contrast, transcripts of the constitutive subunit 
β7 were only slightly but continuously elevated. An induction of the third IFNγ-inducible, catalytical 
subunit β2i could not be detected in RT-PCR. 
In Western analysis immediately after HCMV infection a significant increase of protein levels of the i-
subunits β5i and β1i, but in line with the results of real-time PCR analysis no increase for the β2i sub-
unit was observed (figure 3.6B densitometric analysis and figure 3.6C selected blots). The densitomet-
ric analysis of several experiments showed a significant increase in the expression of both subunits 
within 4h followed by a reduction after 72h, known to be dependent on downregulation mediated by 
HCMV immune escape mechanisms (Kahn et al. 2003). The β5i antibody detected a total of three 
bands, the band at 30kDa represented the proprotein which was cleaved in a two-step autocatalytic 
process to remove the propeptide and liberate the active site threonine of the mature β-subunit 
(Nandi et al., 1997; Schmidtke et al., 1996; Schmidtke et al., 1997). In case of the β5i subunit the 
mature protein occurs in two isoforms at 22.6kDa and 21.3kDa. The β1i antibody was proven to rec-
ognise the i-subunit β1i at 21.3kDa as well as the constitutive subunit β1 at 22.6 kDa.  
Similarly, an induction of PA28α and PA28β was observed between 4 and 24hpi. In contrast, the ex-
pression of the constitutive proteasome subunit α4 showed a continuous increase. Moreover, a transi-
ent induction of the proteasome maturation protein (POMP) which is essential for the incorporation of 
the expressed i-subunits β5i and β1i (Heink et al., 2005) was observed (data not shown). Hence, the 
formation of functional i-proteasomes was verified by co-immunoprecipitation (figure 3.6D). By precip-
Results  P a g e  | 52 
itating the constitutive subunit α2 and staining against β5i and β1i the formation of mixed-type pro-
teasome complexes was proven during the whole course of virus infection.  
 
 
 
Figure 3.6 HCMV infection induces the formation of mixed-type proteasome complexes. MRC5 fi-
broblasts were infected with HCMV Ad169 at moi 5 for the indicated time points. A) Real-time PCR analysis of β5i, 
β1i and β7 mRNA (upper graph) as well as PA28α and PA28β mRNA (lower graph). Results were expressed as 
average fold change from uninfected MRC5 (mean values of 3 experiments, normalised to HPRT1, error bars 
represent ±SD. B) Densitometric analysis of β5i, β1i and α4 protein levels (upper graph) as well as PA28α and 
PA28β in Western blot (lower graph), (n = 6 experiments, normalised to GAPDH, error bars show ±SD). C) Se-
lected immunoblots showing the induction of i-subunits (precursor p and mature m proteins are indicated), con-
stitutive subunit α4 and both PA28 subunits. GAPDH served as loading control. D) Co-Immunoprecipitation of 
proteasome complexes with α-α2 antibody and staining in Western analysis against β5/β5i and β1/β1i. 
 
The appearance of functional i20S complexes in response to HCMV infection was further verified by 
performing Native Page analysis. The electrophoretic separation resulted in discrimination of free 20S 
complexes, 20S associated with PA28 activator and 20S associated with 19S regulator attached to one 
end constituting the 26S proteasome or to both ends composing 30S complexes. Further, an attach-
ment of PA28 to one end and 19S to the other end of the barrel-shaped 20S core was possible thus 
forming hybrid proteasome. The different proteasome complexes were visualized in an activity overlay 
with the Suc-LLVY-AMC substrate reflecting chymotryptic activity (figure 3.7). Immunoblot and incu-
bation with fluorescent antibodies raised against β5i and β1i proved the incorporation of these i-
subunits during the course of infection and showed a continuous increase. Apparently, the downregu-
lation of i-subunit expression on the transcriptional level mediated by immunomodulatory gene prod-
ucts of HCMV (Khan et al., 2004) did not affect the percentage of i-proteasomes to the overall cellular 
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proteasome pool. Not all proteasome complexes from the gel could be detected in the according im-
munoblots. I-subunits seemed to be incorporated in a higher amount in free 20S or 20S complexes 
associated with PA28 than in 26S or 30S proteasomes, whereby methodical complications, due to the 
dissociation of 19S during the preparation of the lysates, could not be ruled out during this thesis.  
Therefore, the formation of mixed-type proteasome complexes at the early time points from 4 to 
24hpi containing β5i and β1i but no β2i and the partial formation of complexes with PA28 was con-
cluded. 
 
 
Figure 3.7 Incorporation of i-
subunits in active proteasome 
complexes in response to HCMV 
infection. MRC5 cells were infected for 
indicated time points with HCMV Ad169 
at moi 5. Total cell lysate was applied 
to Native PAGE analysis. Substrate 
overlay of Native Gel with 1µM Suc-
LLVY-AMC under addition of 1mM ATP. 
Native Blots were incubated with α-β5i 
and α-β1i antibodies. 
 
3.4.2 It’s all in the mix 
To verify whether the formation of mixed-type proteasome complexes also had an impact on the gen-
eration of the pp65495-503 epitope, the expression of i-subunits β5i and β1i was knocked down and 
pp65495-503-epitope presentation was monitored 4h post infection when being at maximum. For this 
purpose, target cells were preincubated 48h prior to virus infection with 25nM PSMB8 and PSMB9 
siRNA. The downregulation of each subunit alone as well as in combination negatively affected the 
antigen presentation (figure 3.8A). Compared to the treatment with OFF-target control siRNA the 
knockdown of β1i with PSMB9 siRNA caused a reduced epitope presentation of approximately 25%, 
while the downregulation of β5i expression with PSMB8 siRNA resulted in almost 40% decreased 
presentation and treatment with both siRNAs together in an even stronger reduction of about 46%. 
The knockdown was verified by immunoblots with α-β5i and -β2i antibody (figure 3.8B). The expres-
sion of the constitutive subunit α4 was not affected by knockdown of both i-subunits. The protein 
levels of pp65 slightly accumulated due to downregulation of i-subunit expression in infected cells 
presumably due to decreased proteasomal degradation of pp65. 
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In conclusion, the effect on the presentation of the pp65495-503 epitope demonstrated a supporting role 
of mixed-type proteasome complexes containing the β5i and β1i subunit for the generation of this 
epitope. 
 
 
Figure 3.8 Mixed-type proteasomes support the generation of the pp65495-503 epitope. MRC5 cells 
were infected with HCMV Ad169 at moi 5 for 4hpi. 25nM OFF-target, PSMB8 and PSMB9 siRNA was applied 48h 
prior to infection. A) IFNγ release by pp65495-503 specific CTL was measured by ELISA and displayed as percentage 
of the response received by loading MRC5 with 1µg/ml pp65495-503 peptide (n = 6 of 3 independent experiments; 
error bars represent ±SD; ∗ p<0.05).  B) Western analysis of siRNA knockdown. α-α4 antibody was used to con-
trol equal amounts of proteasome, αGAPDH served as loading control. 
 
3.4.3 With a little help from PA28 
Moreover, a potential supporting role of proteasome activator PA28 for the generation of the pp65495-
503 epitope was tested. Downregulation of both PA28 subunits with PSME1 and PSME2 siRNA impaired 
the epitope presentation 4h post HCMV infection to a similar degree (figure 3.9A). Compared to 
treatment with OFF-target siRNA epitope presentation was reduced about 46%. The knockdown was 
confirmed in Western analysis with α-PA28α and α-PA28β antibodies. Application of either siRNA re-
sulted in knockdown of each subunit (figure 3.9B) explaining the similar effect on antigen presentation 
when applying PSME1 and PSME2 siRNA alone or in combination. 
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Figure 3.9 Proteasome activator PA28 supports the generation of the pp65495-503 epitope. MRC5 
cells were infected with HCMV Ad169 at moi 5 for 4hpi. 25nM OFF-target, PSME1 and PSME2 siRNA was applied 
48h prior to infection. A) IFNγ release by pp65495-503 specific CTL was measured by ELISA and displayed as per-
centage of the response received by loading MRC5 with 1µg/ml pp65495-503 peptide (n = 4 of 2 independent ex-
periments; error bars represent ±SD; ∗ p<0.05). B) Western analysis to confirm knockdown with α-PA28α and α-
PA28β antibody. GAPDH served as loading control. 
 
3.5 Induction of i-subunits in response to HCMV infection 
In chapter 3.2.1 the induction of mixed-type proteasomes containing β5i and β1i subunits in a very 
early phase of infection, already 4hpi with HCMV Ad169, was shown. One aspect of this work was to 
shed light on the mechanisms leading to the immediate induction of i-subunit expression especially in 
response to HCMV infection. So far, controversial data is published about the induction of the innate 
immune response after HCMV entry into target cells. The investigations are complicated due to the 
ability of the virus to enter an extensive range of different cell types via different cell surface receptors 
which imposes the difficulty to identify cellular sensors. It is proposed that the initiation of the innate 
immune response, which comprises the induction of interferons as well as the secretion of cytokines, 
is directly linked to virus entry into the host cells (Compton et al., 2004). This assumption was verified 
in the here used model system of MRC5 infection with HCMV Ad169 by using UV-irradiated virus. A 
low dose of UV radiation keeps the virus particle intact, i.e. viral proteins remain functional, while the 
viral genome is destroyed so that no viral gene expression will occur. 
HCMV particles attach to cell-type specific receptors which results either in fusion of the virus with the 
host cell membrane or uptake of virus particles via the endosomal pathway. At the end of the process 
viral components access the cytoplasm of the host cell where an unknown cellular sensor recognizes 
the virus particle and activates the IFN response. The recognition of viral PAMPs results amongst oth-
ers in phosphorylation of the transcription factor IRF3 through Tbk1 and IKKε kinase. Activated IRF3 
induces transcription of IFNβ and other ISGs. Thus, expression of IFNβ leads to further amplification 
via auto- and paracrin activation of the IFNα/β receptor and induction of the Jak/Stat pathway, which 
in turn leads to expression of further ISGs. In order to find out if this pathway is also responsible for 
the expression of i-subunits and PA28 in response to HCMV infection it was aimed to interfere with 
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this signaling cascade at different levels. Therefore, the Tbk1 and IKKε kinases, the IFNα/β receptor 
and the transcription factor IRF3 itself were targeted. 
 
3.5.1 Independence of viral gene expression 
Based on preliminary publications it was controlled whether transcriptional activation of i-subunits and 
PA28 was dependent on viral gene expression or whether the entry of the virus particle itself was 
sufficient to induce cellular gene expression. Therefore, viral gene expression was inactivated by UV 
irradiation and expression of i-subunits was analysed on mRNA as well as on protein level (figure 
3.10). mRNA expression of the constitutive subunit β7, the i-subunits β5i and β1i as well as both PA28 
subunits was unaltered by infection with UV-inactivated virus and no statistically significant differences 
were measured. Further, induction of the type I interferons IFNα and IFNβ was analysed on transcrip-
tional level, and demonstrated for IFNβ expression in figure 3.10B. As early as 4hpi a strong increase 
was observed and no difference between infection with intact or UV-inactivated virus was noticed.  
Protein levels were investigated by immunoblot 24h after HCMV infection (figure 3.10A). Strikingly, 
translation of the i-subunits as well as PA28α and PA28β was even more pronounced after infection 
with UV-inactivated virus, which can be explained by the missing expression of immunomodulatory 
HCMV gene products, so called immunevasins, which otherwise would interfere with the expression of 
i-subunits (Khan et al., 2004). The effectiveness of UV irradiation was proven by abolished pp65 ex-
pression 24hpi. Further, phosphorylation of Stat1 was assessed in Western analysis with αpStat1 anti-
body. The Jak/Stat pathway was activated in the amplification phase of the type I IFN response and 
was obviously also activated by infection with UV-inactivated virus. 
 
 
Figure 3.10 HCMV entry directly induces i-subunits. MRC5 were infected for 24h with either intact or 
UV-irradiated HCMV Ad169 at moi5. A) Real-time PCR analysis for the indicated genes comparing infection with 
intact (black bars) and UV-inactivated virus (grey bars). Results were expressed as average fold change from 
uninfected MRC5 (mean values of 3 experiments, normalized to HPRT1, error bars represent ±SD). Total cell 
lysate was subjected to immunoblot and incubated with indicated antibodies. GAPDH served as loading control. 
B) Real-time PCR analysis of IFNβ expression comparing infection with intact (black bars) and UV-inactivated 
virus (grey bars). Results were expressed as average fold change from uninfected MRC5 (mean values of 3 ex-
periments, normalized to HPRT1, error bars represent ±SD).  
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In conclusion, the expression of i-proteasome and PA28 was independent of de novo synthesis of viral 
proteins, but dependent on structural components of the virion. Still it is unclear which cellular recep-
tors or sensors are responsible for the detection of HCMV activating a pathway leading to expression 
of i-proteasomes. 
 
3.5.2 Effects of kinase inhibitor BX-759 and IFNα receptor blocker 
It is known that IRF3 is a key factor for the induction of ISGs and type I IFNβ during HCMV infection 
(DeFilippis et al., 2006). Subsequently, expression of IFNβ leads via auto- or paracrine activation of 
the IFNα/β receptor and the Jak/Stat pathway to expression of further ISGs. The question arose 
whether also the expression of i-proteasomes and PA28 was dependent on this signalling cascade. 
Thus, the Tbk1 and IKKε kinases which phosphorylate the transcription factor IRF3 were inhibited by 
application of the kinase inhibitor BX-759. A second approach was to block the IFNα/β receptor with 
the monoclonal antibody MMAHR2. MMAHR2 is raised against the human interferon α/β receptor 
chain 2 and interacts with the extracellular domain, thereby neutralizing the receptor and blocking the 
biological action of type I IFNs. The cartoon in figure 3.11A shows the point of action of both inhibi-
tors.  
 
 
Figure 3.11 Effects of 
Tbk1/IKKε kinase inhibitor and 
IFNα/β receptor blocker on the 
expression of i-subunits and PA28. 
A) Cartoon illustrating the point of 
action of kinase inhibitor BX-795 
and receptor blocker MMAHR2. B) 
MRC5 cells were incubated 1h prior 
to infection with 1µM BX-795 or 
10µg/ml MMAHR2 and infected for 
24h with HCMV Ad169 at moi 5. 
Total cell lysate was subjected to 
immunoblot with indicated antibod-
ies. GAPDH served as loading con-
trol. Graph represents densitomet-
ric analysis of 3 experiments 
normalised to GAPDH (mean±SD). 
 
 
When MRC5 fibroblasts were pretreated for 1h with Tbk1/IKKε kinase inhibitor or IFNα/β receptor 
blocker the expression of both i-subunits β5i and β1i as well as both PA28 subunits was strongly de-
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creased or even abolished as measured in immunoblots 24h after HCMV infection. Moreover, Stat1 
phosphorylation was downregulated in both cases, which proved that the Jak/Stat pathway down-
stream of the IFNα/β receptor was affected by both inhibitors (figure 3.11B).  
Further, it was analysed if effects on the pp65495-503-specific CTL response could be observed at very 
early time points of epitope presentation when expression of i-subunits and PA28 was downregulated 
by interference with this signalling cascade. Remarkably, application of 1µM BX-759 significantly de-
creased antigen presentation already 4hpi (figure 3.12). The effect of the neutralizing antibody 
MMAHR2 was slightly delayed, a significant negative effect was observed 8hpi.  
Hence, the phosphorylation of IRF3 and the subsequent type I IFN response played an intriguing role 
for the induction of i-subunits and PA28 in response to HCMV infection and thereby also affected the 
processing of the immunodominant pp65495-503 epitope. 
 
 
Figure 3.12 Inhibition of IRF3 phosphorylation and 
IFNα/β receptor activation negatively affects presenta-
tion of the pp65495-503 epitope.  MRC5 were incubated 
for 1h with 1µM BX-795 and 10µg/ml MMAHR2 and 
subsequently infected for 4 and 8h with HCMV Ad169 
at moi 5. IFNγ release by pp65495-503 specific CTL was 
measured by ELISA and displayed as percentage of 
the response received by loading MRC5 with 1µg/ml 
pp65495-503 peptide (n = 6 of 3 independent experi-
ments; error bars represent ±SD; n.s. not significant, 
∗∗ p<0.01, ∗∗∗ p<0.001). 
 
 
3.5.3 Key role for transcription factor IRF3 
Due to the prominent effect of kinase inhibitor BX-795, which was supposed to block the phosphoryla-
tion of IRF3 through Tbk1 and IKKε kinase, further experiments were focused on this transcription 
factor. siRNA-mediated depletion of IRF3 was chosen to investigate the role of IRF3 during the innate 
immune response to HCMV. Real-time PCR analysis as well as Western analysis revealed that down-
regulation of IRF3 by siRNA was accompanied by downregulation of β5i, β1i as well as PA28α and 
PA28β on mRNA and protein level (figure 3.13). Also transcription of IFNβ and IRF7, known to be 
induced after virus infection via this pathway (Kawai and Akira, 2007), was strongly decreased as 
expected due to knockdown of IRF3 (figure 3.13A). Abolished IRF3 expression and subsequently re-
duced Stat1 phosphorylation was verified in Western analysis (figure 3.13B). Moreover, a CAT-β1i 
promoter construct was used to investigate whether IRF3 was essentially required to initiate expres-
sion of β1i in response to HCMV infection. MRC5 fibroblasts were therefore firstly incubated for 48h 
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with either 25nM OFF-target or IRF3 targeting siRNA. Subsequently, the cells were transfected with 
the CAT-promoter construct and a pcDNA3.1/lacZ plasmid serving as transfection control. After incu-
bation for further 24 hours the cells were infected for 8h with HCMV Ad169. The determination of the 
received CAT concentrations showed a significant reduction of the β1i promoter activity after IRF3 
knockdown (figure 3.13C). 
 
 
Figure 3.13 Intriguing role for IRF3 in HCMV-induced expression of i-proteasome and PA28. MRC5 were incu-
bated for 48h with 25nM OFF-target or IRF3 siRNA and subsequently infected for indicated time points with 
HCMV Ad169 at moi 5. A) Real-time PCR analysis of indicated genes 24h after infection. Results were expressed 
as average fold change from uninfected MRC5 (mean values of 3 experiments, normalized to HPRT1, error bars 
represent ±SD) B) Western analysis of indicated proteins 24h after infection. GAPDH served as loading control. 
Graph represents densitometric analysis of 3 experiments normalized to GAPDH (mean±SD). C) CAT concentra-
tion reflects β1i promoter activity (average of 2 experiments, error bars represent ±SD; ∗ p<0.05). D) IFNγ re-
lease by pp65495-503 specific CTL was measured by ELISA and displayed as percentage of the response received 
by loading MRC5 with 1µg/ml pp65495-503 peptide (n = 6 of 3 independent experiments; error bars represent ±SD; 
∗∗ p<0.01, ∗∗∗ p<0.001). 
 
Finally, the impact of IRF3 siRNA knockdown on pp65495-503 epitope presentation was analysed. As 
displayed in figure 3.13D abolished IRF3 expression significantly decreased the presentation of the 
pp65495-503 epitope, already after 2h of infection a reduction of about 40% was measured.  
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Consequently, the induction of i-subunits and PA28 was based on IRF3 activation, the type I IFN re-
sponse and autocrine activation of the IFNα/β receptor. The IRF-3 mediated type I IFN response 
thereby led to formation of i-proteasomes and subsequent, improved epitope generation. 
 
3.6 Processing and modification of viral proteins 
3.6.1 Ubiquitylation and oxidation of the viral protein pp65 
Since a translation independent but still proteasome dependent generation of the pp65495-503-epitope 
was shown, the question arose how non-translated pp65 is targeted for proteasomal degradation.  
It is known that viral infection triggers immediate production of reactive oxygen species, as it was 
described for HCMV infection within minutes in infected smooth muscle cells (Speir et al., 1996). 
Western analysis of total cell lysate of virus-infected cells revealed a remarkably early accumulation of 
oxidant-damaged proteins measured 4hpi (figure 3.14A). Furthermore, 2.5-fold elevated ROS levels 
were observed by DCFDA staining and FACS analysis directly (30 min) after virus infection (figure 
3.14B), 6h later ROS levels were reduced again to normal, uninfected levels. Concomitantly, a degra-
dation of oxidized proteins after 8hpi was detected by oxyblot analysis.  
 
 
Figure 3.14 Accumulation of oxidized proteins in the course of viral infection. A) Infection of MRC5 cells with 
HCMV Ad169 at moi 5 for indicated time points. Carbonyl groups of oxidized proteins in total cell lysate were 
derivatized with DNPH and detected in immunoblot with αDNP antibody. GAPDH served as loading control. Densi-
tometric analysis is given below (mean ± SD; normalised to GAPDH; n = 3). Comparing uninfected MRC5 to 4h 
HCMV-infected MRC5 a highly significant increase of oxidized proteins was measured (small graph; error bars 
show ±SD; ∗∗∗ p<0.001) B) Detection of ROS by DCFH-DA staining and flow cytometry in MRC5 cells infected for 
indicated time points with HCMV Ad169 (black bars) or with UV-irradiated HCMV (grey bars). Graph shows aver-
age of the mean fluorescence intensities (MFI) normalized to uninfected cells (n = 3, error bars show ±SD). 
 
Moreover, transient accumulation of ubiquitin conjugates was observed in total cell lysates (figure 
3.15) which was slightly delayed to the induction of oxidation reaching a peak after 4h. Accumulation 
of poly-ubiquitylated proteins increased till 24hpi, thereafter occurred a decrease.  
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Figure 3.15 Accumulation of ubiquitylated proteins in the course of viral infection. MRC5 fibroblasts were in-
fected with HCMV Ad169 at moi 5 for indicated time points. Total cell lysate was separated by SDS-PAGE and 
poly-ubiquitin conjugates were detected by staining with αubiquitin antibody. GAPDH served as loading control. 
Densitometric analysis of 4 blots normalised to GAPDH is given below (mean values ±SD). Comparing uninfected 
MRC5 to 24h HCMV-infected MRC5 a highly significant increase of poly-ubiquitylated proteins was measured 
(small graph; error bars show ±SD; ∗∗∗ p<0.001). 
 
An implication for the modifications of the viral protein pp65 was tested by immunoprecipitation with 
αpp65 antibody from total cell lysate of HCMV-infected fibroblasts at different time points. The precipi-
tates were stained for ubiquitylated as well as oxidized pp65 (figure 3.16). After 2, 4 and 8h of infec-
tion a significant amount of oxidized as well as ubiquitylated pp65 could be precipitated. Remarkably, 
after 24hpi the amount of modified pp65 was strongly reduced presumably due to proteasomal deg-
radation. 
 
 
Figure 3.16 Ubiquitylation and Oxidation of the viral protein pp65. Infection of MRC5 with HCMV Ad169 at moi 
5 for indicated time points. Pp65 was precipitated from total cell lysate using the αpp65 antibody MA-1569. Pre-
cipitates were either separated on SDS-PAGE and analysed by Western Blot with αubiquitin antibody (right panel) 
or carbonyl groups were derivatized with DNPH and then immunoblotted with αDNP antibody (left panel). Densi-
tometric analysis of 4 blots is given below (mean values ±SD). 
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In conclusion, non-translated pp65 which was delivered exogenously to the cytoplasm of the host cell 
during the virus entry process was oxidized due to elevated ROS levels which increase within minutes 
after infection. Consequently, the oxidized ‘defective’ pp65 was rapidly ubiquitylated providing the 
signal for proteasomal degradation. 
 
3.6.2 Ub-conjugation is essential for epitope generation 
3.6.2.1 Involvement of the E2 enzyme UBE2L6 
Concluding that the observed modifications of non-translated pp65 by oxidation and ubiquitylation 
might affect the generation of the immunodominant pp65495-503 epitope, components of the ubiquityla-
tion and oxidation pathway were analysed for their involvement in the modification of pp65. Subse-
quently, crucial enzymes were downregulated or inhibited in order to interfere with ubiquitylation and 
oxidation, respectively, and to investigate the effect on epitope presentation by CTL assay read out.  
In a publication from 2010 by Seifert and colleagues an induction of the ubiquitin-conjugating enzyme 
UBE2L6 by more than 50-fold was observed in response to stimulation with IFNγ (Seifert et al. 2010). 
Further, a knockdown of UBE2L6 with siRNA abolished the accumulation poly-ub conjugates after IFNγ 
stimulation. Therefore, UBE2L6 was involved in IFNγ-mediated poly-ub accumulation.  
In this thesis an immediate induction of UBE2L6 expression in response to HCMV infection was 
demonstrated on mRNA level by real-time PCR analysis as well as on protein level by Western analysis 
peaking 4 to 8h after HCMV infection (figure 3.17A and B). The depletion of UBE2L6 with siRNA inhib-
ited overall ubiquitylation in total cell lysate 4h after HCMV infection significantly (figure 3.17C), com-
paring a 1.6-fold induction of poly-ub conjugates 4hpi under treatment with OFF-target siRNA and 
0.9-fold reduction by application of UBE2L6 siRNA. 
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Figure 3.17 Involvement of E2 enzyme UBE2L6. 
MRC5 were infected with HCMV Ad169 at moi 5 for 
indicated time points. A) Immediate induction of 
UBE2L6 on protein level shown by immunoblot with 
αUBE2L6 antibody. GAPDH served as loading control. 
Densitometrical analysis of 3 experiments, mean val-
ues given below. B) Real-time PCR analysis of UBE2L6 
induction. Results were expressed as average fold 
change from uninfected MRC5 (mean values of 3 ex-
periments, normalized to HPRT1, error bars represent 
±SD). C) MRC5 cells were treated 48h prior to HCMV 
infection with 25nM OFF-target or UBE2L6 siRNA. 
Knockdown was confirmed by immunoblot with 
αUBE2L6 antibody and decreased accumulation of 
poly-ubiquitin conjugates with αubiquitin antibody. 
Densitometric analysis of 3 experiments normalized to 
GAPDH, data shows mean values ±SD (∗ p<0.05). 
 
Immunoprecipitation of pp65 from cell lysates of 4h HCMV-infected cells either treated with UBE2L6 
siRNA or OFF-target siRNA revealed that the ubiquitylation of pp65 was decreased after knockdown of 
UBE2L6 (figure 3.18). Therefore, UBE2L6 seemed to play an important role for the ubiquitylation of 
the viral protein pp65.  
 
 
Figure 3.18 Decreased ubiquity-lation 
of pp65 after depletion of UBE2L6. Im-
munoprecipitation of pp65 after 8h infec-
tion of MRC5 with HCMV Ad169 at moi 5 
and prior treatment with 25nM OFF-
target or UBE2L6 siRNA. The precipitate 
was stained in immunoblot with αubiqui-
tin antibody. Graph represents densito-
metric analysis of 3 experiments, data 
shows mean values ±SD               (∗ 
p<0.05; bc – bead control). 
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Thus, knockdown of UBE2L6 was used to investigate the role of pp65 ubiquitylation for the processing 
and generation of the pp65495-503 epitope. Comparing 48h treatment with OFF-target control siRNA to 
UBE2L6 siRNA, a significant negative effect on the presentation of the pp65495-503 epitope was ob-
served by CTL assay 2h and 4h post HCMV infection (figure 3.19A). Moreover, pp65 protein levels 
seemed to be stabilized due to reduced ubiquitylation. Western analysis showed increased pp65 pro-
tein levels after knockdown of UBE2L6, while the staining of high molecular weight conjugates, which 
appeared with longer exposure times and presumably represent ubiquitylated pp65, was decreased 
(figure 3.19B). 
 
 
Figure 3.19 Impaired pp65495-503 epitope presentation after UBE2L6 knockdown. MRC5 cells were infected 
with HCMV Ad169 at moi 5 for 2h and 4h and pre-treated for 48h with 25nM OFF-target or UBE2L6 siRNA. A) 
IFNγ release of pp65495-503 specific T cells was measured by ELISA and displayed as percentage of the response 
received by loading MRC5 with 1µg/ml pp65495-503 peptide (n = 6 of 3 independent experiments; error bars repre-
sent ±SD; ∗∗ p<0.01). B) Total cell lysate was analysed in immunoblot with αpp65 antibody. GAPDH served as 
loading control. Densitometric analysis of 4 experiments normalised to GAPDH is given below, data shows mean 
values ±SD. 
 
3.6.2.2 Knockdown of 19S subunit Rpn10 verifies the role of ubiquitylation 
After observing the intriguing effect of the UBE2L6 knockdown on the ubiquitylation of the viral pro-
tein pp65, the 19S regulatory complex was addressed for further investigations. The access to the 
catalytical active sites within the barrel-shaped 20S core proteasome is regulated by the 19S regulator 
which docks at the ends of the barrel to open the channel. 19S subunits recognize ubiquitin moieties 
conjugated to target proteins. One of the subunits, Rpn10, contains an ubiquitin-interacting motif 
(UIM) that exhibits high affinity for poly-ubiquitin chains (Finley, 2009). 
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Thus, we silenced Rpn10 by treatment with PSMD4 siRNA which targets Rpn10. 4h post HCMV infec-
tion the accumulation of poly-ubiquitin conjugates was further increased in comparison to uninfected 
MRC5 and HCMV-infected MRC5 treated with OFF-target siRNA (figure 3.20A). The downregulation 
was verified in Western analysis with αRpn10 antibody. Moreover, pp65 protein levels were also ele-
vated after downregulation of Rpn10 indicating an impaired degradation of poly-ubiquitylated pp65 
(figure 3.20A). Subsequently, by CTL assay analysis a highly significant reduction of epitope presenta-
tion was observed after inhibiting Rpn10 expression with siRNA (figure 3.20B). As early as 2hpi a re-
duction of about 33% was measured which was enhanced 4hpi to more than 48%. These experiments 
further underline the importance of poly-ubiquitylation for the processing of the pp65495-503 epitope. 
 
 
Figure 3.20 siRNA knockdown of the 19S subunit Rpn10 ablates the processing of pp65. MRC5 cells were in-
fected with HCMV Ad169 at moi 5 for 2h and 4h. Either 50nM OFF-target or PSMD4 (Rpn10) siRNA was applied 
48h prior to virus infection. A) Total cell lysate was subjected to immunoblot analysis with αubiquitin, αpp65 and 
αRpn10 antibodies. GAPDH served as loading control. Densitometric analysis of 3 experiments normalised to 
GAPDH is given below (mean values ±SD). B) IFNγ release by pp65495-503 specific CTL was measured by ELISA 
and displayed as percentage of the response received by loading MRC5 with 1µg/ml pp65495-503 peptide (n = 7 of 
3 independent experiments; error bars represent ±SD; ∗∗∗ p<0.001). 
 
3.6.3 Importance of oxidative damage for the processing of the 
pp65495-503 epitope 
After the discovery of the oxidation and ubiquitylation of the non-translated virus protein pp65 and the 
remarkable effect of the downregulation of certain components of the UPS on the generation of the 
immunodominant pp65495-503 epitope, focus was laid on the oxidative damage of pp65 and its im-
portance for the processing of the same epitope. It was assumed that the signal for the immediate 
ubiquitylation of non-translated pp65 represents the induction of reactive oxygen species and subse-
quent rapid oxidation of intracellular proteins. Accumulation of oxidized proteins also preceded the 
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accumulation of ubiquitin conjugates in total cell lysates of fibroblasts after infection with HCMV and in 
HeLa cells after influenza A infection (figure 3.14 and 3.15, IAV data not shown).  
 
3.6.3.1 Antioxidant sulforaphane 
The antioxidant sulforaphane represents an efficient inhibitor of oxidative stress due to the activation 
of phase II enzymes, which help to remove oxidized proteins from cells. Pre-treatment of target cells 
with 10µM sulforaphane for 24h reduced the induction of oxidation as well as ubiquitylation in total 
cell lysate significantly (figure 3.21).  
 
 
Figure 3.21 The antioxidant sulforaphane abolishes accumulation of ubiquitin conjugates as well 
as oxidant-damaged proteins after HCMV infection. MRC5 were pre-treated for 24h with 10µM sul-
foraphane and infected with HCMV Ad169 at moi 5 for 4h. Total cell lysate was subjected to immunoblot with 
αubiquitin antibody (right) and to oxyblot (left). GAPDH served as loading control. Graphs represent densitometric 
analysis of 4 experiments normalised to GAPDH (mean values ±SD; ∗ p<0.05). 
 
Precipitation of the viral protein pp65 revealed that also the oxidation and ubiquitylation of pp65 is 
negatively affected by application of the antioxidant (figure 3.22). 
  
Results  P a g e  | 67 
 
Figure 3.22 The antioxidant sulforaphane impairs the ubiquitylation and oxidation of pp65. Im-
munoprecipitation of pp65 from total cell lysate of MRC5 pre-treated for 24h with 10µM sulforaphane and infected 
with HCMV Ad169 at moi 5 for 2h and 4h. Precipitate was analysed in oxyblot and in immunoblot with αubiquitin 
antibody. Graphs represent densitometric analysis of 3 experiments, data shows mean values ±SD (n.s. not sig-
nificant, ∗ p<0.05, ∗∗ p<0.01). 
 
A remarkable effect of the reduced oxidation and concomitantly decreased ubiquitylation was found 
by CTL assay analysis 2h and 4h after HCMV infection. The antigen presentation of the pp65495-503 
epitope was significantly decreased after 24h pre-treatment with sulforaphane (figure 3.23A). Because 
virus infection or the induction of i-proteasomes might be itself affected by the application of antioxi-
dant, pp65 and β5i protein levels were investigated by Western analysis. The amount of pp65 in total 
cell lysates at early time points after infection remained unaffected revealing unchanged infection 
efficiency. Even slightly elevated pp65 levels were observed probably due to impaired degradation of 
non-modified, more stable pp65. As well the expression of the i-subunit β5i was not significantly af-
fected (figure 3.23B) under the influence of the applied concentration of sulforaphane. Thus, an effect 
on the processing of pp65 by increased i-proteasome expression in response to sulforaphane treat-
ment, which was reported in 2007 by Kwak and colleagues (Kwak et al., 2007), was ruled out.  
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Figure 3.23 The antioxidant sulforaphane compromises the presentation of the pp65495-503 
epitope. MRC5 were treated for 24h with 10µM sulforaphane and infected with HCMV Ad169 at moi 5 for 2h and 
4h. A) IFNγ release by pp65495-503 specific CTL was measured by ELISA and displayed as percentage of the re-
sponse received by loading MRC5 with 1µg/ml pp65495-503 peptide (n = 4 of 3 independent experiments; error 
bars represent ±SD; ∗∗ p<0.01). B) Total cell lysate was employed for Western analysis with αpp65 and α-β5i 
antibody. GAPDH served as loading control. Densitometric analysis of 2 experiments normalised to GAPDH is 
given below (mean values ±SD).  
 
To prove the hypothesis that oxidation as well as ubiquitylation of antigenic peptides plays a general 
role during the processing of viral antigens and the generation of immunodominant epitopes, the ef-
fect of sulforaphane application was analysed within another virus infection model. Permissive HeLa 
cells were infected with influenza A virus and incubated prior to infection with 10µM sulforaphane. 
Again with CTL assay the presentation of the immunodominant M158-66 epitope was investigated and 
likewise to the observed effect on the pp65495-503 epitope a reduced presentation by around 30% was 
observed (figure 3.24). 
 
 
Figure 3.24 The antioxidant sulforaphane 
compromises the presentation of the M158-66 
epitope. HeLa cells were treated for 24h with 10µM 
sulforaphane and subsequently infected with IAV at 
moi 5 for indicated time points. IFNγ release by M158-66 
specific CTL was measured by ELISA and displayed as 
percentage of the 100% response received by loading 
MRC5 with 1µg/ml M158-66 peptide (n = 4 of 2 inde-
pendent experiments; error bars represent ±SD). 
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3.6.3.2  NADPH oxidases 
Following up the prominent effect of the antioxidant sulforaphane a search for the responsible ROS- 
producing enzyme or enzymes was carried out. The quest was concentrated on NADPH oxidases 
which are expressed in the target cells, which might mediate the immediate induction of ROS in re-
sponse to virus infection and which therefore could be involved in antigen presentation. Out of the 
seven known members of the Nox family of NADPH oxidases, two candidates were chosen known to 
be expressed in fibroblasts and to play a role in innate immunity, Nox1 and Nox4 (Rada and Leto, 
2008). By means of PCR analysis Nox4 expression could be detected in unstimulated fibroblasts as 
well as in HeLa cells with a remarkable induction after HCMV and IAV infection, respectively (figure 
3.25A). Application of siRNA targeting Nox4 resulted in downregulation of Nox4 mRNA levels after 
virus infection (figure 3.25A). Moreover, on the Affymetrix microarray about 2-fold Nox4 induction was 
detected after 4h HCMV infection in fibroblasts as well as after 4h IAV infection in HeLa cells (see 
attachment). Further, ROS levels were significantly reduced in response to HCMV infection after Nox4 
siRNA knockdown measured by DCFH-DA staining (figure 3.25B). Notably, these experiments were 
also repeated with similar results in IAV-infected HeLa cells (data not shown). 
 
 
Figure 3.25 Nox4 is responsible 
for the induction of ROS in HCMV-
infected fibroblasts. MRC5 cells were 
infected with HCMV Ad169 at moi 5 for 
indicated time points. 50nM OFF-target 
or Nox4 siRNA was applied 48h prior to 
infection. A) RT-PCR analysis of Nox4 
induction and knockdown with Nox4 
siRNA. B)  Detection of ROS by DCFH-
DA staining and FACS analysis. Data 
represents average of the mean fluo-
rescence intensities (MFI) normalized to 
uninfected cells (mean values of 3 ex-
periments; error bars show ±SD;                 
∗ p<0.05). 
 
Thus, in total cell lysates of HCMV-infected fibroblasts the accumulation of oxidized and ubiquitylated 
proteins was significantly reduced after Nox4 downregulation (figure 3.26).  
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Figure 3.26 Knockdown of Nox4 decreases oxidation as well as ubiquitylation in HCMV-infected 
MRC5. Total cell lysate of 2h and 4h HCMV Ad169-infected fibroblasts after pre-treatment with 50nM OFF-target 
or Nox4 siRNA was subjected to oxyblot (left) and to immunoblot with αubiquitin antibody (right). Graphs repre-
sent densitometric analysis of 3 (oxyblot) and 4 (ub-blot) experiments normalized to GAPDH, data shows mean 
values ±SD (∗ p<0.05, ∗∗ p<0.01). 
 
Further, decreased oxidation and ubiquitylation of the virus protein pp65 was verified by immunopre-
cipitation of pp65 and staining in immunoblot for poly-ubiquitin and carbonyl groups (figure 3.27). 
 
 
Figure 3.27 Depletion of Nox4 
diminishes the oxidation and ubiq-
uitylation of pp65. Immuno-
precipitation of pp65 from lysate of 
MRC5 cells 4h infected with HCMV Ad169 
at moi 5 and prior treatment with 50nM 
OFF target or Nox4 siRNA for 48h. Pre-
cipitate was analysed in oxyblot and in 
immunoblot with αubiquitin antibody. 
Densitometric analysis of 2 experiments, 
data shows mean values ±SD. 
 
Finally, the presentation of the pp65495-503 epitope was found to be remarkably reduced during the 
important early phase of the CTL response to HCMV infection when cells were pre-treated 48h with 
Nox4 siRNA (figure 3.28A). Moreover, monitoring pp65 protein levels in total cell lysate a slight accu-
mulation of pp65 was observed following Nox4 knockdown, which might be explained by decreased 
oxidation and concomitantly reduced proteasomal degradation of pp65 thereby stabilizing pp65. In 
conclusion, the experiments suggested that Nox4 activity supported the oxidation of pp65 and thereby 
affected the generation of the pp65495-503 epitope. 
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Figure 3.28 Depletion of Nox4 with siRNA impairs pp65495-503 epitope presentation. MRC5 were in-
cubated for 48h with 50nM OFF-target or Nox4 siRNA and subsequently infected with HCMV Ad169 at moi 5 for 
2h and 4h. A) IFNγ release by pp65495-503 specific CTL was measured by ELISA and displayed as percentage of the 
response received by loading MRC5 with 1µg/ml pp65495-503 peptide (n = 7 of 3 independent experiments; error 
bars represent ±SD; ∗ p<0.05, ∗∗ p<0.01). B) Total cell lysate was subjected to immunoblot with αpp65 anti-
body. GAPDH served as loading control. Densitometric analysis of 3 experiments normalized to GAPDH, data 
shows mean values ±SD. 
 
3.6.4 A general mechanism 
The previous results arose the question whether oxidation and concomitant ubiquitylation might affect 
antigen presentation in general. Assuming that not only the presentation of the pp65495-503 and M158-66 
epitopes is affected by ROS levels, MHC class I surface expression should be itself downregulated 
when oxidation or hence ubiquitylation is reduced. 
To go to the bottom of this question HeLa cells were treated with IFNγ in order to enhance MHC class 
I surface expression. Additionally, siRNAs were applied to knockdown the ROS-producing NADPH oxi-
dase Nox4 or the 19S subunit Rpn10. Subsequently, cells were labeled with an αHLA-A,B,C antibody 
and MHC class I surface expression was monitored by flow cytometry (figure 3.29). As expected, 
stimulation with IFNγ strongly induced MHC class I complexes on the cell surface in comparison to 
unstimulated cells (0h time point). Upon interference with oxidation by downregulation of Nox4 or 
with degradation of ubiquitylated proteasomal substrates via knockdown of Rpn10 the presentation of 
MHC class I molecules on the cell surface was significantly reduced. Therefore, a fundamental role of 
ROS production and concomitant ubiquitylation of oxidized proteins leading to efficient proteasomal 
degradation during the processing of viral antigens was assumed.  
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Figure 3.29 Inhibition of oxidation as well as 
ubiquitylation impairs MHC class I surface expres-
sion. FACS staining of MHC class I surface expression with 
αHLA-A,B,C-PE antibody. HeLa cells were treated for 48h 
with 50nM OFF-target, Nox4 or PSMD4 siRNA and subse-
quently stimulated for 24h with 100U/ml IFNγ.  Data repre-
sents average of the mean fluorescence intensities (MFI) 
normalized to unstimulated cells (mean values of 3 experi-
ments; error bars show ±SD; ∗ p<0.05, ∗∗ p<0.01). 
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4. Discussion 
A primary virus infection mostly occurs in non-immune cells, as for example influenza A infection is 
initiated in epithelial cells of the lung. Dedicated antigen-presenting cells, such as DCs and macro-
phages, take up pathogens to trigger the priming of naïve CD8+ T cells in a process called cross-
presentation (described in chapter 1.2.2). Subsequently, virus-infected target cells presenting antigens 
via MHC class I molecules can be eliminated by differentiated CTLs.  
Indeed, the work described within this thesis shows that upon virus infection non-immune cells are 
able to present antigenic peptides at remarkably early time points (chapter 4.1). This very early anti-
gen presentation appeared to occur independently of protein synthesis. Two immunodominant 
epitopes, the pp65495-503 of HCMV and M158-66 epitope of IAV, could be shown to be presented before 
the viral gene expression is initiated and therefore to be generated translation-independent (chapter 
4.1.1). Still their generation was dependent on proteasomal degradation and improved by the induc-
tion of i-proteasomes (chapter 4.2). Therefore, the changes imposed by viral infection on the early 
proteasome pool in HCMV-infected cells were scrutinized. Further, it was of interest to understand 
how i-proteasomes can be induced with such fast kinetics in face of viral immunoevasion strategies 
(chapter 4.2.1).  
To answer the question how stable viral proteins are targeted for proteasomal degradation, the re-
cently discovered ability of the i-proteasome to efficiently degrade oxidant-damaged proteins and 
protect cells against the accumulation of toxic protein aggregates was regarded. Posttranslational 
modifications of viral antigens and the impact of these modifications on the generation of immu-
nodominant epitopes were investigated (chapter 4.3). Indeed a link between the two major functions 
of the i-proteasome to protect cells against inflammation-induced oxidative damage and to improve 
the generation of peptides for MHC class I antigen presentation could be revealed (chapter 4.3.3). 
 
4.1 Very early antigen presentation 
The replication cycles of human cytomegalovirus and influenza A virus, as described in chapter 1.5.1 
(HCMV) and 1.5.2. (IAV), exhibit great differences with regard to the time course of infection. HCMV 
represents a rather slow progressing virus: one infection cycle from the entry of virus particles into 
host cells up to the assembly of new particles took around 72 hours in cell culture for infection of pri-
mary human lung fibroblasts. The IAV replication cycle was completed already after eight hours with 
the lysis of infected HeLa cells and the release of new virions. In this regard the observation that in-
fection with both viruses produced a very early antigen presentation of selected immunodominant 
epitopes to specific cytotoxic T lymphocytes was quite surprising. Peak levels of antigen presentation 
of the HCMV pp65495-503 as well as the IAV M158-66 epitope were observed already four hours post in-
fection (figure 3.2 HCMV and figure 3.3 IAV). The presentation of the M158-66 epitope declined eight 
hours post infection coinciding with the lysis of infected cells, which was recognisable in cell culture in 
form of increasing cell death. Therefore the IAV-induced cell lysis explains the reduced antigen 
presentation and concomitant decreased activation of epitope-specific CTLs at later time points. The 
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pp65495-503 specific CTL response to infection with the slow propagating HCMV was significantly re-
duced after 24 hours at the transition of early to late viral replication phase. Notably, infection with 
HCMV also at later time points did not result in cell lysis. Instead, the declining pp65495-503-specific CTL 
response was connected to HCMV immune escape mechanisms. 
Mainly the HCMV-mediated downregulation of MHC class I surface expression was responsible for 
reduced activation of HCMV-specific CTL after 24hpi, which is well described in the literature: Four 
HCMV gene products, so called immunoevasins, are acting together to abolish MHC class I antigen 
presentation in general: i) the glycoproteins gpUS2 and gpUS11 redirect nascent MHC class I com-
plexes from the ER to the cytoplasm and target MHC class I for ubiquitylation and proteasomal degra-
dation ii) gpUS3 inhibits translocation of MHC class I from ER to Golgi and iii) gpUS6 interferes with 
peptide loading on MHC class I by binding to TAP (Ahn et al., 1996; Hengel et al., 1996; Wiertz et al., 
1996). Recently, also a transcriptional downregulation of TAP1 and TAP2 was described (Halenius et 
al., 2011). Further, we had the possibility to test our infection model and CTL assay read-out with the 
HCMV ΔUS2-11 deletion mutant obtained from Hartmut Hengel and Anne Halenius. With the mutant 
virus an ongoing and increasing antigen presentation was observed, since the virus causes no lysis of 
target cells and the expression of the MHC class I-targeting immunoevasins was abolished (see at-
tachment figure 1).  
Notably, also during infection with wild type virus epitope presentation was measured up to 72 hours 
post infection, although the levels were significantly reduced. Already in 2007 Besold and colleagues 
observed that the presentation of the pp65495-503 epitope persists despite the expression of immuno-
evasins while another immunodominant epitope of the non-structural pp72 - the pp72297–305 epitope 
which was described in (Gallez-Hawkins et al., 2003) - was abolished in presence of the glycoproteins 
gpUS2-11 (Besold et al., 2007).  
Importantly, the proportion of CD8+ T cells committed to the anti-HCMV response is extraordinarily 
large in infected humans and the most dominant antigen for the activation of CTLs represents pp65 
(McLaughlin-Taylor et al., 1994). Of all HCMV-directed CTLs 70 to 90% recognise pp65 epitopes and 
moreover the CTL response is often focused on only one peptide (Wills et al., 1996). One of these 
peptides is the here studied HLA-A2+-restricted pp65495-503 epitope (Weekes et al., 1999). Ex vivo pro-
filing of CD8+ T cell responses of infected humans revealed that around 10% of CD8+ T cells in the 
peripheral blood of healthy virus carriers and up to 40% of CD8+ T cells of elderly infected individuals 
can be specific only for HCMV antigens (Elkington et al., 2003). Still the largest expanding CTL clone 
does not have to elicit the most efficient CTL response for the restriction of HCMV infection.  
Moreover, the extensive expansion of HCMV-specific CTL clones could lead to the reduction of the 
naïve T cell pool. Further, in contrast to the immune response to other virus infections, HCMV-specific 
CD8+ T cells accumulate with age, a phenomenon called ‘memory inflation’. HCMV infection may con-
tribute to immune senescence which is characterised by the reduction of levels of naïve T cells and 
the accumulation of clonally expanded memory T cells leading to a decline of the immune responsive-
ness of the individual. Indeed, HCMV-infected individuals show a higher rate of CD8+ T cell clonal 
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expansions and reduced mitogen-stimulated proliferative responses which leads to the conclusion that 
the immunodominance of HCMV antigens may hinder responses to other pathogens (Crough and 
Khanna, 2009). In this regard the question arises: what makes the HCMV pp65 antigen so immuno-
genic to provoke such large immune responses even in the face of viral strategies to subvert the im-
mune control (described in detail in chapter 1.5.1)? To elucidate this question during this thesis the 
time points of expression and processing as well as posttranslational modifications of the pp65 antigen 
were scrutinised. 
 
4.1.1 The DRiP hypothesis 
Surprisingly, HCMV pp65 as well as IAV M1 protein both represent late expressed proteins in the viral 
gene expression cascade, i.e. 24hpi for pp65 and 6hpi for M1, which was confirmed on the protein 
expression level with immunoblot analysis in figure 3.1. Still, presentation of epitopes derived from the 
respective viral proteins was measured already 2hpi (figure 3.2 for HCMV and figure 3.3 for IAV infec-
tion). A possible explanation is that both proteins represent structural components of the virus parti-
cle. Pp65 as component of the viral tegument, which is characteristic for herpesviridae, is embedded 
between the viral envelope and the nucleocapsid (Gibson, 1996). The M1 protein of IAV, an or-
thomyxovirus, constitutes the matrix, a thin layer between viral envelope and ribonucleoprotein com-
plexes (Nayak et al., 2009). 
According to the DRiP hypothesis newly synthesized defective ribosomal products serve as the major 
substrate for the proteasome to generate MHC class I ligands (Yewdell, 2007). Yewdell discriminates 
according to their half-life different pools of polypeptides: i) rapidly degraded polypeptides (RDPs), 
with a half-life of ten minutes on average, and ii) slowly degraded polypeptides (SDPs), which are 
characterised by a half-life over one hour. The generation of peptide ligands from polypeptides of the 
RDP as well as the SDP pool occurs within similar kinetics, which can be explained by the usage of a 
DRiP source (Yewdell, 2007). The DRiP hypothesis therefore delivers an explanation on how long-
lived, stable and also compartmentilised viral proteins can be fed into the MHC class I antigen presen-
tation pathway (Khan et al., 2001a). Consequently, the generation of MHC class I ligands from DRiPs 
is dependent on protein synthesis (Reits et al., 2000; Schubert et al., 2000).  
A direct example for IAV antigenic peptides deriving from DRiPs was given by the group of Yewdell in 
2010 (Dolan et al., 2010). They inserted the SIINFEKL epitope, which is derived from ovalbumin, into 
the stalk of IAV neuraminidase (NA) and precisely quantitated the cell surface expression of Kb-
SIINFEKL complexes by flow cytometry. The epitope was generated in complete lockstep with the 
initiation and abrogation of NA biosynthesis. Moreover Kb-SIINFEKL presentation required proteasomal 
activity as well as TAP transport consistent with its generation from a cytosolic DRiP pool. The differ-
ence in the shutoff kinetics of Kb-SIINFEKL complex expression following inhibition of protein synthesis 
versus proteasome inhibition suggested a half-life of the biosynthetic source of NA peptides of approx-
imately five minutes. 
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Within this thesis the analysis of antigen presentation was focused on early time points before DRiPs 
from a viral protein pool were available. Our work showed that immunodominant epitopes of HCMV as 
well as IAV were presented before viral gene expression started, thus independent of protein synthe-
sis. This could be proven by application of a translation inhibitor as well as by infection with UV-
irradiated virus. Antigen presentation of the pp65495-503 epitope was unaffected by both methods in 
CTL assay analysis (figure 3.5). Further, in immunoblot analysis the non-structural HCMV protein pp72 
could not be detected after UV irradiation or cycloheximide treatment while pp65 was still detected at 
early time points but not at later time points when de novo synthesis would occur (figure 3.4A and B). 
Similarily, expression of the non-structural IAV protein NS1 was abolished by translation inhibition 
while protein levels of M1 remained unaffected at early time points (figure 3.4C). In conclusion, both 
viral proteins, pp65 and M1, as components of the virus particle, appear to be delivered to the cytosol 
of the host cell during the virus entry process. Schmolke and colleagues observed that pp65 translo-
cates to the nucleus of the host cell within five minutes after infection by its NLS (Schmolke et al., 
1995a). Immunofluorescence analysis performed during this thesis confirmed a concentration of pp65 
in the nucleus of MRC5 cells after one hour of infection and only light staining in the cytoplasm and 
the surrounding of the nucleus (data not shown). Likewise, the M1 protein is transported to the nu-
cleus of the host cell, which was reported to occur after 25 minutes while an hour later M1 is evenly 
distributed between nucleus and cytoplasm (Martin and Helenius, 1991). Thereby the antigen pro-
cessing machinery of the host cell gains access to these viral proteins immediately after infection even 
before viral immune escape mechanisms can set in, which has been postulated earlier for pp65 
(Reddehase, 2002).  
The independence of translation inhibition explains the strong and early epitope presentation and 
possibly contributes to the overzealous pp65-directed CTL response. The data suggests that a com-
plementary mechanism to the DRiP hypothesis exists, which makes stable viral proteins available for 
proteasomal degradation and generation of antigenic peptides before defective ribosomal products 
can serve as substrate (see chapter 4.3.3).  
 
4.2 Role of the i-proteasome for epitope generation 
The group of Bodo Plachter had shown that despite resistance against the HCMV-mediated MHC class 
I downregulation the presentation of the pp65495-503 epitope was still dependent on proteasomal activi-
ty (Besold et al., 2007). By application of the proteasome inhibitors epoxomicin or lactacystin the 
presentation of the pp65495-503 epitope was significantly reduced in IFNγ ELISPOT analysis with 
epitope-specific CTLs. Also in this thesis by infection of MRC5 with HCMV Ad169 and application of 
200nM epoxomicin the generation of the pp65495-503 epitope was abolished almost completely at each 
analysed time point during the course of infection from 2 to 72hpi (figure 3.2). Likewise, the M158-66-
specific CTL response was strongly reduced by application of 200nM epoxomicin (figure 3.3). In con-
clusion, the generation of both immunodominant epitopes, although translation-independent, was 
generally dependent on proteasomal degradation. Still, it was unclear if the processing of both viral 
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antigens was also ub-mediated and how non-translated stable viral proteins were targeted for pro-
teasomal degradation (see chapter 4.3). 
Firstly, attention was focused on characteristic changes of the proteasome population, such as subunit 
composition and association with regulatory complexes, in the respective host cells and in response to 
virus infection. Here, the model system of HCMV infection in MRC5 fibroblasts was chosen. In sum-
mary, an increase of proteasome expression was observed together with an additional slight induction 
of mixed-type proteasome complexes containing the β5i and β1i subunit (figure 3.6). Moreover, the 
expression of PA28 α- and β-subunits was induced which suggested an association of 26S pro-
teasomes with the PA28 regulator possibly forming hybrid proteasomes (figure 3.6). By immunopre-
cipitation (figure 3.6D) and Native page analysis (figure 3.7) the incorporation of both i-subunits, 
though at low levels, and association with PA28 was verified. 
Formation of i-proteasomes as well as induction of PA28 has been mostly associated with positive 
effects on the generation of viral antigenic peptides for presentation on MHC class I complexes to 
specific CD8+ T cells. In 2000 Sijts and colleagues could show by using TET-inducible expression of i-
subunits that already low levels of i-proteasomes increase the efficieny of antigenic peptide formation 
(Sijts et al., 2000b). Nevertheless, in vivo studies with knockout mice revealed that i-proteasomes can 
have differential effects on the generation of different epitopes from IAV (using β1i-deficient mice 
(Chen et al., 2001)) or LCMV (using β1i/β5i-deficient mice (Basler et al., 2004; Nussbaum et al., 
2005)) probably influencing immunodominance hierarchies (Sijts and Kloetzel, 2011) (see chapter 
1.4.1). Investigations by Hutchinson and colleagues with β5i knockout mice and MCMV infection re-
vealed that CD8+ T cell responses were generally affected for a range of tested immunodominant as 
well as subdominant MCMV-epitopes which suggested a dominant role of i-proteasomes for CD8+ T 
cell responses to MCMV infection (Hutchinson et al., 2011). 
Previously, our group could show using purified s- and i-proteasome to digest a 33mer pp65 peptide 
containing the pp65495-503 epitope a proteasome-dependent processing of the same epitope (Urban et 
al., 2012). Moreover, in vitro digestion with i-proteasomes resulted in a more efficient substrate deg-
radation as well as generation of pp65 epitopes and epitope-precursors. Thereby s- and i-proteasomes 
used the same cleavage sites so that identical peptide products were received but in a significantly 
higher amount with i-proteasomes leading to more efficient epitope generation. Possibly, the in-
creased capacity of i-proteasomes compared to s-proteasomes to generate antigenic peptides results 
either from an increased chymotryptic activity following the incorporation of β5i (Strehl et al., 2008) or 
from conformational changes improving the substrate accessibility to the active sites (Sijts et al., 
2000a). Further supporting the role for i-proteasomes were experiments in a cellular system: HLA-A2+ 
HeLa cells constitutively expressing i-subunits were transiently transfected with a plasmid expressing a 
14mer precursor peptide of the pp65495-503 epitope. In comparison to HLA-A2+ HeLa cells without ex-
pression of i-proteasomes a stronger epitope-specific CTL response was observed after six hours of 
transient transfection of the pp65-plasmid (Urban et al., 2012). The stability of the pp65 protein sug-
gested that proteasomal degradation and epitope generation occurred via the DRiP pathway transla-
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tion-dependent. In the context of transient transfection experiments the source for proteasomal deg-
radation of pp65 might represent defective translation products, while this was clearly ruled out here 
using whole virus particles for infection because of the very early epitope presentation and independ-
ence of translation. 
Nevertheless, the impact of i-proteasome induction was also analysed during infection of MRC5 fibro-
blasts with HCMV Ad169. Therefore, prior to infection each of the i-subunits β5i and β1i were down-
regulated alone or in combination with siRNA which led to a significant reduction of pp65495-503 epitope 
presentation in CTL assay (figure 3.8). Thereby siRNA knockdown of the β1i, the β5i subunit and both 
i-subunits in combination gradually resulted in a stronger negative impact on the antigen presentation. 
Moreover, siRNA downregulation of PA28 similarly caused a decreased epitope generation (figure 3.9). 
Thus, in concert with previous in vitro data mixed-type proteasome complexes containing β5i and β1i 
as well as the proteasome activator PA28 improved the generation of the pp65495-503 epitope. 
Interestingly, the group of Hartmut Hengel carried out several investigations with MCMV and HCMV 
infection analysing immune escape mechanisms that abolish the induction of i-proteasomes (Khan et 
al., 2004; Le et al., 2008; Zimmermann et al., 2005). Already in 2000 another group had observed an 
inhibition of IFNγ-stimulated expression of the MHC class I antigen presentation machinery including 
proteasome genes peaking after 72hpi with HCMV (Miller et al., 2000). Khan et al. reported in 2004 a 
disturbed induction of i-proteasomes in response to MCMV as well as HCMV infection. Notably, they 
also analysed the expression of i-subunits 72 hours after infection with HCMV. Here, an increase of 
the i-subunits β5i and β1i as well as PA28 was observed on mRNA and protein level already after four 
hours, peaking after eight hours of infection. In agreement with previous data, a decrease was ob-
served 48 to 72hpi (figure 3.6). For MCMV infection Khan and colleagues could show that the down-
regulation occurs on the level of transcription and that the MCMV protein M27 might be responsible 
due to its inhibition of STAT2 (Khan et al., 2004). In 2008 Le and colleagues observed that also during 
HCMV infection the activation of STAT2 is affected: HCMV interferes with STAT phosphorylation and 
further induces proteasomal degradation of STAT2 (Le et al., 2008). Possibly, STAT inhibition is based 
on an interaction with the HCMV immediate early protein pp72 (Paulus et al., 2006). 
Nevertheless, a significant early induction of mixed-type proteasome complexes associated with PA28 
was observed within the scope of this thesis. This induction further resulted in an improvement of the 
generation of the immunodominant pp65495-503 epitope to elicit an efficient early HCMV-specific CTL 
response. In the following chapter the induction of i-proteasomes and PA28 in response to HCMV 
infection will be further discussed. 
 
4.2.1 Induction of the i-proteasome in response to HCMV infection 
Heink and colleagues observed a 4-fold accelerated assembly of i-proteasomes compared to s-
proteasomes in response to IFNγ signalling which was essentially dependent on the induction of, and 
interaction between, proteasome maturation protein (POMP) and β5i (Heink et al., 2005). In the pre-
sent thesis, in response to HCMV infection an immediate and transient increase of POMP and β5i was 
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also observed (figure 3.6C). Moreover, the immediate formation of i-proteasomes was verified by im-
munoprecipitation and Native page analysis (figure 3.6D and 3.7). It is known that in response to IFNγ 
signalling STAT1-dependent expression of all three i-subunits as well as the PA28 α- and β-subunit is 
increased (Ahn et al., 1995; Barton et al., 2002; Chatterjee-Kishore et al., 2000). Further, type I IFNs 
and pro-inflammatory cytokines are reported to induce the formation of i-proteasomes (Shin et al., 
2006). Interestingly, the basal expression level of i-subunits in immune cells is unlikely to be depend-
ent on cytokine stimulation but dependent on intracellular signaling, for example unphosphorylated 
STAT1 was reported to bind to IRF1 forming a complex that docks to the GAS sequences within the 
β1i promoter (Chatterjee-Kishore et al., 2000). 
The remarkably fast kinetics of i-proteasome formation in response to viral infection, with an increase 
of β5i mRNA after two hours and on protein level four hours post infection (figure 3.6), were observed 
here for the first time in a cell culture model of HCMV infection in MRC5 fibroblasts. Thus, it was of 
interest to further examine the underlying innate immune mechanisms and signalling pathways lead-
ing to the expression of i-subunits and PA28. Especially in the case of HCMV infection the question 
arises how i-proteasome formation circumvents the multi-layered immune escape which is initiated by 
the virus. 
Induction of the innate immune response. So far, investigations about the initiation of the innate 
immune response triggered by HCMV infection resulted in controversial publications. The ambiguity of 
the data is based on the ability of the virus to infect many different cell types utilizing different cellular 
receptors and sensors (Compton, 2004). Clearly, the induction of the innate immune response includ-
ing the production of IFNs and the secretion of ICs is directly linked to the entry of the virus into the 
host cell. First evidence derived from microarray analysis of Zhu and colleagues in 1998. They com-
pared uninfected and HCMV-infected human foreskin fibroblasts and observed the induction of many 
antiviral RNAs before the onset of viral gene expression (Zhu et al., 1998). Later, microarray analysis 
comparing HCMV infection of cycloheximide-treated host cells or infection with UV-inactivated virus 
revealed the upregulation of various mRNAs including those encoding for ISGs and IFNβ itself. Inter-
estingly, the induction was independent of gene transcription, presumably triggered solely by HCMV 
binding and entry (Browne et al., 2001). Similarly, in this thesis the induction of i-subunits and PA28 
on mRNA as well as increased protein level were observed after infection with untreated and with UV-
inactivated virus (figure 3.10A). Moreover, elevated levels of β5i and β1i were observed 24 hours after 
infection with UV-inactivated virus, presumably due to the inhibited expression of HCMV immunomod-
ulatory gene products which would normally interfere with the expression of i-subunits (Khan et al., 
2004; Le et al., 2008). Remarkably, also the activation of STAT1 measured by staining with phospho-
STAT1 antibody on immunoblots (figure 3.10A) as well as the production of IFNβ measured on tran-
scriptional level by real-time PCR analysis (figure 3.10B) was unaltered comparing untreated and UV-
inactivated virus. Hence, the type I IFN response including the activation of the Jak-Stat pathway was 
unaffected and probably also after infection with wild type HCMV strong enough to induce the expres-
sion of antiviral genes. Consequently, a component of the virus particle, which interacts with an as yet 
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unknown cellular sensor, appears to be responsible for the induction of the expression of i-subunits 
and PA28. Potentially, this activation occurs via the type I IFN response. 
For several years scientists were searching for the key component of the HCMV particle that activates 
the fast innate immune response. In 2001 the HCMV envelope glycoprotein gB was proposed to be 
the essential factor for initiating antiviral gene expression without the need for viral gene expression 
(Simmen et al., 2001). Compton et al. have observed an interaction of HCMV, possibly gB, with TLR2 
leading to the activation of NFκB and consequently inducing the transcription of pro-inflammatory 
cytokines (Compton et al., 2003). The same group later discovered a crucial role of interferon regula-
tory factor 3 (IRF3) for the induction of the IFN response (Boehme et al., 2004). In 2006 DeFilippis 
and colleagues could demonstrate by downregulation of IRF3, that indeed IRF3 is essentially required 
for the induction of antiviral genes (DeFilippis et al., 2006). Remarkably, in 2008 by usage of TLR2 
knockout cells and further by blocking endosomal TLRs it became clear that the early type I IFN re-
sponse was initiated TLR-independently by an yet unknown process (Juckem et al., 2008) and the 
search for the responsible virus component began anew. 
Certified facts of the process of virus entry are: the initial attachment of virus particles to their target 
cells occurs via low-affinity tethering to cellular heparin sulfate proteoglycans (HSPGs) and interaction 
with viral envelope glycoproteins (Compton et al., 1993). Subsequently, virus particles dock to cellular 
receptors which appears to occur in a cell-type-specific manner. Further, depending on the cell type 
follows either the fusion with the cell membrane (Compton et al., 1992) or uptake via the endosomal 
pathway resulting in the deposition of virion components into the cytoplasm (Bodaghi et al., 1999). 
Somehow during or following this process cellular sensors activate the IFN response. After the dis-
qualification of TLR signalling for the induction of IFNs RIG-1 came into discussion. But in 2010 a cru-
cial observation from the group of Klaus Früh revealed that the DNA sensor ZBP1 plays an important 
role for the initiation of the IFN response by activating the transcription factor IRF3 (DeFilippis et al., 
2010). Consequently, perhaps not glycoproteins but double stranded DNA could represent the crucial 
virus component. As displayed in figure 4.1 the activated IFN response is divided in two phases: an 
initial activation of IRF3 through phosphorylation by Tbk1 and IKKε kinase, after which hyperphos-
phorylated IRF3 shuttles into the nucleus where it activates target genes e.g. IFNβ itself and other 
ISGs. During the subsequent amplification phase the IFNα/β receptor is activated in an auto- or para-
crine manner, which leads to induction of the Jak-Stat pathway and further expression of ISGs 
(Juckem et al., 2008).  
In the present work, the described innate immune pathways were tested for their involvement in the 
activation of i-proteasome and PA28. It was found that both by inhibition of the IRF3 phosphorylating 
kinases and by blockade of the IFNα/β receptor, the expression of the i-subunits β5i and β1i was abol-
ished. The same was true for the expression of the PA28 α- and β-subunits (figure 3.11). Moreover, 
this also affected the presentation of the pp65495-503 epitope which was significantly reduced after 
inhibition of IRF3 phosphorylation or IFNα/β receptor activation (figure 3.12). Notably, the negative 
effect of blocking the IFNα/β receptor on the antigen presentation did not became significant earlier 
than after eight hours of virus infection. Possibly, in the very early phase of two to four hours post 
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infection an induction of i-subunits occured directly by IRF3-activated gene transcription, independent 
of the type I IFN response. Finally, treatment of the host cells with IRF3-targeting siRNA prior to virus 
infection reduced the induction of i-subunits and PA28 on mRNA (figure 3.13A) and protein level (fig-
ure 3.13B). Similarly, the expression of known IRF3-induced ISGs such as IRF7 and IFNβ itself was 
abolished (figure 3.13A). Moreover, β1i-promoter activity, which was induced in response to HCMV 
infection measured by CAT assay, was significantly reduced when IRF3 expression was blocked (figure 
3.13C). Hence, also antigen presentation was inhibited presumably due to lower levels of i-
proteasomes (figure 3.13D). In conclusion, the crucial role for IRF3 in the signalling pathways leading 
to the expression of i-proteasomes and PA28 in response to HCMV infection and subsequently causing 
an improvement of the antigen presentation could be demonstrated.  
Interestingly, pp65 has been reported to act as a potent immunoevasin by interfering with antiviral 
gene expression (Browne and Shenk, 2003). This is possibly triggered by an interaction of pp65 with 
IRF3 and a subsequent reduction of the IFN response (Abate et al., 2004). Now it was demonstrated 
that IRF3 activation significantly improves the generation of an immunodominant epitope of the same 
viral protein. Still, it is unclear whether the subsequent generation of type I IFNs, which definitely 
leads to induction of i-proteasomes at later time points, is also responsible for the very early expres-
sion of i-subunits and the improvement of the antigen presentation at these time points. Alternatively, 
a short-circuit mechanism may exist which could be induced directly by IRF3. The innate signaling 
pathways which are activated by HCMV infection and are potentiamlly involved in i-proteasome for-
mation are summarized in figure 4.1. 
 
 
Figure 4.1 Induction of the IFN type I re-
sponse by HCMV. HCMV particles enter the cell 
in a cell type-specific manner resulting in the re-
lease of viral components into the cytoplasm. 
Possibly, the DNA sensor ZBP1 recognises viral 
double stranded DNA and activates the kinases 
Tbk1 and IKKε, which in turn phosphorylate IRF3. 
Phosphorylated IRF3 shuttles into the nucleus and 
activates the transcription of ISGs and predomi-
nantly IFNβ. In an auto- or paracrine manner IFNβ 
binds to IFNα/β receptors on the cell surface and 
activates the Jak-Stat pathway. Phosphorylated 
Stat1 and Stat2 heterodimerise and activate the 
transcription of further ISGs thereto the i-subunits 
β5i and β1i as well as both PA28 subunits. 
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4.3 The i-proteasome at the interface of innate and adaptive 
immune responses to viral infection  
4.3.1 Modifications of non-translated pp65 
Remarkably, the very early epitope presentation essentially required proteasomal degradation of non-
translated viral antigens which was further improved by the induction and incorporation of i-subunits 
into proteasome complexes. In this chapter the question how non-translated proteins were targeted 
for proteasomal degradation will be clarified. Therefore, posttranslational modifications which might 
label virus proteins for degradation were considered. 
In a publication from 2010 by our group it was shown that after stimulation of cells with IFNγ the 
generation of reactive oxygen species (ROS) caused a transient accumulation of oxidized as well as 
ubiquitylated proteins (Seifert et al., 2010). Earlier, it has been demonstrated that pro-inflammatory 
cytokines trigger the formation of ROS which consequently cause oxidative stress (Sasaki et al., 2008; 
Watanabe et al., 2003). It could be monitored that IFN-induced oxidative stress mainly affected newly 
synthesized proteins. Nascent proteins seemed to be particularly sensitive to oxidative stress, thus 
cytokine stimulation caused an enhanced formation of oxidized and ubiquitylated DRiPs (Seifert et al., 
2010). The subsequent IFNγ-mediated induction of i-proteasomes induced an efficient and rapid deg-
radation of the poly-ubiquitylated DRiPs, thus providing the removal of potentially toxic oxidant-
damaged proteins (Seifert et al., 2010).  
The data discussed above excluded that the pp65495-503 epitope is generated from a DRiP at the ana-
lysed early time points and instead derives independently of its translation from the virus particle it-
self. Still, it was important to check the oxidation and ubiquitylation levels in the virus-infected cells, 
since also during viral infection ROS are generated as part of the innate host response. It has been 
reported that in response to HCMV infection intracellular ROS levels increase significantly within five 
minutes, as was measured by DCFDA staining in smooth muscle cells (Speir et al., 1996). Likewise, 
infection of MRC5 fibroblasts with HCMV Ad169 elicited a strong increase of ROS levels immediately 
after infection (figure 3.14B). Moreover, the innate ROS response was also initiated by infection with 
UV-irradiated virus, thus directly by entry of virus particles into the host cell. For example, activation 
of TLR signaling triggered by virus-cell contact could lead to the production of ROS and RNS (Orient et 
al., 2007; Rada and Leto, 2008). Consequently, also the amount of oxidant-damaged protein in-
creased almost three-fold within a short time span of four hours inside HCMV-infected fibroblasts (fig-
ure 3.14A). This was also reported in response to influenza A infection in HeLa cells (personal com-
munication with Theresa Bergann). Moreover, in agreement with the data published in (Seifert et al., 
2010), poly-ub conjugates transiently accumulated after viral infection (figure 3.15) indicating ubiq-
uitylation of oxidant-damaged proteins, which will be discussed further.  
During ageing or age-related neurodegenerative diseases dysfunctional proteins tend to aggregate in 
large ub-positive structures (Mishto et al., 2006). Further, in response to physiological stress condi-
tions, such as starvation and cytokine stimulation as well as oxidative stress, protein aggregation is 
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enhanced leading to the formation of aggresome-like induced structures (ALISs) (Szeto et al., 2006). 
Moreover, in phagocytic cells such as DCs and macrophages the recognition of PAMPs entails the for-
mation of so-called dendritic cell aggresome-like induced structures (DALISs) (Lelouard et al., 2002). 
Under inflammatory conditions these structures are believed to occur when the accumulation of aber-
rant and oxidant-damaged proteins temporarily exceeds the degradation capacity of the proteasome. 
Notably, the formation of ALIS in response to oxidative stress has been shown to be dependent on 
protein synthesis, while during starvation ALIS occurred translation-independent. At least under oxida-
tive stress conditions ALIS and DALIS are believed to result from excess DRiP levels and to require 
protein synthesis (Szeto et al., 2006). 
In this regard it was of great interest to analyse whether in case of viral infection besides newly-
synthesized cellular proteins also non-translated and completely folded viral proteins might be affected 
by ROS. As displayed in figure 3.16 this could be verified through immunoprecipitation studies for the 
HCMV antigen pp65. Already two hours after infection the oxidized as well as ubiquitylated forms of 
pp65 could be precipitated with pp65-specific antibody (figure 3.16). Due to this observation at very 
early time points as well as after infection with UV-irradiated virus it has to be concluded that non-
translated virus proteins are subjected to oxidation and subsequent ubiquitylation. While the investi-
gations described before concentrated on oxidative damage of newly synthesized proteins, in this 
thesis normally stable virus proteins were shown to be sensitive to oxidative stress, too. The mecha-
nisms for targeting virus-delivered pp65 to oxidation remain unclear. The unmodified pp65 could be 
targeted directly by ROS-producing enzymes. Alternatively, the high abundance of pp65 in the virus 
tegument, representing a major constituent of HCMV particles, leads to accordingly high levels of 
pp65 that are distributed immediately inside infected cells upon virus entry, and this could promote 
oxidation. Possible sources of ROS in response to viral infection will be discussed later in chapter 
4.3.3. 
Further investigations that were applied on the proteasomal degradation of oxidized pp65, an implica-
tion of i-proteasomes and their potential impact on epitope generation will be discussed in the follow-
ing chapter. 
 
4.3.2 Proteasomal degradation of oxidant-damaged viral proteins 
The role of the proteasome in the removal of oxidized proteins has been accepted for a long time. 
Already in 1985 Jennifer Rivett isolated a large protease complex from liver which preferentially de-
graded oxidatively modified model substrates in comparison to unmodified substrates (Rivett, 1985). 
Independently another group purified a 670kDa protease complex from red blood cells which degrad-
ed oxidatively damaged proteins (Pacifici et al., 1989). Later, these proteases were shown to be iden-
tical to the proteasome. Through knockdown of proteasome subunits and proteasome inhibitors the 
proteasomal degradation of oxidized model substrates has been verified (Grune et al., 1997; Sitte et 
al., 1998), still the contribution of free 20S, 26S proteasome complexes and ubiquitylation has since 
been subject to controversial discussions.  
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In vitro, most unfolded proteins including oxidatively damaged proteins could be degraded by purified 
20S proteasomes alone (Davies, 2001; Grune et al., 1998; Pacifici et al., 1989; Rivett, 1985) and in-
deed increasing oxidative damage of model proteins could also reduce the ubiquitylation efficiency 
(Shringarpure et al., 2003). Further, in mammalian cells expressing a temperature-sensitive E1 mu-
tant, oxidant-damaged proteins were still degraded efficiently (Shringarpure et al., 2003). Mechanisti-
cally, the exposure of hydrophobic areas which could occur due to oxidation and unfolding of proteins 
may cause the binding of oxidized substrates directly to α-subunits of the 20S proteasome, which 
could promote the gating process (Kisselev et al., 2002). 
Interestingly, evidence for the ub-mediated degradation of oxidized proteins by the 26S proteasome is 
increasing. Already in 2001 Shang and colleagues observed upon induction of oxidative stress an in-
crease in oxidized and concomitantly ubiquitylated proteins in lens cells (Shang et al., 2001). Ubiquitin 
conjugates isolated from oxidatively stressed mammalian cells were highly enriched in oxidized pro-
teins and blocking of the UPS increased the susceptibility of cells to oxidative stress and induced cyto-
toxicity (Dudek et al., 2005). Further, it has been demonstrated in β5i knockout mice that i-
proteasome deficiency rendered retina cells more susceptible to oxidation-induced cell death (Hussong 
et al., 2010). An inhibitor of the mammalian deubiquitylation enzyme Usp14, which has been shown to 
associate with the 19S regulator, accelerated the degradation of oxidized proteins suggesting a role 
for 26S proteasomes (Lee et al., 2011). Though Pickering et al. discuss that a knockdown of the 26S 
proteasome exerts only a minor effect, they observed in mammalian cells that siRNA-mediated knock-
down of the 19S particle by targeting the Rpt2 subunit resulted in stabilization of oxidized proteins, 
further pointing out a role for the 26S proteasome (Pickering et al., 2010). Medicherla and Goldberg 
observed in budding yeast that the degradation of newly synthesized proteins was enhanced two- to 
three-fold by induction of oxidative stress and that this degradation was dependent on ATP and ubiq-
uitin. Knockdown of E2 enzymes and 26S components like Rpn10 revealed that all these UPS compo-
nents were essentially required for the efficient removal of oxidant-damaged proteins (Medicherla and 
Goldberg, 2008). In this regard also the connection of age and oxidative stress with the proteasome 
activity (Abd El Mohsen et al., 2005) and the observation that proteasome inhibitors cause senescence 
are of importance (Chondrogianni and Gonos, 2004; Chondrogianni et al., 2003). 
Within this thesis, application of the potent antioxidant sulforaphane prior to viral infection was able to 
reduce the overall amount of oxidized proteins significantly (figure 3.21). Sulforaphane acts indirectly 
by activation of phase II enzymes such as glutathione-S-transferase or UDP-glucuronyl transferase 
which detoxify oxidant-damaged proteins by conjugation reactions. By immunoprecipitation analysis 
the treatment with antioxidant also revealed reduced levels of oxidant-damaged pp65 (figure 3.22). 
Interestingly, decreased oxidation of pp65 also resulted in decreased ubiquitylation of pp65, which 
further verified a model in which oxidation precedes the subsequent ubiquitylation of a virus-delivered 
antigen. 
The slight delay of pp65 ubiquitylation to oxidation - peak levels of oxidant-damaged pp65 were 
measured after two hours and poly-ubiquitylated pp65 after four hours of HCMV infection (figure 3.16 
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and 3.22) - again indicates that pp65 is first subjected to oxidation caused by virus-induced oxidative 
stress before it is subsequently ubiquitylated. Hence, it is likely that the oxidation of pp65 gives the 
signal for its ubiquitylation. Possibly, oxidant-damaged pp65 may be ubiquitylated by a specific E3 
ligase, as it is reported for the iron regulatory protein 2 which has been shown to be specifically ubiq-
uitylated after oxidative damage by the E3 ligase HOIL-1 (Yamanaka et al., 2003). Further, the oxida-
tion of pp65 causes unfolding of the protein and this might induce the activation of chaperones. When 
refolding of oxidant-damaged proteins fails, these chaperones are reported to recruit E3 ligases which 
then target irreversibly misfolded proteins to proteasomal degradation (Kriegenburg et al., 2012). In 
this regard it could also be of interest to further analyse the sites of oxidation and ubiquitylation within 
the pp65 protein sequence by means of mass spectrometry-based approaches. 
The presented data approve the ubiquitylation of oxidant-damaged pp65 and suggest an implication 
of 26S proteasomal degradation. By application of proteasome inhibitor epoxomicin subsequent to 
HCMV infection not only poly-ub conjugates in total cell lysate accumulated, but also the degradation 
of pp65 was inhibited (figure 3.2B). Without proteasome inhibitor 24hpi a significant decrease of oxi-
dized and ubiquitylated pp65 was measured by precipitation with pp65-specific antibody (figure 3.16) 
presumably due to degradation by the proteasome.  
Notably, at 24hpi reduced levels of pp65 were observed in Western analysis after treatment with 
epoxomicin when compared to untreated cells. At this time point another effect of proteasome inhibi-
tion was exerted. The expression of pp65, and viral gene expression in general, is dependent on pro-
teasomal activity to eliminate transcriptional repressors (Kaspari et al., 2008; Tran et al., 2010). At 
24hpi de novo synthesis of pp65 would occur which might be blocked by proteasome inhibition there-
fore leading to decreased pp65 levels, while at earlier time points the degradation of non-translated 
pp65 might be inhibited thereby leading to increased pp65 levels. 
Recently, Seifert and colleagues have shown the upregulation of several components of the UPS in-
cluding the ub-conjugating enzyme UBE2L6 in response to stimulation with IFNs. Moreover, they could 
verify the involvement of UBE2L6 during IFN-mediated accumulation of oxidized poly-ub conjugates 
(Seifert et al., 2010). Also in response to virus infection an upregulation of UBE2L6 was observed. 
Microarray analysis revealed an induction of UBE2L6 four hours post infection with HCMV as well as 
IAV (see attachment table 1). This was confirmed by real-time PCR and immunoblot analysis (figure 
3.17A and B). By means of siRNA knockdown it could be verified that UBE2L6 was indeed involved in 
the induction of poly-ub conjugates in infected target cells (figure 3.17C) and moreover affected poly-
ubiquitylation of pp65 (figure 3.18).  
Further underlining the proteasomal degradation of ubiquitylated pp65 was the effect of siRNA-
mediated knockdown of the 19S subunit Rpn10. The access to the catalytical active sites within the 
barrel-shaped 20S core proteasome is regulated by the 19S regulator which docks at the ends of the 
barrel to open gated channels (Finley, 2009). 19S subunits recognize ubiquitin moieties conjugated to 
target proteins. One of the subunits, Rpn10, contains an ub-interacting motif (UIM) that exhibits high 
affinity for poly-ub chains. Mutation of the UIM domain of Rpn10 significantly impaired the proteolytic 
Discussion  P a g e  | 86 
capacity of the 26S proteasome and led to accumulation of poly-ubiquitylated proteins (Finley, 2009). 
Also after HCMV infection knockdown of Rpn10 caused an accumulation of poly-ub conjugates and 
moreover of pp65 (figure 3.20A) which suggested proteasomal degradation of non-translated ubiq-
uitylated pp65 by the 26S proteasome.  
Role of the i-proteasome for efficient degradation of oxidant-damaged viral proteins. Only 
recently evidence has been increasing that i-proteasomes are more efficient in eliminating damaged 
proteins than s-proteasomes. In 2010 our group had observed in response to stimulation with IFNγ a 
significantly increased accumulation of poly-ub conjugates in β5i knockout mouse embryonic fibro-
blasts (MEFs) compared to wild type MEFs (Seifert et al., 2010). At time points when the wild type 
cells were already cleared the formation of ALISs was observed in β5i knockout MEFs. Further, they 
demonstrated in vivo in LPS-challenged liver as well as in EAE-induced brains of i-proteasome-
deficient mice an increased formation of ALIS compared to wild type mice (Seifert et al., 2010). Thus, 
they could show a so far unknown function of i-proteasomes in the maintenance of protein homeosta-
sis upon inflammation-induced oxidative stress. Already earlier, Yewdell had proposed other cellular 
functions of i-proteasomes besides the processing of MHC class I ligands since during the inflamma-
tion process in pathogen-challenged tissue not only infected but also non-infected cells induce i-
proteasomes in response to secreted cytokines (Yewdell, 2005). Uninfected cells have no need to form 
i-proteasomes to improve antigen processing. Therefore, it seemed unlikely that the induction repre-
sents a side effect of cytokine stimulation. Further evidence was delivered by the observation that the 
induction of i-proteasomes is linked to cell stress (Hussong et al., 2010). I-proteasomes are not only 
induced in response to cytokine stimulation and infection but also for example due to heat stress 
(Callahan et al., 2006), arsenite treatment (Zheng et al., 2005) or nitric oxide (Kotamraju et al., 2006) 
supporting a more general physiological function of i-proteasomes besides its role in antigen pro-
cessing. Moreover, i-proteasome deficiency has been associated with inflammatory diseases. In hu-
mans a missense mutation in the β5i gene PSMB8 has been shown to cause the auto-inflammatory 
immune disease Nakajo-Nishimura syndrome (NNS) which is associated with impaired formation of i-
proteasomes and concomitant increased accumulation of poly-ubiquitylated proteins (Arima et al., 
2011; Kitamura et al., 2011). Furthermore, the brain and liver of β1i knockout mice are threatened by 
higher levels of protein carbonyls upon ageing compared to wild type littermates (Ding et al., 2006). 
Also in a viral infection model the function of i-proteasomes to protect against oxidative protein dam-
age has been shown: during acute coxsackievirus B3 (CVB3)-induced myocarditis, i-proteasome-
deficient mice showed exacerbated tissue damage due to increased levels of oxidant-damaged pro-
teins. This led to the conclusion that indeed infection-induced formation of i-proteasomes can protect 
against inflammation- and oxidation-mediated protein damage (Opitz et al., 2011). Consequently, an 
important, newly discovered function of the i-proteasome is to control the innate immune reaction and 
to protect against overshooting inflammatory responses. 
As discussed above, in this thesis also an increase of oxidative damage in response to viral infection 
was observed and moreover viral antigens were affected as well. Concomitantly, the almost immedi-
ate induction of i-proteasomes revealed an improvement of the presentation of an immunodominant 
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epitope processed from the same viral antigen. Further, by siRNA knockdown of the i-subunits β5i and 
β1i pp65 protein levels were increased in HCMV-infected fibroblasts (figure 3.8B) presumably due to 
less efficient degradation of pp65 by inhibition of i-proteasome formation.  
  
4.3.3 The DrOP hypothesis 
The observed effect of oxidation and ubiquitylation on the degradation of viral antigens, e.g. the 
HCMV protein pp65, implied an impact of oxidative stress on the generation of immunodominant 
epitopes from viral proteins, which could be confirmed clearly here. 
Indeed, the observed downregulation of pp65 ubiquitylation by siRNA knockdown of the ub-
conjugating enzyme UBE2L6 resulted also in reduced presentation of the immunodominant pp65495-503 
epitope to specific CTLs (figure 3.19A). In concert with the reduced epitope presentation, also the 
degradation of pp65 was inhibited and unlabelled pp65 accumulated after siRNA knockdown of 
UBE2L6 (figure 3.19B). Thus, content of ubiquitylated pp65 was correlated with the degradation effi-
ciency by the proteasome and consequently with epitope generation. Moreover, the siRNA-mediated 
depletion of Rpn10 impairing degradation of pp65 by the 26S proteasome also caused an accumula-
tion of pp65 (figure 3.20A) and subsequently affected the generation of the pp65495-503 epitope (figure 
3.20B). Hence, the epitope generation was dependent on ub-mediated proteasomal degradation.  
To test whether also the observed oxidation of pp65 was a prerequisite for the efficient processing of 
the immunodominant epitope the impact of antioxidant treatment was monitored. Sulforaphane appli-
cation lowered the amount of oxidized and concomitantly ubiquitylated pp65 (figure 3.22), in turn the 
degradation rate of unlabelled pp65 was reduced, as observed by accumulating pp65 levels in im-
munoblot (figure 3.23B), and consequently the generation of the pp65495-503 epitope was negatively 
affected (figure 3.23A). Notably, the effect of sulforaphane on the antigen presentation could be re-
produced in another model system by infection of HeLa cells with IAV and analysis of the presentation 
of the immunodominant M158-66 epitope (figure 3.24). In summary, reduction of oxidative damage in 
virus-infected cells decreases also ubiquitylation. This consequently affects the degradation of viral 
antigens by the 26S proteasome and the processing and presentation of viral epitopes. 
I-proteasomes protect cells against the accumulation of dysfunctional proteins during the innate im-
mune response (Seifert et al., 2010). Here, this function could be linked to the induction of an effi-
cient adaptive immune response. The induction of ROS and consequently oxidant-damaged proteins in 
virus-infected cells together with the ability of i-proteasomes to efficiently degrade oxidant-damaged 
proteins improved the processing of viral antigens. This mechanism might play an important role dur-
ing the early phase of a virus infection in infected target cells. Before virus replication is initiated 
DRiPs are not available for the generation of viral antigenic peptides. As a complementation to the 
DRiP hypothesis we introduce another protein pool: the DrOPs, directly oxidized proteins. DrOPs might 
provide proteasomal substrates for the generation of MHC class I ligands before the viral gene expres-
sion starts and do not require protein synthesis but the generation of oxygen radicals. 
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4.3.4 Oxidation of viral antigens – NADPH oxidase Nox4 
A central question raised was how pp65 was oxidized so fast besides being a stable virus-delivered, 
non–translated viral protein. As already discussed, the observed fast production of ROS in response to 
HCMV infection (figure 3.14B) is also reported from the literature to occur with minutes in HCMV-
infected SMCs (Speir et al., 1996). Further, ROS induction seems to play a role for the initiation of 
HCMV gene expression via NFκB (Speir et al., 1996).  Interestingly, HCMV also induces an anti-ROS 
response by different virus-specific mechanisms for example the induction of antioxidant glutathione 
(Tilton et al., 2011). Still, the observed accumulation of oxidant-damaged proteins by immunoblot 
(figure 3.14A) and oxidative modification of pp65 (figure 3.16) in response to HCMV infection was 
strong despite ROS-detoxifying viral mechanisms. 
It was tempting to analyse the source of ROS in response to virus infection inside the infected target 
cells. From the literature it is described that ROS as part of the host defense are not only produced by 
the well-known phagocytic NADPH oxidase Nox2 but also by enzymes present in many other cell types 
and tissues (Orient et al., 2007). Nox1 and Nox4 represent the two most prominent NADPH oxidases 
in the target cells. While Nox1 is described to be induced in fibroblasts and epithelial cells in response 
to IFN stimulation, Nox4 is reported to be expressed in almost every cell type (Orient et al., 2007; 
Rada and Leto, 2008). 
Both enzymes, Nox1 and Nox4, were analysed for their expression and induction in response to 
HCMV- and IAV-infection in MRC5 fibroblasts and HeLa cells, respectively. Nox4 was found to be tran-
scriptionally induced in HCMV-infected fibroblasts already after four hours of infection (figure 3.25A) 
and as reported from Theresa Bergann also in IAV-infected HeLa cells (personal communication). 
Further, Nox4 has been proven to contribute to ROS production in HCMV-infected fibroblasts. Deple-
tion of Nox4 by siRNA treatment caused significantly reduced ROS levels in response to HCMV infec-
tion (figure 3.25B). Consequently, siRNA-mediated Nox4 knockdown also affected overall levels of 
oxidized and concomitantly ubiquitylated cellular proteins (figure 3.26) as well as levels of oxidized 
and ubiquitylated pp65 (figure 3.27). Hence, also the epitope presentation measured with pp65495-593-
specific CTLs was drastically impaired (figure 3.28A). In concert, due to impaired degradation of pp65 
levels of unlabelled pp65 accumulated (figure 3.28B). Notably, also expression of Nox1 was found by 
real-time PCR analysis in MRC5 fibroblasts as well as in HeLa cells (personal communication with The-
resa Bergann). Furthermore, siRNA knockdown of Nox1 also had minor effects on the presentation of 
the pp65495-503 epitope in CTL assays (data not shown). Due to the possible different effectiveness of 
siRNAs the effects of Nox1 and Nox4 downregulation cannot be compared directly. In the future a 
possible involvement of Nox1 should be further elucidated.  
The NADPH oxidase Nox1, likewise Nox2, is regulated differently compared to Nox4. While Nox1 and 2 
are mostly regulated by posttranslational modifications such as phosphorylation of regulatory subunits 
or by association with other regulatory proteins like p22phox, Nox4 represents a constitutively active 
NADPH oxidase (Katsuyama, 2010; Rada and Leto, 2008). Nox4 does not require agonist stimulation 
or association with regulatory proteins. In fact, its activity is rather dependent on its level of protein 
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expression and gene transcription. While Nox enzymes in general are reported to be located on the 
apical cell surface, Nox4 has been observed also intracellularly, associated to the ER, and within peri-
nuclear localization (Katsuyama, 2010). Manea and colleagues performed investigations about the 
transcriptional activation of Nox1 and Nox4. They found that Nox1 and 4 are induced by IFNγ via the 
Jak-STAT pathway and also could show a physical interaction of STAT1/STAT3 proteins with GAS ele-
ments in the promoter of Nox1 and 4 in SMCs (Manea et al., 2010a). Further they observed that 
TNFα-induced NFκB signaling induced the transcription of both Nox1 and Nox4 (Manea et al., 2010b). 
Certainly, also TLR signaling activates the production of ROS via NADPH oxidases and in this way di-
rect virus–cell contact could trigger Nox activation (Orient et al., 2007; Rada and Leto, 2008). 
Notably, also independently of NADPH oxidases mitochondrial ROS occur in response to TLR stimula-
tion. It is reported that signaling from TLR1, 2 and 4 leads to translocation of TRAF6 to mitochondria 
where it induces ubiquitylation of ECSIT (evolutionarily conserved signalling intermediate in Toll path-
ways) which is implicated in the mitochondrial respiratory chain leading to increased production of 
mitochondrial and cellular ROS (West et al., 2011). These TLRs are known as bacterial TLRs, but for 
example for TLR2 an interaction with HCMV is well described (Compton et al., 2003). Other possible 
sources for ROS in response to HCMV or viral infection in general cannot be excluded.  
Besides other mechanisms than Nox4-induced ROS production, in future, further investigations on 
how Nox4 is induced by virus infection could be performed. In vivo analyses with Nox4-deficient mice 
were so far mostly concentrated on cardiovascular and neuronal pathologies (Kuroda et al., 2010; 
Sedwick, 2010). Under normal conditions Nox4 knockout mice appear to be healthy without any signs 
of dysfunction in areas where Nox4 is normally expressed. Interestingly, Nox4 activation has been 
associated with the exacerbation of chronic obstructive pulmonary disease (COPD). Apparently Nox4-
mediated ROS generation leads to the release of pro-inflammatory cytokines and tissue damage 
(Michaeloudes et al., 2011; Ngkelo et al., 2012). Further, it has been shown that Nox4 upregulation in 
response to lung injury causes pulmonary fibrosis (Hecker et al., 2009). 
However, the consequences of viral infection have not been analysed in Nox4-deficient mice. In figure 
4.2 a model for HCMV infection, that summarises the mechanisms leading to very early antigen 
presentation in non-immune cells by i-proteasome-improved generation of peptides from oxidized and 
ubiquitylated viral antigens, is displayed.  
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Figure 4.2 Model of HCMV infection in non-immune cells. With the entry of HCMV particles viral com-
ponents are released into the cytoplasm of the host cell. Probably viral dsDNA is recognised by a certain sensor 
which induces transcription factor IRF3 to shuttle into the nucleus and activate the transcription of IFNβ and 
further ISGs. Either directly or via IFNβ feedback signalling (?) the expression of i-subunits is induced. Conse-
quently, i-proteasomes which are probably associated with 19S on one and PA28 on the other side (not shown) 
are formed. Next, by secretion of type I IFN or possibly via an interaction of HCMV with TLRs (?), expression of 
the NADPH oxidase Nox4 is activated. The production of ROS by Nox4 affects viral antigens, such as the HCMV 
tegument protein pp65. Oxidized pp65 is targeted by an unknown mechanism (?) for ubiquitylation and hence 
degradation by the proteasome. The virus-dependent induction of i26S complexes improves the generation of 
antigenic peptides. The resulting peptides are transported via TAP into the lumen of the ER where they are load-
ed on MHC class I molecules. Peptide-MHC class I complexes are transported via the Golgi apparatus to the cell 
surface where they are presented to specific CTLs. In the text mentioned open questions suggesting future inves-
tigations were labelled with question marks. 
 
4.3.5 A new role for ROS production 
Finally, a general mechanism for the production of ROS in response to viral infection could be pointed 
out. As reported earlier also stimulation with inflammatory cytokines such as IFNγ elicits the produc-
tion of ROS and increases the amount of oxidant-damaged and ubiquitylated proteins in cells (Seifert 
et al., 2010). By induction of the i-proteasome and DRiPs IFNγ treatment also enhances the peptide 
supply for MHC class I molecules and upregulates the surface expression of MHC class I (Strehl et al., 
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2005). Here, the upregulation of MHC class I surface expression on IFNγ-treated HeLa cells was veri-
fied, in which an induction by almost 2.5-fold was observed after 24 hours (figure 3.29). Remarkably, 
the downregulation of either Nox4, to diminish the production of ROS, or of Rpn10, to inhibit the deg-
radation of ubiquitylated proteins, strongly affected surface expression levels of MHC class I complex-
es (figure 3.29). In conclusion, the oxidative damage caused by ROS production plays an important 
general role to ensure the peptide supply for the MHC class I antigen presentation pathway in gen-
eral. Supporting this finding is the reduction of total levels of oxidized as well as ubiquitylated proteins 
upon Nox4 knockdown in infected cells (figure 3.26). In conclusion, Nox4-generated radicals affect the 
degradation of newly translated as well as short- and long-lived cellular proteins in the same way as 
exogenously delivered proteins. 
Within this thesis an exciting new role for the production of ROS in response to viral infection has 
been uncovered. A link between innate immune mechanisms and the induction of an efficient adaptive 
immune response has been provided in infected target cells. Presumably, ROS-induced oxidative dam-
age of proteins is able to accelerate the protein turnover by concomitantly induced i-proteasomes 
which in turn more efficiently degrade the oxidized and ubiquitylated protein substrates to generate 
antigenic peptides for the presentation via MHC class I molecules. So far the acknowledged functions 
of ROS were restricted to the direct antimicrobial activity against pathogens, the production of hydro-
gen peroxide (H2O2) for peroxidases and the regulation of gene expression, such as  the induction of 
pro-inflammatory genes by NFκB activation (Gloire et al., 2006). Here, ROS-induced oxidation of intra-
cellular viral antigens leads to ubiquitylation and rapid degradation by the i-proteasome thereby sup-
porting epitope generation and presentation to specific CTLs.  
In the future, certain viral infections could be analysed in this regard. For example, during HCMV in-
fection where overshooting CD8+ T cell responses are problematic the role of ROS could be investi-
gated from a new point of view. Also ROS production is known to play a role in inflammatory autoim-
mune diseases causing tissue damage and affecting gene expression. Maybe inflammation-induced 
ROS during autoimmune diseases also play a role for the presentation of auto-antigens.  
The presented results in this thesis shed new light on the recently discovered link between oxidative 
stress and the induction of i-proteasomes. The ability of the i-proteasome to efficiently degrade oxi-
dized proteins and to protect cells from accumulating toxic aggregates under stress and inflammation 
could be connected again to the initiation of adaptive immunity to fight and control virus infection. 
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(v/v) 
(w/v) 
26S 
ag 
ALIS 
AMC 
α1-7 
APC 
APS 
ATP 
BCA 
BCR 
βi-subunit 
Bp 
cDNA 
CMV 
CNS 
CTL 
Da 
DALIS 
DC 
DCFH-DA 
DMF 
DMSO 
DNA 
DRiP 
DTT 
DUB 
E1 
E2 
E3 
EAE 
EDTA 
ELISA 
ER 
ERAD 
FACS 
FCS 
FITC 
ratio volume to volume 
ratio weight to volumne 
26 Svedberg 
antigen 
aggresome-like induced structures 
7-amino-4-methylcoumarin 
proteasomal α subunit 1 to 7 
antigen presenting cell 
ammonium peroxodisulfat 
adenosine triphosphate 
bicinchoninic acid protein assay 
B cell receptor 
immunosubunit 
base pairs 
complementary DNA 
cytomegalovirus 
central nervous system 
cytotoxic T lymphocyte 
Dalton, unit equal to g/mol 
dendritic cell aggresome-like induced structures 
dendritic cell 
2’-7’-dichlorofluorescin diacetate 
dimethylformamide 
dimethylsulfoxide 
desoxyribo nucleic acid 
defective ribosomal product 
dithiothreitol 
deubiquitinating enzyme 
ubiquitin activating enzyme 
ubiquitin conjugating enzyme 
ubiquitin ligating enzyme/ ligase 
experimental autoimmune encephalomyelitis 
ethylene diamine tetraacetic acid 
enzyme-linked immunosorbent assay 
endoplasmatic reticulum 
endoplasmatic reticulum associated degradation 
fluorescence associated cell sorting 
fetal calf serum 
fluorescein isothiocyanate 
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gpUS2 
GSH 
GST 
h 
HBSS 
HCMV 
HECT domain 
HeLa 
hpi 
HPRT1 
HRP 
IAV 
IFN 
IgG 
IKKε 
IL 
IP 
IPTG 
IRF3 
ISG15 
Jak 
K48 
kbp 
Lmp2 
Lmp7 
M1 
MCMV 
MDA5 
Mecl-1 
MEF 
MHC 
min 
MOI 
MRC5 
MTT 
 
NADPH 
NEM 
Nox 
NS1 
NTP 
o/n 
HCMV glycoprotein unique short 2 
glutathione 
glutathione S-transferase, enzyme family 
hour 
Hank's buffered salt solution 
human cytomegalovirus 
homologous to E6-AP carboxy terminus domain 
cervical cancer cell line derived from patient Henrietta Lacks 
hours post infection 
hypoxanthine phosphoribosyltransferase 1 
horse radish peroxidase 
influenza A virus 
interferon 
immunoglobulin G 
IκB kinase ε 
interleukin 
immunoprecipitation 
isopropyl-β-D-thiogalactopyranoside 
interferon regulatory factor 3 
interferon stimulated gene 15 
Janus kinase 
lysine at amino acid position 48 
kilo base pairs 
low molecular mass protein 2, i-subunit β1i 
low molecular mass protein 7, i-subunit β5i 
matrix protein 1 
murine cytomegalovirus 
melanoma differentiation-associated protein 5 
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RT-PCR 
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Z-DNA-binding protein 1 
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Table 1 Effect of HCMV and IAV infection on the expression of selected genes. MRC5 fibroblasts 
were infected with HCMV Ad169 and HeLa cells with IAV at moi 3. After 4 hours of infection cells were harvested 
and RNA prepared as described for microarray analysis (Human U133 2.0 Plus; Affimetrix). 
 
 
Figure 1 Presentation of the pp65495-503 
epitope is downregulated by the HCMV gene 
products of US2, US3, US6 and US11. MRC5 were 
infected either with HCMV Ad169 ATCC or the dele-
tion mutant ΔUS2-11 at moi 5 for the indicated time 
points. IFNγ release by pp65495-503 specific CTL was 
measured by ELISA and displayed as percentage of 
the response received by loading MRC5 with 1µg/ml 
pp65495-503 peptide (n = 2, error bars represent ±SD). 
 
 
